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3Abstract
Previous work has demonstrated that bone cells are highly sensitive to
extracellular acidification. Low pH is a key osteoclast activation factor, and
reduces bone formation by inhibiting mineralisation of the matrix. The aim of this
thesis was to investigate further the roles played by pH in modulating bone cell
function. Transient receptor potential (TRP) channels detect protons within the
pathophysiological range, so are potential candidates for mediating the
observed effects of acid on bone cells. I found that TRPV1 agonists/antagonists
had no effect on osteoclast formation and activation or bone mineralisation by
osteoblasts. Additionally, TRPV1-/- osteoclasts demonstrated no functional
differences from wildtypes. Furthermore, agonists/antagonists for TRPM8,
TRPV4 and TRPV3 were without effect. Pyrophosphate (PPi) a fundamental
inhibitor of mineralisation in the bone microenvironment is generated from
extracellular nucleotides by ecto-nucleotidases such as E-NPP1. I showed that
E-NPP1 mRNA and protein were up-regulated in osteoblasts cultured at pH 6.9;
total E-NPP activity was also increased. To determine the role of acidification in
tumour-induced osteolysis, I devised an in vitro model to investigate interactions
of osteoclasts with breast cancer cells, which metastasise to bone, sometimes
causing osteolytic disease. Surprisingly, the overall effect of breast cancer cells
on osteoclasts was inhibitory; however, resorption was significantly stimulated
relative to buffered controls when breast cancer cells were allowed to acidify the
culture medium. These results suggest that local acidification in tumour settings
in vivo could be an important factor in determining the degree of osteolysis that
occurs. Finally, I investigated whether two key cytokines implicated in the
vicious cycle model of tumour-mediated osteolysis, B-cell activating factor
(BAFF) and activin A influence osteoclast function. In all experiments only
acidosis stimulated osteoclast resorption. These results provide further
evidence for the fundamental role of acid as a regulator of bone cell function.
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Chapter 1
Introduction
The skeletal system
The skeletal system is a dynamic living tissue comprising bone and cartilage.
The skeleton has numerous important roles in the body, including: (i) it provides
a rigid framework of support for the body; (ii) it protects the major internal
organs from damage; and (iii) it acts as a large reservoir of ions to support both
calcium and phosphate homeostasis (Dempster 2006). Bone is one of the most
highly vascularised tissues in the human body (Ortega et al. 2004).
Anatomy
The bones that comprise the skeletal system can be classified into two groups:
long bones (i.e., femur, tibia and radius); and flat bones such as the skull and
scapula. Long bones contain a hollow central shaft known as the diaphysis,
which contains the bone marrow and is the site of haematopoiesis. There is a
membranous sheath covering the inner surface of the bone called the
endosteum. It contains blood vessels, osteoblasts and osteoclasts and is in
direct contact with the bone marrow. On the outer surface of the long bones is
the periosteum, comprising fibrous connective tissue. It contains blood vessels,
nerve endings and both osteoblasts and osteoclasts. The periosteum is
attached to the bone by collagenous fibres known as Sharpey’s fibres. The
periosteum covers all bone surfaces except at joints where articular cartilage is
found. The ends of the long bones are formed of the metaphyses below the
growth plate and the epiphysis above the growth plate. The metaphyses and
epiphysis are mainly cancellous bone covered in cortical bone, whereas the
long bones are primarily cortical bone. Approximately 80% (by weight) of the
adult skeleton is cortical bone and the remaining 20% is cancellous. Cortical
bone is dense and solid, whereas cancellous bone has a structure akin to
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honeycomb. Cancellous bone is the more metabolically active of the two types
(Dempster 2006).
Development of bone
Bone is formed in two different ways, either by intramembranous ossification or
by endochondral ossification.
Intramembranous ossification
Intramembranous ossification is the process by which mesenchymal tissue is
converted directly into bone, and is how flat bones and the jaw is generated.
Neural-crest-derived mesenchymal cells proliferate and condense; some of
these cells become osteoblasts, the bone forming cells. The bone
morphogenetic proteins BMP2, BMP4 and BMP7 are thought to instruct these
mesenchymal cells to express runt-related transcription factor 2 (RUNX2) (also
known as core-binding factor alpha 1 (Cbfa1), osteoblast specific factor 2 (Osf2)
and acute-myeloid-leukaemia protein 3 (Aml3)) which results in osteoblastic
differentiation as outlined below (Ducy et al. 1997).
Endochondral ossification
Most of the skeleton is formed by endochondral ossification. Initially cartilage is
generated from mesenchymal cells. The avascular cartilage framework is then
gradually replaced by bone (Ortega et al. 2004). Initially mesenchymal cells
commit to becoming cartilage cells as a result of mesodermal cells expressing
Pax1 and Scleraxis transcription factors which activate cartilage-specific genes.
These cells then condense and differentiate into chondrocytes, the cartilage
forming cells, which coincides with expression of the DNA-binding protein
SOX9, a known chondrogenic transcription factor (Cserjesi et al. 1995; Wright
et al. 1995). The chondrocytes then proliferate into a model for bone; at this
stage, the chondrocytes stop dividing but increase their volume. These are
known as hypertrophic chondrocytes. The conversion to bone is also dependent
on expression of vascular endothelial growth factor (VEGF). Increased
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expression of VEGF also coincides with up-regulation of collagen type X and
matrix metalloproteinase 13 (MMP 13). Endochondral ossification happens at
two distinct sites within the long bones, the primary site of which is diaphyseal
(shaft of the long bone), and the secondary site is epiphyseal (end of a long
bone). The secondary site is under independent control and is ossified after the
primary site. Ossification at the secondary site is dependent upon signalling
from Indian hedgehog (IHH), bone morphogenetic proteins (BMPs) and
fibroblast growth factor 18 (FGF 18). This results in ‘resting’ chondrocytes
moving into an area where chondrocytes are proliferating. These chondrocytes
then undergo hypertrophy and apoptosis. The extracellular matrix (ECM) that
surrounds the terminally differentiated chondrocytes, comprising type X
collagen, is calcified and partially degraded by MMP13 expressed by the
chondrocytes themselves as well as by invading osteoclasts (Behonick et al.
2007). This allows for invasion of blood vessels. Following this, osteogenic
progenitors are recruited to the area and deposit trabecular bone. The area
between the hypertrophic chondrocytes and bone marrow where the bone is
initially formed is known as the ossification front (Ortega et al. 2004). MMPs are
key molecules that have been implicated in the degradation of extracellular
matrix molecules. MMPs are structurally related zinc-dependent proteases;
during endochondral ossification, MMP 10 and MMP 13 (a collagenase) are
particularly important. MMP 13 expression is controlled by RUNX2 (Ortega et al.
2004; Mak et al. 2009).
Osteoblasts
There are three main cell types in bone, of which osteoblasts are responsible
for bone formation. They are derived from mesenchymal cell precursors. This is
the lineage that also produces adipocytes, chondrocytes, myoblasts, fibroblasts
and tendon cells. Activation of different transcription factors gives rise to the
different cell types listed. Both Runx2 and osterix (Osx) have been identified as
important transcription factors in the control of differentiation of osteoblasts.
RUNX2 is expressed throughout bone formation (Byers et al. 2002). Runx2
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mRNA first appears at embryonic day 9.5 in mice, coinciding with formation of
mesenchymal condensations that precede branching of chondrogenic and
osteogenic lineages (Franceschi et al. 2009). Runx2-null mice have a
cartilaginous skeleton, although the cartilage is not hypertrophic and additionally
there are neither osteoblasts present in the skeleton, nor any evidence of
alkaline phosphatase activity as a marker of bone formation (Otto et al. 1997).
Furthermore, there is no bony collar development, no vascular invasion and no
marrow formation, all of which provide evidence for the importance of RUNX2 in
skeletal development and osteoblast differentiation (Harada & Rodan 2003;
Franceschi et al. 2009). In Runx2-/- mice, chondrocyte maturation is delayed, an
observation which is consistent with RUNX2 being expressed in hypertrophic
chondrocytes. Mice heterozygous for Runx2 have a defect in intramembranous
ossification, a phenotype that closely resembles the human condition
cleidocranial dysplasia, which is a condition in which the clavicles are
underdeveloped or missing, there is a wide pubic symphysis and sufferers are
short in stature (Otto et al. 1997). Transgenic expression of Runx2 in
chondrocytes resulted in ectopic chondrocyte hypertrophy and endochondral
ossification (Harada & Rodan 2003). Together, these observations have
demonstrated that RUNX2 has a role in the control of differentiation of
osteoblasts and chondrocytes and that there must be other factors downstream
of Runx2 that act upon osteoblasts alone. Expression of Runx2 is controlled by
the down-regulation of expression of the helix-loop-helix protein TWIST, a
negative regulator of osteoblast maturation. Twist haploinsufficiency causes
premature cranial suture fusion, the result of premature osteoblast maturation
(Marie 2008).
Additionally, the zinc finger transcription factor osterix (OSX) was
discovered; its expression has been induced in myoblasts in response to bone
morphogenetic protein (BMP) (Harada & Rodan 2003; Marie 2008). Osx-null
mice have a normally patterned skeleton of cartilage but no bone formation
occurs. Mesenchymal cells, osteoclasts and blood vessels invade the cartilage
matrix but there are no osteoblasts present to lay down mineralised bone
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matrix. Osterix has been shown to direct pre-osteoblasts to become immature
osteoblasts and, therefore, without it, cells are unable to differentiate into
osteoblasts (Marie 2008). Osx-/- cells do express Runx2, but Runx2-/- mice do
not express Osx, demonstrating that OSX functions downstream of RUNX2
(Nakashima et al. 2002).
Terminal osteoblast differentiation is demonstrated by depositions of an
organised collagenous matrix which is subsequently mineralised and requires
activating transcription factor 4 (ATF4), also known as cAMP-response element-
binding protein (CREB2) (Matsuguchi et al. 2009). Atf4-null mice at embryonic
day 13 (E13) show no differences in skeletal elements, with wildtype animals
indicating that Atf4 is not important in the earlier stages of skeletal development.
However, by E14 and E16 Atf4 knockouts have less mineralised tissue
compared to wildtype. Specifically, the delay in differentiation of osteoblasts
resulted in absent trabeculae in the frontal bones of the skull in the Atf-null
mice. By E16, trabeculae were present only rarely in the skulls of Atf4-null mice;
when present they were short and thin in contrast to wildtype animals where
trabeculae were long, thick and numerous. Many Atf4-/- die perinatally, possibly
because the skull is much thinner in these animals and thus the brain is poorly
protected during birth. The same delay in bone formation was observed in the
rest of the skeleton (Yang et al. 2004). Bone sialoprotein (Bsp) is a molecular
marker of differentiated osteoblasts and it was absent in Atf4 knockouts at E15
and E16 when normally present. Osteocalcin (Ocn) is the last marker of
differentiated osteoblasts to appear; it was decreased in both Atf4-null mice at
E16 and shortly after birth when compared to wildtypes. Transcription factors
expressed earlier in osteoblast differentiation (i.e. Runx2 and Osx) were
unaffected by the absence of Atf4, which provides evidence that Atf4 acts
downstream of both Runx2 and Osx (Yang et al. 2004). ATF4 acts with Runx2
to control transcriptional activity of osteocalcin (Marie 2008). ATF4 has also
been shown to be important for bone mass acquisition post-natally. Osteocalcin
expression was decreased 2-fold in Atf-deficient mice, demonstrating lack of
terminal differentiation of osteoblasts. As a consequence mice never gain a
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normal bone mass. This is the result of decreased amino acid import by ATF4
which results in deficient synthesis of type I collagen (Yang et al. 2004).
Two other transcription factors, distal-less homeobox 5 (Dlx5) and MSH
homeobox homologue 2 (Msx2), are important in the early stages of osteoblast
differentiation. Functional analysis of the pair in vitro has revealed a reciprocal
relationship between the two whereby Dlx5 functions as an activator of
transcription and Msx2 a repressor. Mutations of these genes in both humans
and mice have demonstrated that they are essential for normal
intramembranous ossification (Samee et al. 2008).
Distal-less homeobox 5 (DLX5) is a homeobox protein and an activator
of Runx2 that has been shown to also function as a regulator of bone formation.
Analysis of Dlx5-deficient osteoblasts in vitro has demonstrated a decrease in
both osteoblast proliferation and differentiation. Furthermore, decreases in
expression of the following were observed: Runx2, Osx, Ocn and Bsp,
demonstrating that DLX5 functions upstream of these. Additionally, in co-
cultures containing osteoclast precursor cells and Dlx5-null osteoblasts, there
was a significant increase in osteoclast number and resorption. The
RANKL/OPG ratio was also increased. These results indicate that as well as
inducing expression of Runx2 directly, DLX5 has a role in coupling
osteoblast─osteoclast activity and therefore functions as a regulator of bone 
turnover (Samee et al. 2008).
Another member of this family of transcription factors, Dlx3, is expressed
at all stages of osteoblast differentiation, and is highest in mature osteoblasts.
Dlx3 has both positive and negative effects on Ocn expression. Msx1 and Msx2
are also homeodomain proteins that function as transcription factors. In both
Msx1-/- and Msx2-/- mice, there is a delay in formation of the cranial bones.
Double knockouts of both of these genes result in severely inhibited cranial
bone formation. Msx2 is expressed most highly in osteoprogenitor cells and
then down-regulated as differentiation progresses, inactivation of its expression
causes delay in skull ossification associated with decreased Runx2 expression
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(Marie 2008). The exact role Msx2 in osteoblast differentiation is unknown, with
some studies showing both suppression of differentiation of preosteoblasts and
others showing promotion of differentiation and/or proliferation of osteoblasts
(Komori 2006). In vitro, Msx2 promotes osteoblastic differentiation and
proliferation from mesenchymal stem cells but inhibits Runx2 activity and
osteoblastic gene expression in mature osteoblasts. Msx2 also controls
osteoblast apoptosis in vitro, in contrast however, in vivo Msx2 is a positive
regulator of osteoblasts differentiation (Marie 2008). More work is needed to
elucidate the precise roles of the genes in vivo.
Wnt signalling
Wnt (Wingless and Int-1) signalling is important in many processes during both
development and throughout life. Canonical Wnt signalling involves binding of
one of the Wnt molecules to a frizzled (Fz) receptor on the cell surface along
with a co-receptor low density lipoprotein-5 (LRP5) or LRP6 (Piters et al. 2008).
Binding of Wnts to the Fz/LRP5/6 complex activates the cytoplasmic protein
Dishevelled (Dvl) which subsequently phosphorylates glycogen synthase kinase
3b (GSK3b) and renders it inactive. This allows for stabilisation of β-catenin 
followed by translocation to the nucleus where it activates target genes
(Johnson et al. 2004). If Wnt signalling is prevented, β-catenin is 
phosphorylated by GSK3b following its association with the β-catenin 
destruction complex comprising GSK3b, axin and adenomatous polyposis coli
(APC). β-catenin is therefore marked for degradation, and ultimately not 
translocated to the nucleus and does not activate gene transcription (Johnson
et al. 2004; Yavropoulou & Yovos 2007). Wnt signalling can be regulated by
binding of the secreted regulator Dickkopf (Dkk) to LRP5/6 which then binds to
the transmembrane protein Kremen. The tertiary complex is internalised,
making LRP5/6 unavailable at the cell surface and so Wnt signalling is
prevented (Yavropoulou & Yovos 2007; Piters et al. 2008).
Wnt signalling is important during bone development, where Wnts
enhance expression of Runx2 (Komori 2006). Later on in life, Wnt signalling
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plays an important role in the regulation of bone mass via the action of
sclerostin (Moester et al. 2010) and this is discussed later in this chapter.
Bone matrix
Once osteoblasts are terminally differentiated they begin to produce and
secrete proteins that comprise the extracellular matrix (ECM), the organic
portion of the bone (Xiao et al. 2007). This organic scaffold provides bone with
its strength, while also providing elasticity and flexibility. The proportions of
mineral, organic material and water are critical to ensure the correct balance
between stiffness and flexibility; in adult human cortical bone, the proportions
are 60% mineral, 20% organic material and 20% water (Crockett et al. 2011).
The major constituent of the ECM is collagen, comprising approximately 80% of
the organic content of bone. Non-collagenous protein is also found in the ECM.
These proteins comprise between 10 and 15% of the total protein found in
bone.
Collagen
Of the collagen found in bone, around 95% is type 1. Other collagens present at
much lower levels are types III and V; these types are thought to have a role in
collagen fibril diameter regulation (Tavassoli & Yoffey 1983; Robey & Boskey
2006). Type 1 collagen is a fibrillar collagen comprising three α-polypeptide 
chains arranged into a triple helix. Two of the chains are genetically and
structurally identical and are encoded by the gene COL1A1. These are
designated α1(I) chains. The third chain is genetically different COL1A2, but 
structurally similar, designated the α2(I) chain (Prockop & Kivirikko 1995; Robey 
& Boskey 2006). The polypeptide chain is made of a repetitive sequence of
amino acids, glycine-X-Y, where X can be any amino acid, although it is usually
proline, and Y is usually hydroxyproline. The polypeptide chains are also
subject to the post-translational modifications: hydroxylation of lysyl residues
and glycosylation of lysyl or hydroxlysyl residues. This composition allows the
three chains to interweave tightly together and enables the formation of both
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intra- and inter-molecular covalent cross links (Robey & Boskey 2006). These
helices are then arranged into fibrils, which are positioned according to their
role. In type I collagen, fibrils have a diameter of between 50 and 200nm, and
adjacent collagen molecules are 67nm apart from one another, displaced by
approximately a quarter of their length. In bone, collagen is arranged in
concentric weaves (Prockop 1995; Lodish 2000; Viguet-Carrin 2006). Prolyl
hydroxylases require vitamin C as a co-factor, without it hydroxylation does not
occur. This results in failure of helix formation at normal body temperature and,
consequently, fibrils are also not formed. Non-hydroxylated procollagen chains
are degraded, which results in the disease scurvy (Lodish 2000).
Non-collagenous proteins
There are several different classes of non-collagenous proteins made and
secreted by bone cells, each of which performs a different role. Some of the
specific roles of some of these individual proteins are still undefined. Many are
thought to be involved in the control of hydroxyapatite crystal propagation. A list
of non-collagenous proteins and their specific roles can be found in Table 1.1.
Protein Role
Albumin inhibits hydroxyapatite growth
α2-HS glycoprotein promotes endocytosis; opsonic properties; chemo
attractant for monocytic cells; bovine analogue (fetuin) a
growth factor
Aggrecan matrix organisation; retention of water and ions;
resilience to mechanical forces
Versican ‘capture’ space destined to become bone
Decorin binds to collagen; regulates fibril diameter; binds to TGF-
β; may modulate activity; inhibits cell attachment to 
fibronectin
Biglycan binds to collagen; may bind to TGF-β; pericellular 
environment; genetic determinant of peak bone mass
Asporin / Periodontal
ligament associated
involved in chondrogensis; negatively regulates
mineralisation of periodontal ligament cells by down-
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protein-1 (PLAP-1) regulating BMP-2
Fibromodulin binds to collagen and regulates fibril formation; binds to
TGF-β
Osteoadherin/osteomodulin may mediate cell attachment
Lumican binds to collagen; may regulate fibril formation
Osteoglycin/mimecan Binds to TGF-β
Hyaluronan May work with versican molecule to ‘capture’ space
destined to become bone
Alkaline phosphatase hydrolyses inhibitors of mineral deposition; potential Ca2+
carrier
Osteonectin/SPARC regulates collagen fibrillogenesis; binds to growth factors;
may influence cell cycle; positive regulator of bone
formation
Tetranectin binds to plasminogen; may regulate matrix mineralisation
Tenascin-C interferes with cell-FN interactions
Tenascin-W may be involved in regulating osteogenesis
Osteopontin binds to cells; inhibits mineralisation in bone and soft
tissues; inhibits remodelling; involved in tumourogenesis;
inhibits nitric oxide synthase; may regulate resistance to
viral infection
Bone sialoprotein binds to cells; initiates mineralisation in vitro
DMP-1 in vitro regulator of mineralisation
MEPE possible regulator of phosphate metabolism
Dentin sialophosphoprotein
(DSPP)
possible role in osteogenesis
Thrombospondins cell attachment; binds to: heparin, platelets, collagen
(types 1 and 5), thrombin, fibrinogen, laminin,
plasminogen, plasminogen activator inhibitor and
histidine rich glycoprotein
Fibronectin binds to: cells, fibrin heparin, gelatine and collagen
Vitronectin cell attachment protein; binds to: collagen, plasminogen,
plasminogen activator inhibitor and heparin
Fibrillin 1 and 2 regulates elastic fibre formation
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Matrix Gla Protein (MGP) negative regulator of mineralisation
Osteocalcin (OCN) regulates activity of osteoclasts and precursors; may
mark turning point between bone formation and
resorption
Protein S primarily a liver product; may be made by osteogenic
cells
Table 1.1 Non-collagenous proteins found in the matrix and their roles
Adapted from (Robey & Boskey 2006). Additional information from (Roach 1994; Qin et
al. 2002; Yamada et al. 2007)
Mineralisation of the extracellular matrix
Matrix mineralisation is a tightly controlled process, which is regulated in vivo by
the ratio of phosphate (Pi) to pyrophosphate (PPi). Phosphate is required for
mineralisation because it is a component of hydroxyapatite and pyrophosphate
is a potent inhibitor of the process. Tissue-nonspecific alkaline phosphatase
(TNAP) is the primary enzyme within the ECM that hydrolyses PPi; PPi itself is
generated from extracellular nucleotides by the action of ecto-nucleotide
pyrophosphatase/phosphodiesterase 1 (E-NPP1). PPi is also channelled into
the extracellular space from within cells via progressive ankylosis (ANK) protein
(Yadav et al. 2011). During endochondral bone formation, mineralisation begins
in membrane bound matrix vesicles; once they have budded from osteoblasts
and are located within the matrix; formation of hydroxyapatite (Ca10(PO4)6(OH)2)
is promoted within the lumen of the vesicles (Anderson 1995; Anderson 2003;
Thouverey et al. 2009). Matrix vesicles were initially identified in the calcifying
zone of the mouse bone epiphyseal plate where the vesicles were closely
associated with needle-like structures identified to be hydroxyapatite and were
deduced to be required to initiate hydroxyapatite nucleation (Anderson 1969).
The matrix vesicles are full of phosphatases to provide Pi for hydroxyapatite
and to remove pyrophosphate, which inhibits mineralisation (Fleisch et al. 1966;
Ali et al. 1970). Matrix vesicles provide a site for Ca2+ and PO43- accumulation
which are both required to initiate mineralisation and are key components of
hydroxyapatite (i.e. the mineral component of bone). Once crystal formation has
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started, crystals will eventually propagate so much as to perforate the matrix
vesicle membrane, which causes the hydroxyapatite to be exposed to the
extracellular fluid; mineralisation of the organic component of bone is then
governed by levels of Ca2+ and/or PO43- in the extracellular fluid, the pH and
presence of non-collagenous proteins (see Table 1.1) which control the rate of
crystal propagation. Mineral will continue to grow until the matrix is full
(Anderson 1995; Thouverey et al. 2009; Yadav et al. 2011).
Matrix mineralisation in mature bone differs, however, insofar that
grooves within the collagen provide nucleation sites. Crystals begin to form with
a specific orientation at these sites, where large amounts of calcium and
phosphate ions have been electrostatically attracted by phosphoproteins within
the collagen matrix (Mann 1988).
Osteocytes
Osteocytes account for approximately 90% of the cells in bone (Noble 2008;
Dallas & Bonewald 2010). Osteocytes start life as osteoblasts, but those that
eventually become embedded within the bone matrix are osteocytes. As the
osteoblast becomes embedded, changes to the cell occur that result in its
classification as an osteocyte. Osteocytes form a network of cytoplasmic
dendritic processes known as canaliculi (Noble 2008).
Once osteoblasts have completed the bone formation phase of their
lives, there are several stages through which they can proceed: 1) they become
embedded in bone as osteocytes, this is thought to account for between 10 and
20% of osteoblasts; 2) they become bone lining cells (inactive osteoblasts); or
3) they undergo apoptosis (Noble 2008; Dallas & Bonewald 2010).
Current opinion states that ostocytogenesis is an active rather than a
simply passive process in which osteoblasts are ‘buried alive’. The change from
osteoblast to osteocyte involves substantial changes to the cell, specifically the
formation of dendrites. This process involves the cell becoming polarised and
dendrites first extend towards the mineralising front of bone and then toward the
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vascular space or the bone surface. Once the cell is embedded, this polarity is
maintained. Formation of dendrites is thought to require collagen cleavage and
that of other matrix proteins; mice that are homozygous for metalloproteinase
14 (Mmp 14), a collagenase, have less and shorter dendritic processes than
wildtype (Dallas & Bonewald 2010). MMP 2 is thought to have a role in
formation of the canalicular system. Mmp 2 null animals have reduced numbers
of canaliculi (Noble 2008).
As expected, owing to the significant changes in cell morphology that
result from the transition from osteoblast to osteocyte, the actin-associated
proteins fimbrin, filamin and α-actinin translocate to within the dendritic 
processes. It is proposed that these proteins are required to maintain the unique
shape of the osteocyte (Kamioka et al. 2004). More recent work has
demonstrated that osteocytes are enriched with proteins associated with
cytoskeletal function (Dallas & Bonewald 2010).
A key marker of osteocytes is dentine matrix protein 1 (DMP-1), which in
bone is predominantly expressed by osteocytes but also at much lower levels
by osteoblasts. Cells null for DMP-1 do not differentiate into mature osteocytes.
Furthermore, Dmp-1 knock-out mice demonstrate pathological changes in their
osteocyte lacunocanalicular system. DMP-1 controls maturation by down-
regulating the osteoblast specific genes osterix and type I collagen and by up-
regulating expression of the osteocyte specific gene sclerostin (Sost) (Lu et al.
2011). Osteocytes inhibit bone formation via the action of SOST. SOST binds to
low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) and LRP6 which
inhibit the Wnt signalling pathway, thus β-catenin does not promote expression 
of Runx2 to stimulate osteoblastogenesis (Marie 2008; Piters et al. 2008;
Krause et al. 2008).
Osteoclasts
Osteoclasts are derived from haematopoietic stem cells in the bone marrow.
This is the same lineage that gives rise to all the cells of blood. Osteoclasts are
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multinucleated cells that form from the fusion of mononuclear progenitors of,
more specifically, the monocyte/macrophage lineage (Teitelbaum 2000). The
first transcription factor necessary for osteoclast formation is PU.1 which is
essential for macrophage maturation. Nuclear factor of activated T cells,
cytoplasmic 1 (NFATc1) is also required to induce osteoclast-specific genes
(Crockett et al. 2011). NFATc1 has been described as the master regulator of
osteoclast differentiation (Nakashima & Takayanagi 2008). Subsequently, M-
CSF is required for the proliferation and survival of these macrophages. In
order for osteoclasts to form in vivo, osteoblasts or their progenitor cells or
monocytes, granulocytes, endothelial cells, fibroblasts or dendritic cells are
required, as they produce two factors that are essential for osteoclast formation;
these are macrophage colony-stimulating factor (M-CSF) and receptor for
activation of nuclear factor kappa B (NF-κB) (RANK) ligand (RANKL) 
(Teitelbaum 2000). M-CSF is required initially for differentiation of cells, and
RANKL is required subsequently. (RANKL is also known as osteoprotegerin
ligand (OPGL), tumour necrosis factor (TNF) ligand super family member 11
(TNFSF11), TNF-related activation-induced cytokine (TRANCE) and osteoclast
differentiation factor). Mice lacking either of these two factors do not form
osteoclasts (Teitelbaum 2000). Differentiation in vivo then depends upon
expression of RANKL in addition to C-FOS, encoded for by the gene Fos; this
commits the precursors to the osteoclastic lineage (Teitelbaum 2000). In
haematopoietic precursors deficient in Fos, osteoclasts are not produced and
these knockout animals develop osteopetrosis (Grigoriadis et al. 1994; Matsuo
et al. 2000). The NF-κB transcription complex is needed for differentiation into 
osteoclasts (Teitelbaum 2000).
A number of other factors are thought to have a role in monocyte fusion
to produce multinucleated osteoclasts (Oursler 2010) these include: E-cadherin,
the V-ATPase V0 subunit d2 and, the protein: a disintegrin and
metalloproteinase (ADAM) 8 and 12. ADAMS cleave extracellular parts of
transmembrane proteins that are involved in cell─cell and cell─matrix 
interactions (Oursler 2010).
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More recently, is has been proposed that osteoclast fusion is driven by a
specific protein, namely dendritic cell specific transmembrane protein (DC-
STAMP) (Iwasaki et al. 2008), which was identified by microarray on RAW
264.7 cells (Oursler 2010), DC-STAMP has also been demonstrated on primary
human monocytes that give rise to osteoclasts. Blocking DC-STAMP with an
antibody blocked formation of osteoclasts (Chiu et al. 2011). Expression of DC-
STAMP by osteoclast precursors is rapid following RANKL application. siRNA
knockdown of DC-STAMP resulted in suppression of osteoclast fusion. DC-
STAMP also directly induces expression of tartrate resistant acid phosphatase
(TRAP) (Kukita et al. 2004). A separate protein that has a c-terminal structure to
DC-STAMP, osteoclastic stimulatory transmembrane protein (OC-STAMP), has
been shown to be up-regulated following administration of RANKL (Verron et al.
2010), and this may have a role in driving osteoclast fusion.
A number of P2 receptors, have been implicated in osteoclast formation,
ATP has been shown to cause increased osteoclast formation as well as activity
(Morrison et al. 1998), additionally ADP signalling via the P2Y1 receptor, causes
significant increases in osteoclast activation (Hoebertz et al. 2001). A role for
the purinergic receptor P2X7 has been proposed. When primary osteoclasts
were cultured with an antibody blocking the P2X7 receptor, multinucleated
osteoclasts were prevented from forming; and conversely, over expression of
the P2X7 receptor resulted in spontaneous fusion of osteoclast precursors. It
has been proposed that one means by which ATP exits cells is via P2X7 which
forms a pore in the cell membrane. Once released into the extracellular
environment, ATP is hydrolysed to adenosine, AMP or ADP. Adenosine has
been proposed to facilitate osteoclast fusion (Pellegatti et al. 2011) Therefore,
blocking the P2X7 receptor prevents ATP release from cells, adenosine is thus
not generated by hydrolysis of ATP and fusion is inhibited; if P2X7 is over-
expressed, more ATP leaves the cell and more adenosine is generated, thereby
driving an increase in fusion, so that more osteoclasts are formed (Pellegatti et
al. 2011). Also, removal of extracellular adenosine prevented fusion and
addition of exogenous adenosine resulted in increased fusion (Pellegatti et al.
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2011) however, these data could not be confirmed in our laboratory (Morrison et
al. 1998; Hajjawi et al. 2011). P2X7 antagonists have been shown to inhibit
human osteoclast precursor fusion, and the authors note that mononuclear cells
appear to aggregate and are thus following a normal path to fusion but are then
unable to fuse. (Agrawal et al. 2010)
Figure 1.1 Proteins important in osteoclast development and function
Overview of proteins necessary for each stage of osteoclast development and/or
activity are indicated below the black arrows. For details of the abbreviations see
Appendix II.
Osteoclastic resorption and bone remodelling
Bone remodelling is the process whereby mature bone is removed by
osteoclasts in a process called resorption. This area is then filled with newly
made bone by the osteoblasts (Crockett et al. 2011). Osteoblasts and
osteoclasts work in coordination with each other at discrete locations in the
(Andersen et al. 2009).
Osteoclasts seal tightly to the bone surface, where they become
polarised. Recognition of the bone surface by the osteoclast involves integrins,
in particular integrin β1, which recognises type I collagen and integrin ανβ3 
which is the major attachment molecule; it recognises the Arg-Gly-Asp amino
acid motif which is present in osteopontin and bone sialoprotein. Without ανβ3 
actin rings will not form and the ruffled border is abnormal (Teitelbaum 2000;
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Udagawa 2003). The ανβ3 integrin comprises part of the podosomes, which are 
the equivalent of focal adhesions in other cells. Their role is to form a stable
structure between the extracellular matrix, cytoskeletal and signalling molecules
of the osteoclast. Podosomes are found associated with the actin ring and
comprise an actin core surrounded by ανβ3 and other cytoskeletal proteins (Teti
et al. 1991).
Once sealed to the bone surface, osteoclasts become polarised, which
requires expression of TNF receptor activating factor 6 (TRAF-6) (Zaidi et al.
2003). The rearrangement of the osteoclast’s cytoskelton is dependent on the
actions of the Rho family of GTPases. Following attachment to the cell surface,
Rho and Rac bind GTP and translocate to the cytoskelton. Rho signalling
mediates formation of the actin ring the role of which occurs primarily in cell
attachment. Rac, however, is responsible for cytoskeletal changes necessary to
allow osteoclast migration (Faccio et al. 2005). TRAP5b, which is commonly
used as a marker of osteoclasts, is thought to modulate osteoclast attachment
to the bone surface by dephosphorylating the matrix proteins bone sialoprotein
and osteopontin (Ek-Rylander et al. 1994). Osteoclasts form a ‘ruffled border’
which involves formation of infolds of the plasma membrane, a process which is
dependent on cellular-src (C-SRC) (Edwards et al. 2006). TRAP is targeted to
the ruffled border but how this initial targeting occurs here is not known
(Crockett et al. 2011). Surrounding the ruffled border is an area known as the
sealing zone which is contained within an actin ring. Appearance of the ring
indicates that the osteoclast is resorbing the bone at this point and is not motile
(Teitelbaum 2000). The sealing zone allows the osteoclasts to create a micro
environment between it and the bone matrix beneath it, while protecting the
surrounding area from exposure to the drop in pH. This area is acidified to
approximately pH 4.5 via the actions of an H+-ATPase. This ATPase locates to
the ruffled border upon polarisation and associates with the actin ring via its N-
terminal domain (Zaidi et al. 2003). The chloride-proton antiporter ClC7 works in
conjunction with the ATPase, to transport Cl- into the resorption lacuna,
necessary to maintain electoneutraility (Kornak et al. 2001; Crockett et al.
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2011). The intra-osteoclastic pH is maintained via an energy-independent Cl-
/HCO3- exchanger at the anti-resorptive surface of the osteoclast (Teitelbaum
2000). The protons that are required to decrease the pH are generated by the
actions of carbonic anhydrase II which hydrates CO2 and yields H2CO3 which
then spontaneously dissociates, generating protons (Vaananen & Laitala-
Leinonen 2008). The drop in pH within the sealing zone results in dissolution of
the mineral component of bone and leaves the organic phase exposed to the
lysosomal enzyme cathepsin K and matrix metalloproteinases which are
exocytosed into the sealing zone from the osteoclast (Teitelbaum & Ross 2003)
Products of the bone degradation, namely collagen fragments, calcium and
phosphate ions, are then endocytosed by the osteoclast and transported to the
anti-resorptive surface where they are released and eventually reach the blood
stream (Teitelbaum 2000; Crockett et al. 2011).
Transcription of cathepsin K occurs in response to stimulation of the
osteoclast by RANKL. Cathepsin K is a protease which is synthesised as a pre-
proenzyme and is secreted by osteoclasts into the resorption lacuna once the
osteoclast has sealed onto the bone surface. The low pH results in activation of
cathepsin K. Cathepsin K is able to cleave triple helix collagens as well as
osteopontin, thereby degrading the organic portion of the extracellular bone
matrix (Zhao et al. 2009). It is thought that TRAP may also have a role in further
proteolytic degradation of the collagen fragments (Crockett et al. 2011).
Regulation of bone remodelling
Bone remodelling is a process that is tightly controlled in healthy individuals to
ensure that appropriate amounts of bone are removed and replaced with new
bone. One of the most important regulators of osteoclast activity is the
osteoblast, in a process known as coupling (Andersen et al. 2009). The process
must be regulated, as osteoclasts are able to remove 2–4 times their own
volume in one day (Vignery & Baron 1980).
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Osteoprotegerin (OPG)
One of the most important endogenous factors that prevent osteoclast formation
and activity is OPG. OPG is produced by both osteoblasts and stromal cells. It
is a soluble decoy receptor to RANKL and prevents binding of RANKL to the
RANK receptor on osteoclast precursor cells and osteoclasts by out competing
it. This prevents new osteoclasts from forming and as RANKL is required for
osteoclast survival it negatively affects osteoclasts that are already formed,
therefore down-regulating bone resorption (Crockett et al. 2011; Kohli & Kohli
2011).
There are numerous other factors important in the regulation of bone
remodelling; some of the key factors are discussed briefly below.
Mechanical loading
One of the most fundamental regulators of bone turnover is mechanical strain.
Increasing strain results in increased bone formation by osteoblasts and a
decrease in osteoclastic resorption and therefore increased bone mass.
Unloading has the opposite effect, a decrease in strain requires less mechanical
strength and thus less bone mass (Harada & Rodan 2003). How mechanical
strain is detected and then transduced to changes in transcription is complex.
The osteocyte is now widely regarded as the mechano-sensor in bone. When
load is applied to any cell it will deform the cell membrane, in bone cells this is
Figure 1.2 Resorption pits created
by acid-activated human peripheral
blood-derived osteoclasts over a
48 hour period (in the presence of
RANKL)
(osteoclasts – red, resorption pits –
orange)
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detected by the stretch-activated cation channel (SA-CAT). This results in an
increase in cytosolic Ca2+, from internal stores and influx via the voltage-
sensitive calcium channel (VSCC). Increased calcium causes initiation of
various kinase cascades, these ultimately lead to up-regulation of c-fos which in
turn up-regulates expression of Runx2 (Ziros et al. 2002); Pavalko et al.,
2003a). There is increasing evidence that dentin matrix protein 1 (DMP1)
expressed by osteocytes is able to act as a mechano-sensor; Dmp1 mRNA is
up-regulated in osteocytes in vivo in response to mechanical loading (Gluhak-
Heinrich et al. 2003; Harris et al. 2007). Fluid shear stress also affects bone
cells, causing release of prostaglandin E2 (Jiang & Cheng 2001; Pavalko et al.
2003), which is anabolic. The overall effect of the detection of mechanical
stimulation is the up-regulation of osteoblastic genes and the down-regulation of
osteoclastic genes, which therefore results in increased bone formation and
decreased bone resorption (Marie 2009).
Oxygen / hypoxia
Bone is one of the most vascular tissues in the body (Ortega et al. 2004), with
the skeleton receiving approximately 10% of the cardiac output (Vakaet &
Boterberg 2004) and as such is well oxygenated. There are certain situations
when this oxygen supply to the bone is disrupted and oxygen tension drops.
Oxygen tension in arterial blood is approximately 95mmHg (12%) and in venous
and capillary blood is around 40mmHg (5%). In normal tissue the interstitial pO2
is between 24 and 66mmHg (three and 9%) (Vaupel et al. 1989; Lewis et al.
1999). In rabbits, pO2 within a haematoma, 4 days post fracture, was measured
to be 0.8% (Brighton & Krebs 1972). Hypoxia is not only associated with
fractures but also with inflammation, tissue damage and tumours (Thomlinson
1977; Murdoch et al. 2005). It has been demonstrated that hypoxia has a strong
inhibitory effect on osteoblast function, at levels of extreme hypoxia, (0.2% O2)
bone nodule formation in vitro was reduced by more than ten times. Hypoxia
down-regulates alkaline phosphatase activity and appearance of osteocalcin
was also delayed (Utting et al. 2006; Lechler et al. 2011). Additionally the three
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procollagen lysine, 2-oxoglutarate, 5-dioxygenases (PLOD1-3) were down-
regulated in response to hypoxia. These enzymes are needed for formation of
hydroxylysine residues (Utting et al. 2006), therefore, collagen production is
reduced. Hypoxia has also been shown to cause ATP release from osteoblasts
(Orriss et al. 2009). Discussed later in this chapter, ATP has an inhibitory effect
on bone formation and this may therefore contribute to this effect. These effects
demonstrate that osteoblast function and bone formation is a process highly
dependent on proper oxygenation (Utting et al. 2006).
Hypoxia also has profound effects on osteoclast function, hypoxia
causes an increase in number of osteoclasts formed, they are additionally of
greater size, with increased numbers of nuclei and have greater resorptive
activity (Arnett et al. 2003; Utting et al. 2010). Exposure to hypoxia also results
in stabilisation of the hypoxia inducible factors (HIF) 1α and 2α, and up-
regulation of vascular endothelial growth factor (VEGF) and interleukin 6 (IL 6).
VEGF has been shown to stimulate osteoclast formation and IL 6 has also been
reported to be osteoclastogenic. The HIF subunits are proteasomaly degraded
under normoxic conditions but hypoxia results in their stabilisation and they
allow the transactivation of genes involved in angiogenesis and metabolic
adaptation (Knowles et al. 2010; Utting et al. 2010). This adaptation to hypoxia
may be important when bone is damaged because it would stimulate removal of
damaged bone before the fracture is repaired by generation of new bone by
osteoblasts, for example. This additionally demonstrates the importance of the
vasculature supply in normal bone turnover.
Temperature
Core body temperature is known to fall as we age, with young healthy adults
typically having a core body temperature of 36.9˚C, falling to 35.5˚C in 10% of 
people aged 65 (Howell 1948; Fox et al. 1973). Temperature is known to have
an effect on cell function, typically slowing down enzyme reaction rates, cell
proliferation and differentiation by slowing progression through the cell cycle.
Osteoblasts are negatively affected by exposure to cooler temperatures.
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Exposure to mild hypothermia (35.5ºC) and severe hypothermia (34ºC) reduced
bone formation in vitro by 75 and 95% respectively. Additionally, Runx2,
alkaline phosphatase, type 1 collagen and osteocalcin were all down-regulated
in osteoblasts cultured in hypothermic conditions (Patel et al. 2009).
Hypothermic conditions have reciprocal effects on osteoclast formation and
activity, whereby formation and resorption by osteoclasts were both increased
by between 1.5- and 2-fold respectively (Patel et al. 2009). The reciprocal
effects of hypothermia seen on osteoclasts are similar to the reciprocal effects
caused by hypoxia and acidosis, whereby the overall effect on bone formation is
negative. Exactly why decreases in temperature may also have this effect are
not currently known but this clearly has significant implications to bone health in
the elderly.
Hyperthermia (40ºC) has been shown to decrease osteoblast
proliferation and bone nodule formation by 75%; furthermore, ATP release from
osteoblasts was also significantly increased (Orriss 2005). As outlined later,
ATP has a negative effect on bone formation and this may contribute to the
decrease in bone formation. Additionally, it has been reported that procollagen
denatures at 37.9ºC (Rosenbloom et al. 1973); without stable collagen, normal
bone formation will not be able to take place. The effect of severe hyperthermia
(40ºC) on human osteoclasts is also striking: osteoclast number was decreased
by 4 times and resorption per osteoclast was decreased by 10 times (Utting et
al. 2005). The effects of hyperthermia are overall bone formation being reduced
and osteoclastic bone removal being also decreased (Patel et al. 2009).
Temperatures of 40ºC may occur in bone as a consequence of infection and/or
inflammation (Utting et al. 2005).
Oestrogen
Oestrogen is a steroid hormone derived from cholesterol which is initially
converted into androgens including testosterone and androstendione and then
into the oestrogens oestrone and oestradiol via the action of an aromatase.
Oestrogen has profound effects on bone turnover. Increases in levels of
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oestrogen in girls at menarche are associated with a large reduction in bone
turnover markers. At this stage of life, the effects of oestrogen are biphasic, low
doses accelerate growth rates, but at higher doses growth is inhibited and
fusion of the epiphyses is stimulated. Oestrogen is required for the closure of
the growth plate, therefore higher levels of oestrogen in girls compared to boys
of the same age account for women eventually having shorter bones than men
as the growth plate is closed more quickly. The effect of oestrogen on closure of
the growth plate is also more potent than that of testosterone in men (Eastell
2005). At menopause, the decreases in oestrogen levels result in increased
levels of bone turnover (Parfitt 1991). The mechanism by which oestrogen
works involve it binding to the oestrogen receptor on osteoblasts, which results
in increased production of OPG and decreases in production of M-CSF.
Oestrogen also causes decreased secretion of interleukin 1 (IL-1) and TNFα by 
monocytes; additionally, oestrogen acting via oestrogen receptor α (ERα) 
results in up-regulation of Fas ligand (FasL), binding of which to its receptor
induces apoptosis. Combined, these effects result in decreased osteoclast
production, activity and survival (Eastell 2005; Jeong & Choi 2011). Decreases
in the level of oestrogen in women at the menopause therefore result in loss of
this mechanism of osteoclast regulation and as such, and bone remodelling is
altered in favour of bone destruction.
Parathyroid hormone (PTH)
There are four parathyroid glands in humans, located behind the thyroid gland.
The majority of each gland comprises chief cells and it is these that detect
calcium ion levels. It is also from these that PTH is secreted. Ca2+ is detected
via a calcium sensing GPCR, decreased Ca2+ results in decreased
phospholipase C and increased adenylate cyclase activity, cyclic adenosine
monophosphate (cAMP) generation results in PTH secretion (Nussey &
Whitehead 2001). PTH is synthesised as a preprohormone, the amino terminal
sequence is the only region of the polypeptide absolutely required for mineral
homeostasis, as such this segment, PTH(1-84), is highly conserved in all
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vertebrate species. The principle physiological role of PTH is to generate
release of calcium from the bones in order to maintain plasma calcium levels,
and a lack of PTH results in hypocalcaemia. Decrease of calcium ion
concentration from normal levels results in PTH secretion within minutes,
persistent decreases in calcium ion levels can cause hypertrophy of the glands,
in some cases up to five fold (Potts 2005).
The actions of PTH are mediated via its receptor, the GPCR PTHR1.
PTH acts at the kidney where it promotes formation of 1,25(OH)2D3 in order to
promote intestinal calcium absorption as outlined previously. Additionally, PTH
regulates calcium and phosphate transport in the kidneys. Dietary lack of
phosphate is therefore uncommon; PTH promotes its excretion simply by
preventing its reuptake. When calcium levels are lacking, PTH promotes
calcium reabsorption in the distal tubules of the kidneys in order to prevent
excretion (Agus et al. 1973; Potts 2005).
PTH also exerts direct actions on bone cells. PTH, acting on osteoblasts
causes increased expression of RANKL and decreased expression of OPG,
therefore resulting in increased osteoclast formation (Lee & Lorenzo 1999).
Primary human osteoclasts express the PTHR1 and addition of PTH(1-34) to
osteoclasts in vitro, caused a 2–3-fold increase in resorption, demonstrating that
PTH has direct effects on osteoclasts (Dempster et al. 2005). This
demonstrates that PTH has dual effects on osteoclasts via interacting with them
directly and via the action of PTH on osteoblasts; whereby increased resorption
ultimately increases calcium release from the bones.
Parathyroid hormone related protein (PTHrp)
PTHrp is derived from a different gene to PTH, although they are thought to be
evolutionary related. PTHrp is produced by many tissues in the body and exists
in three different isoforms that are generated by alternative splicing. PTHrp
functions in a paracrine manner and exerts its effect via PTHR1, the same
receptor as PTH. The role of PTHrp is thought to be more important during
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development, where, along with Indian hedgehog (Ihh) and other
morphogenetic proteins, it functions to delay differentiation of chondrocytes in
the growth plate of developing long bones (Gardella & Juppner 2001). The role
of PTHrp in the adult is not entirely clear, although it may have a role in Ca2+
regulation between maternal and foetal circulations and regulate calcium ion
concentration in breast milk as (Nussey & Whitehead 2001) PTHrp has been
shown in induce osteoclast formation in vitro (Akatsu et al. 1989).
Prostaglandin E2 (PGE2)
Prostaglandins are a class of eicosonoid hormones which are derived from
arachidonic acid. There are at least sixteen different prostaglandins split into
nine chemical classes designated PGA-PGI. Prostaglandins are continuously
made and secreted by many cell types but are often broken down rapidly by
enzymes in the extracellular fluid; as a consequence, they mostly function in an
autocrine or paracrine manner (Lodish et al. 2000).
PGE2 is the most widely produced of the prostaglandins and is also the
most important in terms of skeletal biology. The physiological roles of PGE2 are
difficult to elucidate as in vivo PGE2 has a strongly osteogenic and anabolic
effect (Yao et al. 1999). In vitro, PGE2 induces osteoclast formation (Collins &
Chambers 1992) and stimulates osteoclasts to resorb (Klein & Raisz 1970).
Transforming growth factor beta (TGFβ) 
Transforming growth factor beta is a family of related growth factors that
account for a substantial portion of intercellular signalling. Members of the
family regulate cell proliferation, lineage determination, differentiation, motility,
adhesion and cell death. Family members have significant roles in
development, homeostasis and repair of almost all tissues. Both activins and
bone morphogenetic proteins (BMPs) are members of the TGFβ super family 
(Kingsley 1994). TGFβ regulate gene expression via activation of a 
serine/threonine kinase that activates the SMAD signalling pathway (Massague
1998). TGFβ is highly abundant within the ECM of bone, although here it is 
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present in its latent form; upon bone resorption it is released into the
extracellular environment where it becomes active (Juarez & Guise 2011).
Three TGFβ isoforms have been identified in humans, designated TGFβ 
1─3. All three isoforms are crucial for bone development; knockout mice for 
each of the isoforms demonstrated substantial defects in normal bone
development. Changes in temporal expression of the isoforms control bone
remodelling. TGFβ1 stimulates bone formation by increasing migration of 
osteoblast progenitors and stimulating proliferation (Janssens et al. 2005); later,
TGFβ blocks osteoblast differentiation and prevents mineralisation (Alliston et
al. 2001). It does, however, also prevent apoptosis of osteoblasts in order to
allow for some to transdifferentiate into osteocytes (Juarez & Guise 2011). The
role of TGFβ in osteoclast formation and function is complex and depends on 
cellular context. In mouse foetal long bones for example, TGFβ prevents 
osteoclastic resorption. It has been demonstrated that TGFβ can induce OPG 
production by osteoblasts which therefore leads to decreased availability of
RANKL and so osteoclastogenesis is decreased (Takai et al. 1998). In contrast,
however, in the presence of M-CSF and RANKL, but absence of stromal cells or
osteoblasts, TGFβ increased osteoclast formation. This suggests that TGFβ 
might mediate its effects via acting on osteoclast precursors. Despite conflicting
results from in vitro experiments, in vivo TGFβ inhibitors consistently show  that 
TGFβ stimulates both osteoclast formation and resorption (Mohammad et al.
2009; Juarez & Guise 2011).
Bone morphogenetic proteins (BMPs) are important members of the
TGFβ superfamily, initially named as early members of this sub family were able 
to induce bone formation. However, they have many and diverse roles including
regulation of cell division, apoptosis, cell migration and differentiation (Dimitriou
& Giannoudis 2005).
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Fibroblast growth factors (FGFs)
Fibroblast growth factors are a group of signalling factors that have an important
role in skeletal biology. Some members are expressed almost all of the time
and others are restricted temporally and spatially. There is a certain amount of
redundancy between some of the FGFs, but others have very specific roles;
there are upwards of twenty family members so far identified (Ornitz & Marie
2002). There are three FGF receptors (FGFR), designated FGFR1─3, and 
binding of different ligands to these receptors activate different intracellular
signalling pathways to ultimately alter transcription of target genes (Dailey et al.
2005).
In bone development, the FGF receptors are particularly important.
Mutations in FGFR3 result in dwarfism, which occurs as a result of abnormal
endochondral ossification (Rousseau et al. 1994; Shiang et al. 1994). Mutations
in FGFR1 and 2 mostly effect intramembranous ossification and as a
consequence result in abnormal craniofacial development, including premature
closure of the skull sutures (Dailey et al. 2005). FGFs themselves are also
important for normal bone development; Fgf2-/- mice had inhibited bone
formation (Montero et al. 2000) and Fgf18-/- mice demonstrated delayed suture
closure and an expanded growth plate (Liu et al. 2002; Ohbayashi et al. 2002).
Insulin-like growth factors (IGFs)
Bone is rich in growth factors including IGF-1 and -2, both of which enhance
production of type I collagen by osteoblasts. Both mRNA expression and protein
production of IGF-1 and -2 are increased in response to PTH (McCarthy et al.
1989; Giustina et al. 2008). IGF is also important during bone development
because it stimulates growth during endochondral ossification (Giustina et al.
2008).
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Vascular endothelial growth factor (VEGF)
VEGF is essential for bone formation as vascular invasion is needed for
endochondral bone formation and fracture healing. VEGF promotes
differentiation of osteoblasts and mineralisation of the new bone (Carlevaro et
al. 2000; Keramaris et al. 2008).
Tumour necrosis factor (TNF)
TNFα is a cytokine that mediates a wide variety of cellular functions. Levels of 
serum TNFα increase with age and have a negative effect on bone formation. 
TNFα prevents deposition of the ECM (Lam et al. 2000). TNFα causes 
osteoblast apoptosis; this may occur via generation of reactive oxygen species
(ROS) which go on to antagonise the anabolic effects of WNT signalling by
suppressing of RUNX2, osterix and bone morphogenetic protein (BMP) induced
osteoblast differentiation (Almeida et al. 2011).
 TNFα has been shown to stimulate both osteoclast formation and 
resorption (Pfeilschifter et al. 1989; Yamashita et al. 2007). In order to stimulate
formation, there must be RANKL present, although this is only required at 1% of
the amount usually required to induce osteoclast formation. RANKL is a
member of the TNF superfamily (Wong et al. 1997). When TNFα and RANKL 
are added to in vitro osteoclast precursors together, it results in a marked
increase in translocation of NFκB to the nucleus. Increases in resorption may be 
a result of TNFα causing increased MMP synthesis (Lam et al. 2000).
TNFβ, also known as lymphotoxin, is homologous to TNFα in terms of 
activities that they carry out and receptors that they bind too, however, they
have limited sequence homology and TNFβ acts only in a paracrine manner, as 
much smaller amounts are produced (Ruddle 1992). TNFβ has been reported to 
stimulate resorption by osteoclasts (Garrett et al. 1987).
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Interleukins
Interleukins are a group of cytokines that mediate a wide variety of cellular
responses. Although produced by many cell types, interleukins are mainly
produced by immune cells and are critical in the proper functioning of the
immune system. As osteoclasts are derived from the same lineage as immune
cells, this may explain why interleukins have a role in osteoclast function.
Several interleukins are of particular significance in bone, Interleukin-1 (IL-1) is
able to stimulate osteoclast formation by enhancing expression of RANKL in
stromal cells and therefore stimulating osteoclast precursors to differentiate
(Wei et al. 2005). Interleukin-6 (IL-6) has also been shown to stimulate
osteoclast differentiation via a RANKL independent mechanism, and stimulate
osteoclastic resorption (Kurihara et al. 1990; Tamura et al. 1993; de la Mata et
al. 1995; Kudo et al. 2003). Interleukin-8 (IL-8) has been reported to stimulate
both osteoclastogenesis and osteoclastic resorption (Bendre et al. 2003).
Interleukin-11 (IL-11) has a negative effect on bone volume overall as it both
inhibits bone formation by down-regulating alkaline phosphatase expression
(Hughes & Howells 1993) and it also stimulates osteoclast formation in a
RANKL independent mechanism (Kudo et al. 2003).
Sclerostin
Sclerostin (SOST) is the product of Sost gene, the loss of which results in two
rare, closely related disorders characterised by an increase in bone mass,
sclerosteosis and van Buchem disease. SOST acts as an in vivo endogenous
negative regulator of bone mass. SOST is expressed by osteocytes, and only
appears late in differentiation, presumably once osteocytes have become buried
within the matrix (Yavropoulou & Yovos 2007). SOST inhibits bone formation by
inhibiting Wnt signalling via preventing signalling through LRP5/6, therefore, β 
catenin is degraded and downstream genes that initiate osteoblast
differentiation are not transcribed (Piters et al. 2008). It has recently been
proposed that BMP7 stimulates Sost expression, though BMP7 has been used
as an anabolic treatment for long bone non-union fracture so the exact
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mechanism by which BMP7 elicits its effects is not fully understood (Kamiya et
al. 2011).
Nucleotides
Nucleotides mediate a wide variety of biological functions, which includes
the activity of bone cells. Nucleotides mediate their effects via P2 receptors.
These can be further subdivided into P2X receptors, which are ligand-gated ion
channels, and P2Y receptors, which are GPCRs. ATP has been shown to
stimulate osteoclast formation and increase resorptive activity (Morrison et al.
1998; Orriss et al. 2010). Like osteoblasts, nucleotides are detected through P2
receptors which have been reported on osteoclasts (Bowler et al. 1995;
Naemsch et al. 1999; Hoebertz et al. 2000; Buckley et al. 2002; Ke et al. 2003;
Gartland et al. 2003; Korcok et al. 2005). It has been suggested that ATP
mediates this effect by signalling through the P2Y1 receptor on osteoclasts,
however, this may not be the case as a study has shown that ATP causes this
effect indirectly by up-regulating RANKL expression by osteoblasts and thus
cause increased osteoclast formation (Buckley et al. 2002). More recently UDP
has been shown to signal through the P2Y6 receptor to stimulate both
osteoclast formation and resorption (Orriss et al. 2011). The ADP receptor
P2Y13 has also been shown to signal via in osteoclasts (Wang et al. 2012).
The effect of nucleotides on osteocytes is not currently known as their
location within the ECM makes them difficult to study (Orriss et al. 2010).
Osteoblasts, have been reported to express several P2X and P2Y
receptors (Hoebertz et al. 2000). Both adenosine triphosphate (ATP) and uridine
triphosphate (UTP) inhibit bone nodule formation in vitro by preventing
mineralisation of the ECM. The effects of ATP and UTP are mediated via a dual
inhibitory mechanism; ATP or UTP acting via P2Y2 results in decreased
expression of alkaline phosphatase mRNA, thus, there is less alkaline
phosphatase enzyme produced and so hydrolysis of the mineralisation inhibitor
PPi is decreased and mineralisation is impeded (Orriss et al. 2007).
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Unlike most of the rest of the body, bone, teeth and mineralised cartilage
are the only tissues where deposition of calcium phosphate in the form of
hydroxyapatite is intended. The high concentration of calcium within the body
and its high affinity for inorganic phosphate leading to calcium phosphate crystal
deposition have led to strategies being developed to prevent ectopic
mineralisation in most of the body (Terkeltaub 2006; Kornak 2011). The most
important organic inhibitors of this deposition are oxalate and citrate, which
function by chelating calcium ions. A number of proteins also inhibit calcium
phosphate crystal formation, mainly in the extracellular space, these include:
fetuin-A, matrix-Gla-protein, osteopontin and osteocalcin (Kornak 2011). ATP,
along with other nucleotides, is hydrolysed to generate the corresponding
nucleotide monophosphate and PPi via the actions of the ectonucleotide
phosphodiesterase/pyrophosphatase 1 (E-NPP1) (Orriss et al. 2007)
Pyrophosphate (PPi) is a potent inhibitor of mineralisation, and the ratio of
phosphate (Pi) to pyrophosphate in bone microenvironment is a fundamental
regulator of bone mineralisation (Felix & Fleisch 1976; Kornak 2011). Both Pi
and PPi can be generated from extracellular nucleotide triphosphates (NTPs) by
the actions of ecto-nucleotide pyrophosphatase/phosphodiesterases (E-NPPs)
(Stefan et al. 2005; Orriss et al. 2007) and, ecto-nucleoside triphosphate
diphosphohydrolases (E-NTPdases), ecto-5’-nucleotidases and alkaline
phosphatases (Yegutkin 2008). Within the bone microenvironment, tissue-
nonspecific alkaline phosphatase (TNAP) is the most important enzyme
responsible for phosphate generation. In addition to PPi preventing
mineralisation, in vitro, ATP has been shown to be a potent inhibitor of
mineralisation (Orriss et al. 2007). Figure 1.3 illustrates the decreased
mineralisation by primary rat osteoblasts cultured in vitro in the presence of PPi
or ATP.
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Figure 1.3 Inhibition of bone
nodule mineralisation by
osteoblasts cultured with
PPi or ATP
PPi at concentrations of
1µM and above significantly
inhibited the amount of
mineralisation of matrix
nodules. ATP also inhibited
mineralisation significantly
at concentrations of 10µM
and above (n = 6, *** = p
<0.001, ** = p<0.001). Data
courtesy of Dr Isabel Orriss.
Ecto-nucleotide pyrophosphatase/phosphodiesterases
Ecto-nucleotide pyrophosphatase/phosphodiesterases (E-NPPs) are a family of
seven structurally related ecto-enzymes that hydrolyse pyrophosphate or
phosphodiester bonds in a number of extracellular compounds, including
nucleotides, lysophospholipids and choline phosphate esters. The catalytic
domain contains around 400 amino acid residues. The catalytic domains of
each enzyme share between 24 and 60% identity at the amino acid level. E-
NPP1 and E-NPP3 are both type 2 transmembrane proteins, that is, their c-
terminus is on the outside of the cell. E-NPP2 is secreted and E-NPPs 4–7 are
type 1 transmembrane proteins (Stefan et al. 2005). Table 1.2 gives details of
the substrates of each of the E-NPPs.
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Gene/pr
otein
name
Alternative protein name(s) Substrate(s)
E-npp1 major acidic fibroblast-growth-factor stimulated
phosphoprotein (MAFP);
nucleotide pyrophosphatase phosphodiesterase
(NPPase);
nucleotide pyrophosphatase phosphodiesterase
γ (NPPγ);  
nucleotide triphosphate
pyrophosphohydrolase(NTPPPH);
plasma cell differentiation antigen 1 (PC-1)
nucleotides; diadenosine
polyphosphates (Ap3A,
Ap4A, Ap5A)
E-npp2 Autotaxin;
lysophospholipase-D;
nucleotide pyrophosphatase phosphodiesterase
α (NPPα); 
phosphodiesterase-Iα (PD- Iα) 
nucleotides; diadenosine
polyphosphates (Ap3A,
Ap4A, Ap5A);
lysophospholipids
E-npp3 B10;
CD203c (cluster of differentiation203c);
Gp130RB13-6;
phosphodiesterase β (NPPβ); 
phosphodiesterase-1β (PD-Iβ); 
Nucleotides; diadenosine
polyphosphates (Ap3A,
Ap4A, Ap5A)
E-npp4 unknown
E-npp5 unknown
E-npp6 choline phosphate esters
E-npp7 alkaline sphingomyelinase choline phosphate esters
Table 1.2 E-NPP nomenclature and substrates. (Stefan et al. 2005; Yegutkin 2008).
E-NPPs catalyse the following reactions: nucleoside triphosphate (NTP) → 
nucleoside monophosphate (NMP) + pyrophosphate (PPi) or nucleoside
diphosphate (NDP) → nucleoside monophosphate (NMP) + phosphate (Pi). E-
NPPs1–3 are expressed by osteoblasts (Vaingankar et al. 2004).
E-NNP1
E-NPP1 is thought to be the most important E-NPP in bone mineralisation and
is highly expressed in bone and cartilage; additionally, it is expressed by
arteries, kidney, liver and B-lymphocytes (Vaingankar et al. 2004; Terkeltaub
2006; Yegutkin 2008; Kornak 2011). E-NPP1 is preferentially targeted to the
plasma membrane and, in bone, it is mainly associated with matrix vesicles
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(Vaingankar et al. 2004; Terkeltaub 2006; Yegutkin 2008). E-NPP1 mutations in
humans are associated with idiopathic infantile arterial calcification whereby the
lack of functional E-NPP1 protein means there is decreased PPi in areas of the
body in which calcium build up can lead to life threatening conditions such as
arterial and vascular calcification. (Rutsch et al. 2003) The hypothesis here is
that an increase in E-NPP1 will have the opposite effect where there is an
increase in levels of PPi; this will be of concern in areas of the body where PPi
is not useful and calcification is necessary (i.e. the bones). There is a naturally
occurring mouse E-NPP1 ‘knockout’, known as tip-toe walking (Ttw/Ttw) in
which a mutation in the gene results in a homozygous stop codon between the
catalytic site and the helix-loop-helix EF hand, causing truncation of the gene
product and more than a third of the functional protein (Johnson et al. 2003).
The Ttw/Ttw mice exhibit ossification of the spinal ligaments, peripheral joint
hyperostosis and calcification of articular cartilage, and this has similarities to
the human disease ‘Ossification of the posterior longitudinal ligament of the
spine’ (OPLL) (Okawa et al. 1998a; Okawa et al. 1998b; Zhang et al. 2007). It
should be noted that the role of E-NPP1 as an inhibitor of mineralisation is also
dependent on the activity of alkaline phosphatase, because the two enzymes
together determine the final concentration of PPi.
E-NPP2
E-NPP2 is synthesised as a pre-pro-enzyme. Following N-terminal signal
peptide removal and further trimming by furine-type protease, E-NPP2 is
secreted. E-NPP2 primarily functions as a lysophospholipase-D, converting
lysophosphatidylcholine into lysophosphatidic acid (LPA). LPA binds to many
signalling pathways and activates those involved in cell survival, proliferation,
contraction and migration. E-NPP2 knockout mice die at embryonic day 9.5 and
have profound vascular defects, supporting a role for LPA as a lipid mediator in
vascular development (Stefan et al. 2005; Yegutkin 2008).
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E-NPP3
E-NPP3 has similar enzymatic activity and substrate specificity as E-NPP1;
however, it is not targeted to the matrix vesicles, so its role in bone
mineralisation is not thought to be as important as that of E-NPP1 (Vaingankar
et al. 2004). E-NPP3 is expressed strongly by mature chondrocytes (Johnson et
al. 2003) and is thought to have a role in allergic responses, as it is present on
basophils and mast cells but no other blood cells. Following exposure to an
allergen, there is an immunoglobulin E (IgE) response that results in basophils
and mast cells releasing histamine and other mediators of an allergic response
(Stefan et al. 2005) .
E-NPP4 and E-NPP5
The natural substrates for E-NPP4 and E-NPP5 are unknown.
E-NPP6
E-NPP6 is highly expressed in the human brain and kidney. It is shown to
hydrolyse the classical phospholipase C substrate p-nitophenyl
phosphorylcholine but not the classical nucleotide phosphodiesterase substrate
p-nitrophenyl thymidine 5’-monophosphate (Sakagami et al. 2005).
E-NPP7
The enzyme intestinal sphingomyelinase was discovered over forty years ago
and was recently identified as E-NPP7 by cloning studies (Stefan et al. 2005;
Duan 2006). E-NPP7 is not thought to have nucleotide pyrophosphatase activity
but instead, it has phospholipase C activity against sphingomyelin in the gut.
Sphingomyelin is found in animal cell membranes, particularly those that
comprise the myelin sheath. Sphingomyelin comprises a ceramide core (the 18
carbon amino alcohol, sphingosine, bonded to a fatty acid) and either a
phosphocholine or phosphoethanolamine.
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Ecto-nucleoside triphosphate diphosphohydrolases
E-NTPdases hydrolyse NTP → NDP + Pi and NDP → NMP + Pi. They are 
unable to hydrolyse nucleotide monophosphates (Vaingankar et al. 2004;
Yegutkin 2008). There are currently eight known family members. E-NTPdases
1, 2, 3 and 8 are located on the cell surface, E-NTPdases 5 and 6 are localised
intracellularly and then secreted following heterologous expression and E-
NTPdases 4 and 7 are found only intracellularly, facing the lumen of
cytoplasmic organelles (Yegutkin 2008).
E-NTPdase 1
Also known as CD39 and is found on vascular endothelial and smooth muscle
cells, dendritic cells and lymphocytes (Yegutkin 2008).
E-NTPdase 2
This family member is thought to have an important role in purinergic control of
embryonic, post-natal and adult neurogenesis. Expression of the protein is
associated with adventitial surfaces of muscularised vessels and astrocytes,
non-myelinating Schwann cells and glial cells of the central and peripheral
nervous systems (Yegutkin 2008).
E-NTPdases 3–8
E-NTPdase 3 is thought to have a role in pre-synaptic regulation of extracellular
ATP levels and coordination of homeostatic systems (Yegutkin 2008). Little is
currently known about E-NTPdases 4, 5, 6 and 7. E-NTPdase 8 is most highly
expressed in the liver, particularly the bile canaliculi and large blood vessels. It
is not clear whether its role is in bile secretion or nucleoside salvage, or possibly
both (Yegutkin 2008).
Acid-base balance
Acid-base balance is one of the most tightly regulated processes of
homeostasis owing to the effect of pH on numerous biological functions (Orr-
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Walker et al. 1999). This is a process in constant dynamic equilibrium as the
body is constantly producing carbon dioxide and non-volatile acids as by-
products of normal metabolic activity.
Regulation of acid-base balance in healthy individuals
The normal [H+] is maintained between 40─45 nmoles of free hydrogen ions per 
litre which corresponds to a blood pH of between 7.35 and 7.4. Blood pH below
6.8 or above 7.7 is considered incompatible with life (Pocock & Richards 2009).
Any changes in hydrogen ion concentration are combated in a number of ways;
by chemical buffering via the body fluids to prevent excessive changes in H+
concentration, via removal of CO2 and therefore the acid H2CO3 from
extracellular fluid, and, finally, via the kidneys which excrete either acid or
alkaline urine to adjust the H+ concentration back to normal (Guyton & Hall
2000).
There are several ways in which the [H+] is buffered in vivo. One is the
bicarbonate buffer system. H2CO3 is formed in the body by reaction of water
and carbon dioxide; carbonic anhydrase catalyses this reaction, which is
otherwise very slow. H2CO3 is a weak acid and ionises slightly to generate
hydrogen ions and HCO3-. The second component of this buffer system is
sodium bicarbonate which ionises to yield HCO3- and Na+. Overall, this gives:
CO2 + H2O H2CO3 H+ + HCO3- (+ Na+)
Dissociation of H2CO3 is weak and therefore the overall hydrogen ion
concentration is low. When buffering metabolic acidosis, the increased
hydrogen ions are buffered by the HCO3- to give H2CO3, which in turn generates
CO2 and H2O. The increase in CO2 results in increased respiration and removal
of CO2 from the extracellular fluid and hence its excretion via the lungs. The
opposite reaction happens in situations when alkalosis may occur. The
bicarbonate buffer system is the most important buffer in the body (Guyton &
Hall 2000).
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Proteins within the plasma also function as useful buffers as they are
plentiful. Free carboxyl and amino groups can dissociate to buffer changes in H+
concentrations (Ganong 2005). Within the blood, changes in the binding
property of haemoglobin makes it an important buffer (Austin & Cullen 1925).
The imidazole groups of the histidine residues are much more important than
the free carboxyl or amino groups as there are thirty-eight histidine residues in
the haemoglobin molecule. In addition, there is a lot of haemoglobin which
means it has six times the buffering capacity of plasma proteins (Ganong 2005).
In addition to buffering within the body, acid-base balance is maintained
via respiratory regulation which functions to eliminate carbon dioxide from the
extracellular fluid. CO2 is made constantly in vivo as a by-product of intracellular
metabolic processes. It diffuses out of cells into the interstitial fluid and then into
the blood where it is transported to the lungs and is then excreted through the
lungs after diffusing into the alveoli. Changes in extracellular fluid pH will alter
the alveolar ventilation rate to change increase or decrease CO2 excretion as
required (Guyton & Hall 2000).
The kidneys also have a vital role in regulation of acid-base balance by
excreting excess acid or base in the urine. Bicarbonate ions are filtered
constantly through the tubules and if excreted into the urine, will remove excess
base from the blood. Hydrogen ions are also filtered to remove excess acid.
Non-volatile acids (i.e., not H2CO3) cannot be excreted via the lungs and are
removed by the kidneys. When healthy and under normal conditions, almost all
of the bicarbonate is reabsorbed by the kidneys. Hydrogen ions are actually
required for this reabsorption. Any excess hydrogen ions are excreted in the
urine after combination with ammonia (Guyton & Hall 2000).
Perturbations to acid-base balance
There are a number of situations whereby the pH of the blood drops to below
7.35, and results in acidaemia. Respiratory acidosis is the result of decreased
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CO2 excretion via the lungs. Initially small increases can be compensated for by
plasma bicarbonate but certain conditions lead to hypercapnia that cannot be
compensated for in this way and therefore acidosis results. These conditions
include chronic obstructive or restrictive pulmonary diseases, upper-airway
obstruction, and central nervous system (CNS) depression (Adrogue & Madias
1998).
Metabolic acidosis is the term given to all types of acidosis that occur in
the body except those caused by an increase in CO2 in the body fluid. Metabolic
acidosis is the result of a number of situations detailed here. Metabolic acidosis
can be caused by end stage chronic renal failure, whereby acid excretion is
decreased (Kraut 2000). Additionally, acidosis can result from a high protein
diet such as that followed on the ‘Atkins diet’ (Denke 2001; Chen et al. 2006a).
Despite increases in glomerular filtration rates and increased permeability of
renal capillaries, and consequently increased uric acid excretion, the uric acid
load is increased to such a degree that not all is excreted and therefore blood
pH decreases (Denke 2001).
It is rare that large enough quantities of acid are consumed in food to
result in acidosis , however, metabolic acidosis can sometimes arise following
ingestion of acetylsalicylic acid (aspirin) or methyl alcohol which is metabolised
to formic acid (Guyton & Hall 2000). Ageing also results in worsening low-level
metabolic acidosis: at 80 years of age, blood [H+] is 6-7% higher than at 20
years of age, plasma [HCO3-] is 12-16% lower and blood pCO2 is 7-10% lower.
This is due to the progressive decline in renal function with age. The kidney is a
major determinant of plasma [HCO3-] regulation; renal insufficiency also results
in reduced conservation of bicarbonate and decreased excretion of acid as a
by-product of normal cellular function. Additionally, acid-excretory ability in
response to exogenous acid is reduced (Frassetto & Sebastian 1996). Severe
cases of diabetes mellitus can result in metabolic acidosis when fats are split to
generate acetoacetic acid which is metabolised by tissues to generate energy in
Chapter 1 Introduction
51
the place of glucose. Blood levels of the acetoacetic acid can rise to sufficiently
high levels to cause metabolic acidosis (Guyton & Hall 2000).
Acidosis also occurs as a consequence of the menopause; loss of
progesterone results in respiratory hypoventilation and therefore mild
respiratory acidosis (Hodgkinson 1984; Orr-Walker et al. 1999; Preston et al.
2009).
Acidosis can also occur at a more localised level which can influence
bone cells depending on the location itself. Situations in which this may be the
case include inflammation, where lactic acid production will result in acidosis at
the site (Saadi et al. 2002). Also, a reduced vascular supply will result in
acidosis as by-products of cellular reactions are not removed at a normal rate
and so build up at the location. Circumstances under which reduced vascular
supply will occur include: inflammation, infection, tumours, diabetes and aging
(Arnett 2010). Consideration of local acidosis in relation to tumours is covered in
greater detail in Chapter 6.
Effect of acid base balance on the skeleton
The detrimental effect of acid on the skeleton has been known for many years
(Goto 1918). Bone functions as a ‘fail-safe’ store of alkali if overall bodily pH
drops to dangerous levels and requires buffering to maintain the pH within
normal but narrow limits (Arnett 2010). Solubility of hydroxyapatite increases as
pH decreases; at pH 7.39 calcium ion concentration is 0.16 mmol/l and
phosphate ion concentration is 0.21 mmol/l, when pH is reduced to 6.9,
solubility has increased to give calcium ion and phosphate ion concentrations of
0.28mmol/l and 0.78mmol/l respectively (Larsen & Jensen 1989). Acidosis does
however also have more direct effects on bone cells; culture of osteoblasts at
pH 6.9 prevents bone nodule formation in vitro by inhibiting mineralisation of the
collagenous matrix (Brandao-Burch et al. 2005b). The action of TNAP,
expressed by osteoblasts, which generates phosphate for incorporation into the
hydroxyapatite, is down-regulated as a consequence of acidosis (Brandao-
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Burch et al. 2005b). As a consequence of this down-regulation there is less Pi
for incorporation into the hydroxyapatite but it also alters the ratio of Pi and PPi
in the bone microenvironment such that there is more PPi present, which is an
important inhibitor of mineralisation (Fleisch et al. 1966).
In addition to the direct effects of acid on osteoblasts, acidosis also
affects osteoclasts. It was demonstrated over twenty-five years ago that protons
are the key stimulator of osteoclast resorption. Small drops in pH from the
physiological norm of pH 7.4 to pH 6.8 resulted in dramatic increases in the
resorptive activity of osteoclasts (Arnett & Dempster 1986). Once osteoclasts
have been activated by acid, cells can be further stimulated with RANKL (Arnett
2010). Acidosis also results in up-regulation of carbonic anhydrase II by
osteoclasts (Biskobing & Fan 2000); which is required to generate protons from
CO2 and H2O which are secreted into the resorption pit in order to generate the
acidic environment required for resorption (Vaananen & Laitala-Leinonen 2008).
Chronic acidosis causes an increase in activity of the H+-ATPase at the ruffled
border, thus delivering more protons into the resorption pit and ultimately
leading to increased resorption as a consequence of metabolic acidosis
(Nordstrom et al. 1997). The mechanism by which protons are detected by bone
cells however, remains elusive; potential acid-sensors include members of the
Transient Receptor Potential (TRP) channel super family and these are
discussed below.
Acidosis has an overall negative effect on bone whereby the action of
bone mineralisation by osteoblasts is decreased and the bone removing activity
is increased leading to a net reduction in bone mass; this is likely to be an
evolutionary ‘fail-safe’ mechanism to release base into the body to buffer
acidosis that may occur as a result of situations previously outlined.
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Transient receptor potential (TRP) channels
Transient receptor potential (TRP) channels are a super family of cation
channels, made up of seven smaller families of related proteins (Clapham
2003). The different families are listed in Table 1.3 below. Individual members
are named according to the different family and then a number (i.e., Transient
Receptor Potential Vanilloid type 1 is abbreviated to TRPV1).
All members of the TRP channel family are structurally related and
comprise six transmembrane domains; these assemble as homo- or hetero-
tetramers to form the active channel, with the pore loop situated between the
fifth and sixth transmembrane domains (Abed et al. 2009). Both the C- and N-
termini are located intracellularly (Holzer 2009). There are varying degrees of
sequence homology between the channels and all are cation permeable
(Venkatachalam & Montell 2007). The TRP channel family is distinct from other
groups of ion channels because of the large range of cellular functions they
mediate; their sensory roles include vision, taste, hearing and smell and they
also act as acid, mechano-, chemo- and thermo-sensors (Montell 2005; Voets
et al. 2005). Most of the TRP channels characterised to date are permeable to
Ca2+ ions, the exceptions being Transient Receptor Potential Melastatin type 4
(TRPM-4) and -5. Different groups of TRP channels also behave in different
ways, some open upon activation and result in Ca2+ movement into the cell,
others are constitutively open (Nilius et al. 2007).
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Abbreviation Name Number of mammalian
members
TRPC -Canonical 7
TRPM -Melastatin 8
TRPV -Vanilloid 6
TRPA -Ankyrin 1
TRPP -Polycystin 3
TRPML -Mucolipin 3
TRPN -No mechanopotential 0
Table 1.3 Mammalian TRP (transient receptor potential) channel families (Nilius et al,
2007; Wu et al. 2010)
Currently TRP channels are the subject of much interest as they appear
to be widely expressed throughout the body (Desai & Clapham 2005);
furthermore they have been implicated in some human diseases. Mutations in
TRPM6 result in hypomagnesmia and hypocalcaemia, mutations in Transient
Receptor Potential Canonical type 6 (TRPC6) cause kidney disease, in
Transient Receptor Potential Polycystin type 2 (TRPP2) or -1 they cause
autosomal dominant polycystic kidney disease, and in Transient Receptor
Potential Mucolipin type 1 (TRPML1) they cause mucolipidosis type IV
(Venkatachalam & Montell 2007). Furthermore, there is functional evidence
from transgenic mouse models that many of the TRP channels could be linked
to a whole host of human diseases. There have, however, been few studies that
investigate the presence or role of TRP channels on bone cells (Abed et al.
2009).
TRPV1
TRPV1 was the first member of the vanilloid family of TRPs to be discovered. It
was originally named VR1 (Voets et al. 2005), and it is assembled as a
homotetramer. TRPV1 is gated open when the pH drops to below pH 6.0,
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however, mild acidosis (pH 6.0─7.0) sensitises TRPV1 to other stimuli such as 
capsaicin (the ‘hot ingredient in chilli peppers) and heat. The TRPV1 cation
channel is activated and therefore opened in response to temperatures above
43°C, and is additionally stimulated by endovanilloids (Latorre et al. 2007;
Holzer 2009).
Activation of TRPV1 by protons and merely sensitising TRPV1 to
stimulations by other factors depend on two different amino acid residues. Glu-
600, which is located on the extracellular side of transmembrane segment 5, is
necessary for proton-sensitisation of TRPV1. Several amino acid residues are
essential for proton-induced gating of the channel, these residues are: Val-538,
located in the intracellular linker between segments three and 4; Thr-633, found
within the pore helix; and Glu-648, which is found in the linker between the pore
and transmembrane 6 (Holzer 2009).
The TRPV channels are non-selective for cations and moderately
permeable to Ca2+ and activation of the channel results in cation influx (Nilius et
al. 2007); (Yang et al. 2010). TRPV1 has been shown to be expressed by
neurons, the bladder and testis (Venkatachalam & Montell 2007). Preliminary
work in our laboratory also indicated that TRPV1 is expressed by osteoclasts
(Brandao-Burch 2005a) and that addition of capsaicin to osteoclast cultures
resulted in osteoclastic resorption (Brandao-Burch et al. 2006). TRPV1 has
been implicated in bone cancer pain, where the microenvironment is acidic
(Ghilardi et al. 2005; Prevarskaya et al. 2007). Furthermore, it has been
suggested that TRPV1 may have a role in osteoarthritis (Nilius et al. 2007).
TRPV4
TRPV4, like TRPV1, responds to multiple stimuli including osmotic cell swelling,
warm temperatures (27˚C) and acidosis (Montell 2005; Holzer 2009). 
Synoviocytes in joints are reported to abundantly express TRPV4, in addition to
being expressed by chondrocytes and osteoblasts. TRPV4 has been proposed
to act as a mechanical sensor in bone (Nilius et al. 2007).
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TRPM8
TRPM8 is related to both TRPV1 and TRPV4 because it is also a
thermosensor, detecting ‘cool’ temperatures between 23─28˚C. It is activated 
by menthol and a synthetic agonist, icilin. Its activation is also pH modulated
(Venkatachalam & Montell 2007). An abnormal bone phenotype in Trpm8-/- mice
has not been reported.
Cancer metastasis to bone
Cancer metastases are a common feature of disease progression and, account
for approximately 90% of cancer deaths (Fokas et al. 2007; Kingsley et al.
2007). Cancers go through similar stepwise processes in order to metastasize
to an organ different from the primary tumour site. The simple timeline of cancer
metastasis involves a number of key processes: 1) local invasion; 2)
intravasation, that is, entry of the tumour cells into the blood stream; 3) survival
in the circulation; and 4) extravasation, that is, exit of tumour cells from capillary
beds into ‘target’ organ (Nguyen et al. 2009). Different types of cancer
preferentially metastasize to different organs; this is known as the ‘seed and
soil’ theory, first described by (Paget 1889). The theory states that certain
tumour cells (i.e., the ‘seeds’) colonise distinct distant organs (i.e., the ‘soil’) that
have conditions most favourable to growth of that particular tumour (Fokas et al.
2007).
Both breast and prostate cancer preferentially metastasize to the bone,
although the types of disease that typically result are different. Breast cancer
most commonly results in incurable osteolytic bone disease caused by aberrant
osteoclast stimulation (Guise 2000; Fokas et al. 2007; Kingsley et al. 2007),
whereas prostate cancer more often results in osteoblastic metastases
(Roodman 2004). The resulting bone destruction causes hypercalcaemia;
pathological fractures and nerve compression, the latter two causing
considerable pain which is not attenuated satisfactorily by traditional pain relief
regimens such as opiates owing to the intermittent nature of the pain
(Mercadante 1997; Guise 2000; Slatkin 2006). Common sites of bone
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metastases are the back, pelvis, upper leg, ribs, upper arm and skull (Fokas et
al. 2007).
The vicious cycle of bone metastases
When tumour cells metastasize to bone, the cancer cells will initially adhere to
the endosteal surface of the bone before colonisation. The ‘vicious cycle’
hypothesis proposes that cancer cells secrete numerous growth factors and
cytokines into the micro-environment that stimulate osteoclast activity. Once
osteoclasts are stimulated to resorb bone, the growth factors which are trapped
in the bone matrix, including transforming growth factor β (TGFβ), of which 
bone is the richest source (Clezardin 2011; Patil et al. 2011), are released into
the bone/cancer micro-environment where their presence is postulated to
stimulate further cancer cell growth. More tumour cells means there are more
growth factors and cytokines in the extracellular environment to stimulate further
osteoclast activity and, hence, this is the cycle which results in further tumour
growth, more osteoclast stimulation and increased bone destruction (Guise
2000; Yoneda & Hiraga 2005; Kingsley et al. 2007). Cytokines produced by the
breast cancer cell lines used for this work are detailed here. Some of these
have been implicated in the vicious cycle model.
Cytokines produced by breast cancer cells
A number of cytokines known to have a role in bone cell function have been
reported to be expressed by both MCF-7 and/or MDA-MB-231 breast cancer
cell lines. These are the breast cancer cells most commonly used in research
(Lacroix & Leclercq 2004) and are used for the work presented in this chapter.
The MDA-MB-231 cell line was isolated from the metastatic pleural effusion of a
51-year-old Caucasian woman. MDA-MB-231 cells are oestrogen receptor
negative. The MCF-7 breast cancer cell line was isolated from the metastatic
pleural effusion of a 69 year old Caucasian woman. MCF-7 cells are oestrogen
receptor positive (Lacroix & Leclercq 2004).
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As previously stated, TGFβ induces and regulates many cellular 
processes; bone provides a rich source of TGFβ (Juarez & Guise 2011; Patil et
al. 2011).  One of the mechanisms TGFβ regulates is cell proliferation; cancer 
cells, however, often lose this regulatory nature owing to loss of members of the
signalling pathway. In the breast cancer microenvironment, TGFβ has been 
reported to increase tumour cell invasiveness, increase angiogenesis and
induce immunosuppression (Buijs et al. 2011). TGFβ2 has been reported to 
both promote osteoclastogenesis, whereby it makes pre-osteoclasts more
sensitive to RANKL (Stadelmann et al. 2008). TGFβ2 and TGFβ3 have been 
reported to be produced by MCF-7 cells (Perera et al. 2008). TGFβ2 is 
expressed by MDA-MB-231 cells (Li & Sidell 2005).
Activin A is a multifunctional growth factor and a member of the TGFβ 
super family (Phillips et al. 2005). The diverse roles of activin A include cell
proliferation, differentiation, apoptosis, the immune response and wound repair
(Sulyok et al. 2004; Chen et al. 2006b). It has been reported that breast cancer
patients with bone metastases have higher serum concentrations of activin A
than those patients without cancer metastases to bone; therefore indicating that
activin A may play a part in the vicious cycle of cancer metastases (Leto et al.
2006).
Interleukin-6 (IL-6) has well-documented effects on osteoclasts, whereby
it promotes osteoclast differentiation via a RANKL independent mechanism;
additionally, it has been reported to stimulate osteoclastic resorption (Kurihara
et al. 1990; Tamura et al. 1993; de la Mata et al. 1995; Kudo et al. 2003). IL-6 is
expressed by MDA-MB-231 and MCF-7 cells, (Lacroix et al. 1998; Li & Sidell
2005; Lee 2006; Joimel et al. 2010) . IL-6 has been implicated as a marker of
cancer progression in several different cancer types. In patients with metastatic
malignant melanoma, higher IL-6 levels are correlated with an increased tumour
burden (Mouawad et al. 1996). Similarly, patients with metastatic renal cell
carcinoma have higher levels of circulating IL-6 compared with healthy adults.
Additionally, when these patients were compared with each other those with the
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highest levels of IL-6 had a worse prognosis and shorter life expectancy than
those with lower IL-6 levels (Blay et al. 1992). Equivalently, in patients with
prostate cancer, the patients with the highest IL-6 levels were those with
metastases, followed by those with only localised cancer who in turn had higher
IL-6 levels than normal healthy adults. This study also found that in patients
whose cancer recurred, IL-6 levels became elevated when prostate-specific
antigen (PSA), (the current standard marker of prostate cancer), became
elevated upon recurrence of the disease (Michalaki et al. 2004). Furthermore, in
breast cancer patients with metastases, higher levels of IL-6 have been
correlated with shorter periods of survival (Bachelot et al. 2003).
Interleukin(IL)-8 (IL-8) is produced by MCF-7 cells (Lee 2006; Perera et
al. 2008) and MDA-MB-231 cells (Li & Sidell 2005; Joimel et al. 2010) and has
been reported to stimulate both osteoclastogenesis and osteoclastic resorption
(Bendre et al. 2003).
Other cytokines and growth factors produced by MDA-MB-231 breast
cancer cells include: granulocyte macrophage-colony stimulating factor (GM-
CSF); growth related oncogene (GRO), GRO-α; IL-11; angiogenin; platelet-
derived growth factor-B (PDGF-B); insulin-like growth factor-binding protein
(IGFBP) -1 and -4; tissue inhibitor of metalloproteinases (TIMP) -1 and -2; and
leukaemia inhibitory factor (LIF) (Lacroix et al. 1998; Li & Sidell 2005; Joimel et
al. 2010). MDA-MB-231 cells grown on bone matrix in vitro produce the matrix
metalloproteinases MMP2 and MMP9 (Yoneda & Hiraga 2005).
MCF-7 cells have also been reported to produce osteoprotegerin (OPG)
(Perera et al. 2008) which may have a role in disrupting the bone remodelling
balance in vivo.
Other cytokines and growth factors produced by MCF-7 cells include: VEGF
(Lee 2006; Perera et al. 2008), TNFβ, macrophage inflammatory protein (MIP)-
1β, also known as chemokines (C-C motif) ligand 4 (CCL4); brain derived 
neurotrophic factor (BDNF); fibroblast growth factor 9 (FGF9); IGFBP-2;
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interferon gamma induced protein 10 (IP-10); LIF; neutrophil-activating protein 2
(NAP-2); TIMP-1 and TIMP-2 (Perera et al. 2008); TNFα; IL-1β; IL-10; and IL-
12p70 (Lee 2006).
Multiple myeloma (MM) is a cancer of mature B lymphoid cells (Skinner
2011) which presents with symptoms including unexplained anaemia, bone
pain, renal failure, infection and hypercalcaemia (Scharschmidt et al. 2011).
Osteolytic bone destruction is a hallmark of multiple myeloma (Scharschmidt et
al. 2011) and, thus, cytokines implicated in MM may play a part in osteolytic
bone disease.
B-cell activating factor (BAFF) is a tumour necrosis factor (TNF) family
member expressed by T-cells and dendritic cells (Schneider et al. 1999).
Members of the TNF super family were initially characterised by their
cytotoxicity to tumour cells, causing tumour regression. Since their discovery,
however, TNF family members have been implicated in some normal functions
and disease states including: the immune response, haematopoiesis and
morphogenesis, tumourigenesis, transplant rejection, septic shock, viral
replication, rheumatoid arthritis, diabetes and bone resorption (RANKL is a TNF
family member) (Aggarwal 2003). Given that multiple myeloma is a B cell
neoplasm, it was proposed that inhibiting BAFF, tumour growth may be
suppressed and subsequent disease progression thus reduced (Hideshima et
al. 2007). Preliminary experiments carried out by collaborators at the University
of Sheffield using a soluble BAFF receptor-FC construct to block in vivo BAFF
activity showed that there was no effect on tumour burden but osteolytic bone
lesions were reduced compared to control animals. Additionally, in mice that
over-express BAFF, bone density and trabecular bone volume were both
reduced. These results together suggest that osteoclasts may be affected by
BAFF and the decreased number of osteolytic lesions results from decreased
osteoclast activity as BAFF is blocked. (Croucher, personal communication; Xu
et al. 2007)
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Despite the fact that much work has been undertaken in an attempt to
understand the mechanisms underplaying the vicious cycle of cancer
metastasis to bone, the exact mechanisms are still not understood. Additionally,
little attention has been paid to the role of acid, which is surprising given that the
tumour microenvironment is known to be acidic, and acid is the key factor that
results in stimulation of osteoclastic resorption (Arnett 2010).
General aim of the thesis
The overall aims of this PhD are to further elucidate the role that extracellular
acidosis has in negatively affecting bone remodelling. More specifically, to
determine the mechanisms by which extracellular acidosis prevents
mineralisation of the extracellular matrix; to investigate the mechanism by which
acid is sensed by osteoblasts and osteoclasts; and to elucidate the role of
acidosis in the vicious cycle of cancer metastasis in osteolytic bone disease.
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Chapter 2
Materials and methods
All chemicals were purchased from Sigma-Aldrich (Gillingham, UK) unless
otherwise stated. Tissue culture reagents were purchased from Gibco (Paisley,
UK).
Cell Culture
Osteoblast cell culture
Primary rat osteoblasts were obtained by sequential enzyme digestion of
calvarial bones isolated from two-day-old neonatal Sprague-Dawley rats. The
process comprised three steps: 1% trypsin in PBS for 10 minutes; 0.2%
collagenase type II in Hanks balanced salt solution (HBSS) for 30 minutes;
0.2% collagenase type II in HBSS for 60 minutes. The first two digests were
discarded and the cells resuspended in Dulbecco’s Modified Essential Medium
without phenol red supplemented with 10% foetal calf serum (FCS), 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml 
amphotericin (complete mixture abbreviated to DMEM). Cells were cultured for
3─4 days in a humidified atmosphere of 5% CO2-95% air at 37°C until
confluent. Once confluent, cells were seeded into 6 or 24-well trays (105 and
2.5 x 104 cells/well, respectively) in DMEM supplemented with β-
glycerophosphate (2mM), ascorbic acid (50μg/ml) and dexamethasone (10 nM).  
Osteoblasts were cultured for 4─15 days with half medium changes every 3─4 
days. Throughout the culture, medium pH, pCO2 and pO2 were monitored using
a blood gas analyser (ABL-700, Radiometer, Copenhagen, Denmark).
To investigate the effects of TRP channel agonists, these were added to
the medium at half media changes every 3─4 days. 
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Quantification of bone nodule formation
After 4─15 days experiments were terminated to determine the extent of bone 
nodule formation. Cell layers were washed with PBS, fixed with 2.5%
glutaraldehyde for 5 minutes, washed again with PBS and washed three times
in 70% ethanol. The plates were then left to air dry. Mineralised bone nodules
were visualised by staining with alizarin red (1% solution w/v in water) for 5
minutes, rinsed with 50% ethanol to remove excess stain, then air-dried. The
plates were imaged at 800 dpi using a high-resolution flat-bed scanner (Epson
Perfection Photo 3200). Using ‘Adobe Photoshop’ (version 6, Adobe Systems
Inc.) images of individual wells were first changed to greyscale before
conversion to binary images using Scion Image software (Scion Corporation;
http://www.scioncorp.com). These images were then subjected to automated
analysis, using constant ‘threshold’ and ‘minimum particle’ levels, to determine
the number and plan surface area of mineralised bone nodules.
Human peripheral blood mononuclear cell culture
Blood was taken from healthy volunteers, and peripheral blood mononuclear
cells (PBMNC) were isolated by density gradient separation. PBMNC were
washed once in PBS and then sedimented on to 250µM thick, 5mm diameter
dentine discs cut transversely from elephant ivory (kindly donated by HMRC,
Heathrow, UK) in 96-well trays in Minimum Essential Medium without phenol
red, 15% heat inactivated FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 
2mM L-glutamine (complete mixture abbreviated to ‘MEM’). After 4 hours, discs
were washed in PBS before being placed into 96-well trays in MEM containing
7.5 ng/ml M-CSF (Insight Biotechnology Ltd., Wembley, UK).  After 3─4 days 
incubation, discs were transferred to 6-well trays containing MEM with the pH
adjusted to 7.4 by the addition of 7.5 meq/L OH- (as NaOH), and further
supplemented with 7.5 ng/ml M-CSF and 1 ng/ml RANKL (R&D Systems
Europe Ltd., Abingdon, UK).  Half of the medium was replaced every 3─4 days 
and medium was acidified to pH 7.0 by the addition of 10 meq/L H+ (as HCl) 48
hours prior to termination of the culture. Cells were fixed in 2.5% glutaraldehyde
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and stained for tartrate resistant acid phosphatase (TRAP) using the leukocyte
acid phosphatase kit (387-A, Sigma-Aldrich, Gillingham, UK) according to the
manufacturer’s instructions. The numbers of TRAP-positive multinucleated
osteoclasts were assessed ‘blind’ using transmitted light microscopy. The area
resorbed per disc was quantified by dot-count morphometry under reflected
light.
To investigate the effect of TRP channel agonists or cytokines implicated
in the vicious cycle of cancer metastases on osteoclast formation, test
substances were added at the same time as RANKL, on day 4. To investigate
the effect on osteoclast activity they were added upon acidification 48 hours
prior to the termination of the culture.
Murine osteoclast culture
Long bones were isolated from two 6─8 week old MF1 mice killed by cervical 
dislocation. The epiphyses were removed and the marrow was flushed out with
PBS using a 25-gauge needle. Marrow was collected and cells pelleted by
centrifugation at 1500g, followed by a PBS wash, before being in Minimal
Essential Medium without phenol red containing 10% FCS, 2 mM L-glutamine,
100 U/ml penicillin, 100 µg/ml amphotericin B (mixture abbreviated ‘MEM’)
supplemented with 10-7 M prostaglandin E2 (PGE2), and 50ng/ml M-CSF
(Wyeth, Maidenhead, UK). Cells were placed into a 75 cm2 tissue culture flask
and incubated for 24 hours at 37°C / 5% CO2 to allow attachment of stromal
cells. Non-adherent cells were collected by centrifugation and resuspended in
MEM containing 10-7 M PGE2, 150 ng/ml M-CSF and three ng/ml RANKL.
Dentine slices in 96-well trays were incubated with 200µl of cell suspension (106
cells) overnight at 37°C / 5% CO2 to allow attachment of osteoclast precursors
to dentine discs. Discs were then transferred to 6-well trays containing MEM
with the pH adjusted to 7.4 by the addition of 7.5 meq/L OH, and further
supplemented with 150 ng/ml M-CSF and three ng/ml RANKL. Half of the
medium was replaced every 3─4 days and medium was acidified to pH 7.0 by 
the addition of 10 meq/L H+ 48 hours prior to termination of the culture. Cells
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were fixed in 2.5% glutaraldehyde and stained for tartrate resistant acid
phosphatase (TRAP) using the leukocyte acid phosphatase kit according to the
manufacturer’s instructions. The numbers of TRAP-positive multinucleate
osteoclasts were assessed ‘blind’ using transmitted light microscopy. The area
resorbed per disc was quantified by dot-count morphometry under reflected
light.
To investigate the effect of TRP channel agonists or cytokines implicated
in the ‘vicious cycle’ model of cancer metastases on osteoclast formation, test
substances were added when RANKL was added. To investigate the effect on
osteoclast activity they were added upon acidification 48 hours prior to the
termination of the culture.
Maintenance of breast cancer cell lines
Both MCF-7 (passage: 6) and MDA-MB-231 (passage: 48) breast cancer cell
lines were a gift from Dr Kay Colston (St. George’s Medical School, University
of London). Cells were maintained in RPMI medium (Sigma-Aldrich, Poole, UK)
with 5% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin 
and 0.25 μg/ml amphotericin (complete mixture abbreviated to RPMI).  Cells 
were passaged every 3–4 days.
Monitoring and adjustment of medium pH
Medium pH, pCO2 and pO2 were monitored at every medium change and
experiment end using a blood gas analyser (ABL 705, Radiometer, Crawley,
UK). The blood gas analyser equilibrates two buffer solutions at a low and high
pH with air and CO2. These equilibrated solutions are then used for electrode
calibrations. Accuracy of the measurements is achieved as the blood gas
analyser is also internally calibrated with known standards. Approximately
200µl of culture medium is taken into a syringe and injected into the machine.
The CO2 of samples taken subsequently fell therefore causing pH to rise, so
these were back-corrected to CO2 from the first reading which is assumed to
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represent the CO2 in all wells. Calibration curves to allow for back-correction
can be found below (Fig 2.1 A)
The pH of medium was adjusted using additions of small volumes of
concentrated acid or alkali. The graph below (Fig 2.1 B) demonstrates the
effect of additions of protons or hydroxyl ions on pH of MEM with 10% FCS. To
maintain pH of MEM at 7.4, 7.5meq/l OH- as NaOH was added; to adjust the pH
of MEM to 7.2 or 6.9, 5meq/l or 10meq/l H+ as HCl was added respectively.
Figure 2.1 A Relationship between pH, pCO2 and HCO3- in tissue culture
medium.
Data obtained using a blood gas analyser. Courtesy of Prof. Tim Arnett.
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Figure 2.1 B Adjustment of pH of MEM with 10% FCS by addition of H+ or
OH- which had been equilibrated with 5% CO2.
Assays
Cell proliferation assay
Osteoblast number was measured at 4, 7, 10 and 14 days of culture using the
CytoTox 96® non-radioactive cytotoxicity assay (Promega UK, Southampton,
UK). This assay quantitatively measures cellular lactate dehydrogenase (LDH),
a stable cytosolic enzyme that is released upon cell lysis. LDH oxidises lactate
into pyruvate, generating NADH, which is then used to convert a tetrazolium salt
into a red formazan product. The amount of colour formed is proportional to the
number of lysed cells. One hour prior to assaying, osteoblasts were switched to
serum free DMEM containing lysis buffer (1% (v/v) Triton X-100 in water);
following sample collection the assay was performed as per manufacturer’s
instructions. A standard curve for determination of cell numbers was
constructed using cells seeded at 102 to 106/well. Manual cell counts were
performed in parallel for assay validation.
meq/L
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pH
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Cell viability assay
Osteoblast viability was determined at days 4, 7, 10 and 14 of culture using the
CytoTox 96® non-radioactive cytotoxicity assay (Promega UK, Southampton
UK). Cells were cultured with the test substance (TRP channel agonist or
antagonist) until the day of the assay. One hour prior to the assay, medium was
removed and replaced with serum free DMEM. Samples were collected and the
assay performed according to the manufacturer’s instructions. Following sample
collection, cells were lysed in order to determine cell number (described
previously) to calculate percentage viability.
Ecto-nucleotidase activity assay
This assay exploits the fact that ecto-nucleotidases (E-NPPs) are able to
hydrolyse p-nitrophenyl thymidine 5’-monophosphate (pNP-TMP) to generate
thymidine 5’-monophosphate and p-nitrophenol, which has a yellow colour at
alkaline pH and can be measured colorimetrically (RAZZELL 1963). Therefore,
enzyme activity can be deduced from the amount of p-nitrophenol generated.
Total E-NPP activity was measured on days 4, 7, 10 and 14. Osteoblasts were
cultured as described above. Medium was removed from wells and cell
monolayers were washed with phosphate-buffered saline (PBS). Lysis buffer
(1% Triton X in 0.2M Tris base with 1.6mM MgCl2 pH 8.1) was added to wells
and monolayers were collected and kept on ice. Cell debris was pelleted by
centrifugation at 500 x g for 5 minutes at 4ºC. 90µl of supernatant was removed
to be assayed with 10µl of pNP-TMP (the final concentration of pNP-TMP was
5mM). The assay plate was kept in the dark at 37ºC and measurements taken
at regular intervals. Absorbance at 405nM was recorded using a plate reader
(ELx800, Bio-Tek International, Fisher Scientific UK, Loughborough, UK).
Amounts were adjusted for total protein content.
Phosphate assay
The amount of phosphate (Pi) released by osteoclasts was determined using
the Pi ColorLock™ Gold (Innova Biosciences Ltd., Cambridge, UK) microplate
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assay kit. The assay was performed at day 10 of culture. The effect of short and
long term acidosis was investigated. For short term effects, osteoblasts were
grown in 24-well trays as described previously to day of assay at pH 7.4, they
were then transferred to assay buffer at pH 6.9 one hour prior to assay. To
investigate long term effects, culture medium was adjusted to pH 6.9 as
previously described. Assay buffer was added to cells one hour prior to assay at
the same pH as the osteoblasts had been cultured at. Osteoblasts cultured at
pH 7.4 were used as a control. One hour prior to assay, DMEM was removed
from monolayers and cells were washed with assay buffer (0.01M HEPES,
0.1% NaCl, 1% BSA pH adjusted to be pH 7.4 or pH 6.9 at 37˚C) to remove any 
phosphate and pyrophosphate. 500µl of the assay buffer was then added to the
wells and osteoblasts incubated at 37˚C for one hour. The assay was then 
performed according to the manufacturer’s instructions. The assay is based on
the principle that the absorbance of the dye malachite green changes in the
presence of phosphomolybdate complexes. When unbound to Pi, the dye is
orange, but when bound to phosphate (Pi), it is green. Absorbance was read at
630nm. The amount of Pi was determined using a standard curve produced
using known amounts of phosphate.
A cell viability assay using the lactate dehydrogenase assay CytoTox
96® Non-Radioactive Cytotoxicity Assay (Promega, Southampton, UK),
described previously, was performed alongside.
Pyrophosphate assay
Osteoblasts were prepared as above to determine pyrophosphate generation.
Pyrophosphate was measured using the PiPer™ Pyrophosphate Assay Kit
(Invitrogen, Paisley, UK.) The principle is that inorganic phosphatase converts
pyrophosphate to two molecules of inorganic phosphate. In the presence of
inorganic phosphate, maltose phosphorylase converts maltose to glucose 1-
phosphate and glucose. Glucose is converted to gluconolactone and H2O2 by
glucose oxidase. With hydrogen peroxidise as a catalyst, H2O2 reacts with
amplex red to generate the product resorufin. The increase in absorption above
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the background is proportional to the amount of pyrophosphate in the sample. A
standard curve of known amounts of pyrophosphate was prepared alongside
samples that were assayed.
ATP release assay
Osteoblasts were grown in 12-well trays, as described previously. ATP release
assays were performed at days 4, 7, 10 and 14 of culture. Both the effects of
short and long term acidosis were investigated. For long term acidosis,
osteoblasts were cultured in medium at pH 6.9 from plating out, for short term
acidosis, osteoblasts were transferred to acidic medium immediately before the
assay began. Serum free DMEM containing L-glutamine and ABAM and pH
adjusted to pH 6.9 or left at the running pH of 7.4 were put into the incubator
overnight to equilibrate. On the day of the assay, medium was removed from
the wells and replaced with 500µl of the serum free DMEM that had been
equilibrating overnight. Samples were taken 60 minutes after addition of serum
free DMEM. The cells were returned to the incubator between readings after the
5 minute sample has been taken, taking care not to move the plate more than
necessary as this would result in additional ATP release. 25µl per well was
removed into an eppendorf that already contained luciferase reagent. An
additional 25µl was also removed into a 96-well plate to assay for cell viability.
The ATP in the medium was measured using the CellTiter-Glo® Luminescent
Cell Viability Assay (Promega, Southampton, UK). The assay utilises a reaction
catalysed by luciferase, whereby in the presence of ATP and O2 and Mg2+,
luciferin is converted to oxyluciferin, AMP, PPi, CO2 and light. This was
detected using the GLOMAX® 20/20 luminometer (Promega, Southampton,
UK). A standard curve using known amounts of ATP was generated and, from
this, the amount of ATP released from the cells was quantified.
Apoptosis assay
Primary mouse osteoclasts were isolated as described previously. Following
collection and cell count, osteoclasts were seeded onto plastic in a 96-well tray,
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at 106 cells, in 300µl of MEM per well. pH was adjusted to 7.4 or 6.9 with small
additions of NaOH or HCl respectively, as outlined previously. Cells were half
media changed every other day and pH, pCO2 and pO2 monitored throughout
as previously described. Cells were fixed on days 4, 6, 8 and 10. Cells were
fixed and apoptosis performed as outlined in the manufacturer’s instructions.
The apoptosis kit used was HT TiterTACS Assay Kit (Trevigen®, Gaithersburg,
MD, USA) which allows in situ detection of apoptotic cells in either monolayer or
suspension formats. The assay utilises one of the final stages, and a hallmark
of apoptosis, DNA fragmentation. The DNA breaks generate free 3’ hydroxyl
groups. The assay exploits this by providing a target for terminal
deoxynucleotidyl transferase (TdT) to sequentially add nucleotides to the 3’ end
of this DNA, the nucleotides are tagged and can be measured colorimetrically.
Increases in absorbance levels indicate increased apoptosis. Both positive and
negative controls were performed at each time point. This assay has been used
to demonstrate apoptosis in mouse osteoclasts by (Orriss et al. 2011).
Bradford assay for total protein
Bradford reagent (B6916, Sigma-Aldrich, Gillingham, UK) was used to perform
total protein determination in 96-well plate format according to manufacturer’s
instructions.
Visualisation methods
Western Blotting
Osteoblasts were cultured as outlined previously at pH 7.4 or pH 6.9 for 4, 7, 10
or 14 days. DMEM was removed and cell monolayers washed in PBS; mouse
osteoclasts were cultured on dentine for up to 12 days; at days 2, 6, 8 and 12;
total protein was extracted from the cells. MEM was removed and dentine discs
washed in PBS. The following is the same for both cell types: ice cold radio
immunoprecipitation (RIPA) buffer (0.05M Tris HCl pH 7.4, 0.15M NaCl, 1%
Triton X 100, 0.1% SDS, 5mM EDTA, 1l/ml protease inhibitor cocktail (104mM
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4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 80µM
aprotinin, 4mM bestatin, 1.4mM proteinase inhibitor E-64, 2mM
leupeptin,1.5mM pepstatin A), 100l/ml sodium deoxycholate, 5l/ml activated
sodium vanadate, 10ul/ml phenyl methyl sulfonyl fluoride (PMSF)) was used to
lyse the cells and release total cell protein. Following sonication for 5 minutes,
cell homogenates were stored at -80ºC until required for blotting. Protein
content of the samples was determined using the Bradford assay. 20µg of
protein was added per well and before loading these were denatured using
reducing buffer (60mM Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 10% β-
mercaptoethanol and 0.1% bromophemol blue) at 100ºC for 5 minutes.
Samples were run on a 10% SDS-PAGE resolving gel for one hour at 150V.
Samples were then transferred to hydrophobic polyvinylidene difluoride (PVDF)
membrane (GE Healthcare, Amersham, UK) using a wet blot tank (Bio-Rad
Laboratories Ltd., Hemel Hempstead, UK) at 100V for one hour. Following
successful protein transfer, the PVDF membrane was blocked with 5% milk in
PBS for one hour with gentle agitation then washed in dH2O. The membrane
was then incubated overnight; agitating gently, with the primary antibody diluted
in 2% milk solution. The following day, antibody solution was removed and
membrane washed three x 15 minutes in 0.05% (v/v) Tween in PBS. The
membrane was then incubated with the HRP-conjugated secondary antibody
diluted in 1% milk in PBS and incubated for one hour with gentle agitation.
Membrane was then washed three x 15 minutes in 0.05% (v/v) Tween in PBS.
To visualise the immunoreactivity, Immobilon western chemiluminescent HRP
substrate (Millipore (U.K.) Limited, Watford, UK) was used according to the
manufacturer’s instructions. Following visualisation of chemiluminescence, the
membrane was then stained with Ponceau S (0.5% (w/v) Ponceau S, 1% (v/v)
acetic acid, 200µM NaOH, 20% (v/v) acetonitrile) for 10 mins at room
temperature with shaking, and then rinsed with tap water until clear. The
membrane was allowed to air dry.
Anti E-NPP1 antibody was purchased from Abcam (Cambridge, UK) and
used at a concentration of 1:500. HRP-conjugated anti-rabbit secondary
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antibody diluted to 1:20,000 was purchased from Jackson ImmunoResearch
Europe Ltd. (Newmarket, UK).
Anti-TRPV1 primary antibody used at 1:200 (raised in rabbit) was
purchased from Alomone Labs Ltd. (Jerusalem, Israel). HRP-conjugated anti-
rabbit secondary antibody diluted to 1:30,000 was purchased from Jackson
ImmunoResearch Europe Ltd. (Newmarket, UK).
Immunofluorescence
Rat osteoblastic cells were seeded onto 1cm2 squares of Melinex® clear
polyester film (DuPont UK Ltd, Stevenage, UK), in 24-well trays at 2.5 x 104
cells/well and cultured in supplemented DMEM for up to 14 days. At required
time points, the Melinex® squares were fixed in 3.7% paraformaldehyde in 0.1M
phosphate buffer with Triton X 100 for 20 minutes at room temperature washed
three x 5minutes in PBS. Each square was incubated with a blocking solution
of 10% FCS in PBS containing 0.1% Triton x 100 for one hour. Primary antibody
was diluted in 10% FCS in PBS. Melinex® squares were incubated overnight in
the primary antibody solution with gentle agitation; negative controls were
incubated overnight in 10% FCS in PBS, containing no primary antibody.
Following removal of the primary antibody solution, cells were subjected to
three further 5-minute washes with PBS before incubation for one hour with the
secondary antibody solution and a DAPI counter stain (1:10000), diluted in PBS
with 1% FCS. After three further 5-minute PBS washes Melinex® squares were
mounted onto microscope slides using Citifluor AF2 solution (Citifluor, London,
UK) and viewed under a fluorescence microscope. All images were acquired
using identical camera settings to allow comparison of staining intensity.
Murine and human osteoclasts were subject to the same procedure as
rat osteoblasts following fixation. Murine osteoclasts were seeded onto Melinex
squares at a density of 4 x 106 cells/well and cultured in MEM supplemented
with 150ng/ml MCSF and three ng/ml RANKL. Murine osteoclasts were fixed on
day 10. Human osteoclasts were seeded at 8 x 105 cells/well and cultured in
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MEM supplemented with 5 ng/ml MCSF and one ng/ml RANKL. Human
osteoclasts were fixed on day 10.
Anti E-NPP1 antibody was purchased from Abcam (Cambridge, UK) and
used at a concentration of 1:100. Fluorescein isothiocyanate (FITC) labelled
rabbit anti-goat secondary antibody (DakoCytomation, Glostrup, Denmark) was
used at 1:100.
Anti-TRPV1 primary antibody used at 1:100 (raised in rabbit) was
purchased from Alomone Labs Ltd. (Jerusalem, Israel). Donkey anti-rabbit Cy3
labelled secondary antibody used at 1:400 was purchased from Jackson
ImmunoResearch Europe Ltd. (Newmarket, UK).
Quinacrine staining
Quinacrine is an acridine derivative and weak base that binds ATP with high
affinity. When excited by light at 476nm it fluoresces between 500 and 540nm.
Quinacrine has been used to stain ATP in sub-cellular compartments (IRVIN &
IRVIN 1954; Olson et al. 1976). Osteoblasts were cultured on Melinex polyester
film, cut into 1cm2 pieces in 24-well trays at 2.5 x 104 cells in supplemented
DMEM, pH adjusted to 6.9 with an addition of 10meq/l H+ as HCl, with a half
medium change at day three. DMEM was removed and cells twice washed with
PBS. To visualise ATP, 30µM quinacrine in DMEM at pH 7.4 or 6.9 was added
for one hour to investigate the effect of acid on ATP release. Melinex pieces
were then mounted on a slide and visualised using fluorescence microscopy
with a digital camera attachment (AxioCam MRc5, Imaging Associates Ltd.,
Bicester, UK). This method has been described previously (Orriss et al. 2009).
Toluidine blue staining of cancer cells
Toluidine blue stock solution (1% (w/v) toluidine blue in dH2O, 1% (w/v) sodium
borate) was diluted to 2.5% (v/v) in deionised H2O (dH2O) with 1% (w/v) sodium
borate. Enough of this solution was added to cover the discs completely and
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cells allowed staining for between 5 and 10 minutes. Excess dye was washed
with water. Discs were allowed to air dry.
Molecular biology
RNA Isolation and RT-PCR
Osteoclasts or osteoblasts were cultured as described previously and were
lysed in TRIZOL solution (Invitrogen, Paisley, UK), and total RNA was extracted
according to the manufacturer’s instructions. RNA was treated with RNase-free
DNase I (Promega UK, Southampton, UK) to eliminate any DNA contamination
and was quantified by using NanoDrop 1000 spectrophotometer (LabTech
International, Ringmer, UK). cDNA was then generated using Superscript III
reverse transcriptase (Invitrogen, Paisley, UK) and oligo (dT)15 (Promega UK,
Southampton, UK) according to the manufacturer’s protocol, using 200ng of
RNA per reaction. PCR was performed using GoTaq® Flexi DNA polymerase
(Promega UK, Southampton, UK) according to the manufacturer’s instructions,
with cycles of denaturation at 95oC for 30 seconds, annealing at XoC for 30
seconds; extension was performed at 72oC for 40 seconds. Details of primer
sequences and annealing temperatures (X) can be found in appendix I.
Quantitative real-time PCR (qRT-PCR)
Cancer cells were seeded at a density of 106 cells per well in a 6-well tray in
3ml of RPMI. Cells were grown to confluence and collected into trizol after three
days. RNA extraction and cDNA generation were performed as described
previously. 300ng/µl cDNA was amplified using SYBR® Green Jumpstart™ Taq
ReadyMix™ (Sigma-Aldrich, Poole, UK) on a Chromo 4 PTC-400 real-time
detector (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) according to the
manufacturer’s instructions with initiation of the reaction (94˚C for 2 minutes) 
followed by forty cycles of denaturation (94˚C for 15 seconds), annealing (60˚C 
for 1 minute), elongation (72˚C for 1 minute) and detection.  Data were analysed 
using the Pfaffl method whereby the relative quantification of the gene of
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interest is compared to a reference gene (Pfaffl 2001). For all genes
investigated, the reference gene used was β actin. All reactions were carried 
out in triplicate. Primer sequences can be found in appendix I.
Statistical Analysis
Statistics
Statistical comparisons were made using one-way analysis of variance
(ANOVA) applying the Bonferroni correction, performed using GraphPad InStat
(version 3.06, GraphPad software Inc.). Results are one experiment
representative of those performed at least in triplicate. All data are presented as
means ± SEM, n represents the number of replicates for each single
experiment, indicated below each graph.
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Chapter 3
Characterisation of the effects of acid on
osteoclast formation and survival
Introduction
The effects of acid on osteoclast activation are clear; small drops in pH within
the physiological range stimulate osteoclasts to resorb (Arnett & Dempster
1986). This short chapter characterises the effects of acid on osteoclast
formation and survival in view of the conflicting reports (Murrills et al. 1993;
Bushinsky 1995; Meghji et al. 2001; Pereverzev et al. 2008; Kato & Morita
2011; Ahn et al. 2012). A substantial amount of work during the course of this
PhD has involved careful control and observation of the pH of cell culture
medium and, therefore, of the pH environment of both osteoclasts and
osteoblasts. It was observed that for osteoclasts cultured at pH 7.4 for the
duration of an experiment (i.e. clamped at normal physiological pH, and
therefore not resorbing dentine), there were significantly less osteoclasts when
compared to those that had been stimulated to resorb for the final 48 hours of
culture (Fig. 3.1).
Figure 3.1 The effect of acid on
osteoclast number and resorption
Murine marrow cells were
cultured with M-CSF and RANKL
for 7 days at pH 7.4 or for 5 days
at pH 7.4 followed by two days at
pH 6.9. Acid significantly
increased the number of
osteoclasts and resorption per
osteoclast in comparison to
control. (n = 8, *** = p<0.001).
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Hypothesis – Exposure to acid will increase osteoclast survival by preventing
osteoclast apoptosis.
Results
Number of nuclei per osteoclast is decreased when osteoclasts are
cultured at pH 6.9
Osteoclasts were cultured in the presence of M-CSF and RANKL on dentine for
7 days and pH was maintained at either pH 7.4 or pH 6.9 for the duration of the
experiment. Osteoclasts cultured in acidic conditions have significantly less
nuclei per osteoclast than those cultured at physiological pH (pH 7.4) (Fig. 3.2).
Figure 3.2 Osteoclasts cultured in acidic
conditions have significantly less nuclei
than those cultured at pH 7.4
Murine marrow cells were cultured in the
presence of M-CSF and RANKL for 7
days at either pH 7.4 (A) or pH 6.9 (B).
Culture in acidic conditions resulted in
significantly less nuclei per osteoclast
compared to cells that had been
cultured at physiological pH (C). Note
areas of resorption (red arrows)
adjacent to osteoclasts (black arrows) in
(B) that are not present in (A). (n = 10,
** = p<0.01). Scale bar = 150µm.Culture pH
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Culture of osteoclasts at acidic pH does not significantly alter the amount
of apoptosis which occurs
Osteoclasts were cultured for up to 10 days on plastic and an apoptosis assay
performed on these cells at days 4, 6, 8 and 10 of culture. Apoptosis was
significantly increased in cells cultured at pH 6.9 compared with pH 7.4 at day 4
only. (Fig. 3.3) At all other time points, apoptosis was slightly increased in cells
which had been cultured at pH 6.9 throughout or had been transferred from
medium at pH 7.4 to pH 6.9 48 hours prior to the assay being performed; these
increases, however, were not statistically significant.
Figure 3.3 Effect of
medium pH on mouse
osteoclast apoptosis
Apoptosis was significantly
increased in cells cultured
for 4 days at pH 6.9
compared to those at pH 7.
Culture of osteoclasts at
pH 7.4, pH 6.9 or pH 7.4
then 6.9 for 48 hours did
not cause any significant
changes in apoptosis at
days 6, 8 and 10. Overall
apoptosis decreased over
time regardless of culture
pH (n = 6, ** = p<0.01).
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Osteoclast numbers are increased when cultured in acidic conditions on
dentine, without affecting their viability
Osteoclasts were cultured on either dentine discs or on plastic for up to 9 days
in medium adjusted to pH 7.4, pH 6.9 or at pH 7.4 and then adjusted to pH 6.9
48 hours prior to the assay being performed. At all days when cultured on
dentine, osteoclast number is increased when osteoclasts were cultured at
acidic conditions compared to those at physiological pH whether for the duration
of the experiment or for just 48 hours (Fig. 3.4). In comparison, osteoclasts
cultured on plastic did show the same effect on cell number at day 5 whereby
there are significant increases in numbers of osteoclasts when cultured at pH
6.9 for the duration or at pH 7.4 and then pH 6.9 for the 48 hours prior to
performing the assay. At days 7 and 9 there were no statistically significant
differences observed in numbers of osteoclasts in those cultured on plastic.
There were no significant differences in viability at any stage or between the two
substrates except at day 5, when cells transferred to pH 6.9 medium for pH 7.4
for 48 hours showed a small but significant decrease in viability. Additionally,
there were no differences in viability between the cells when cultured on dentine
versus plastic.
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Figure 3.4 Effect of medium pH on mouse osteoclast viability
Murine marrow cells were cultured in the presence of M-CSF and RANKL for up to 9
days at pH 7.4, pH 6.9 or pH 7.4 then pH 6.9 for 48 hours prior to assay. Culture for
any time period in acidic medium on dentine resulted in increased cell number. On
plastic acid resulted in increased cell number at day 5. Viability was only affected in
osteoclasts at day 5 when transferred to pH 6.9 for 48 hours prior to the assay being
performed. (n = 8, * and # = p<0.05, ** = p<0.01, *** = p<0.001).
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Discussion
Over the course of this PhD, it was observed that osteoclasts cultured for the
duration of an experiment at pH 7.4 were much larger than those which had
been initially clamped at pH 7.4 and then stimulated to resorb by artificially
dropping the pH to 6.9 for the final 48 hours of culture. The osteoclasts which
had been held at 7.4 did not resorb at all. Additionally, it was observed that
there were less osteoclasts at pH 7.4 compared to pH 6.9, both cultures had the
same number of osteoclast precursors initially seeded onto dentine discs (Figs.
3.1, 3.2 A and 3.2 B).
It has been reported that acidosis promotes osteoclast formation (Kato &
Morita 2011), however, the same group reports that these osteoclasts are larger
than those cultured at physiological pH which is in contrast to observations
made here. I hypothesised that the cause of larger osteoclasts at pH 7.4 was a
result of them beginning to undergo apoptosis owing to the cytoplasmic
vacuoles that were sometimes present; and are a characteristic of apoptotic
cells (Hacker 2000). Apoptosis of osteoclasts at pH 7.4 would also account for
the differences in osteoclast number recorded (Fig. 3.1). These osteoclasts
may have begun to die as the lack of acid resulted in them being inactive as
they are not stimulated to resorb and are therefore would not be required in an
in vivo setting. This is in contrast to those osteoclasts cultured at pH 6.9 or
transferred to this medium that were stimulated and ‘switched on’ to resorb
dentine. In order to investigate whether acidosis was preventing osteoclasts
from undergoing apoptosis an assay for this was performed.
Owing to the nature of this assay, the osteoclasts had to be grown
directly on plastic rather than the dentine substrate, which meant that they were
unable to resorb. It was observed that apoptosis was significantly increased in
osteoclasts cultured at pH 6.9 compared with those at 7.4 at day 4 of culture.
The high levels of apoptosis seen at this stage were likely to be a consequence
other cell types dying; this is because these cultures were of primary cells and
so are not homogenous. Although the isolation method used allowed for
separation of the cell types it is possible for small numbers of other cells to be
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present at early stages of culture. As a result these other cells, likely to be
stromal cells, and which were not in their optimal growing conditions, died. Also
at this stage, pH would have been detrimental to most cell types; hence the
greater levels of apoptosis seen at pH 6.9 at the early stages of culture. This is
in agreement with data presented by Murrills (1993). It was then observed that
apoptosis decreased over the course of the experiment, which was surprising
given the observation that when osteoclasts were grown on dentine at pH 7.4,
number decreased and sometimes had large vacuoles. It may be that as these
osteoclasts were not behaving as they normally would, owing to the fact that
they are on plastic rather than dentine. This adds further weight to the argument
that osteoclasts should be grown on dentine or an equivalent substrate to allow
them to resorb as they would in vivo. In order to ascertain the effect of acid on
apoptosis in osteoclasts grown on dentine an assay to assess this that allows
for osteoclasts to be culture on dentine could be performed in the future.
In order to determine whether growing on plastic rather than dentine was
affecting results, an LDH assay to assess cell viability was performed; this
assay could be performed on cells grown both on dentine and on plastic. This
assay revealed that there were no significant differences in osteoclast viability
when grown in acidic conditions compared with normal physiological pH (Fig.
3.4), which is broadly in agreement with results from the apoptosis assay (Fig.
3.3). Furthermore, no differences in viability were recorded between the two
substrates. The substrates did show, however, that there were differences in
cell number when osteoclasts were cultured on the more physiologically
relevant dentine compared to plastic. This has implications for in vitro research
as it would indicate that osteoclasts cultured on plastic, in addition to not being
to resorb, may not form in the same way as those cultured on dentine. The
results presented in this chapter, however, indicate that culture at pH 7.4 does
not affect osteoclast viability or induce apoptosis; as a consequence, there must
be another process in place to account for the differences in cell number
observed.
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One likely explanation is that switching osteoclasts to acidic culture
medium prevents osteoclast fusion. Osteoclasts cultured at pH 7.4 are not
‘switched on’ and so do not resorb, therefore they may continue the fusion
process. This will generate large cells and therefore decrease the overall cell
number, as more precursor cells progressively fuse to become less and less
osteoclasts. Osteoclast activation to resorb involves substantial changes to the
osteoclast structure and cytoskeleton, observed as polarisation and formation of
a ruffled border (Crockett et al. 2011) therefore osteoclasts at this point may be
unable to fuse to any more cells. This provides an area for further research and
regulation of the recently discovered osteoclast fusion molecule DC-STAMP
(Miyamoto 2006) may be an opportune place to begin.
Furthermore, this work reinforces the role of acid as the osteoclast
activation factor, rather than RANKL as proposed by (Boyle et al. 2003). It has
already been demonstrated that when osteoclasts are treated with RANKL at
physiological pH, they barely resorb, however, treatment with the same amount
of RANKL at pH 6.9 results in a 20-fold increase in resorption (Orriss & Arnett
2012). Osteoclasts cultured for the work presented in this chapter were treated
with the same amount of RANKL regardless of pH, but osteoclastic resorption
occurred when the pH had dropped to approximately 6.9.
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Chapter 4
Osteoblasts and the regulatory role of acid
Introduction
As previously outlined, acidosis has an overall detrimental effect on the
skeleton. Previous work has shown that acidosis (pH 6.9) prevents bone nodule
formation in vitro by inhibiting mineralisation of the collagenous matrix; this was
partly explained by dissolution of the mineral in a physico-chemical effect
(Brandao-Burch et al. 2005a). However, in the bone microenvironment most of
the phosphate required for incorporation into hydroxyapatite is generated by the
actions of alkaline phosphatase; when osteoblasts were cultured at pH 6.9,
alkaline phosphatase activity was reduced by approximately 80% compared to
those cultured at pH 7.37(Brandao-Burch et al. 2005b); therefore acidosis also
appears to be causing a cell-mediated negative effect on mineral deposition.
The mechanism by which acid prevented mineralisation, however, was
unknown and elucidating this mechanism was the focus of the work presented
in this chapter.
Hypothesis – Acidosis will cause up-regulation of E-NPP1, therefore resulting in
increased pyrophosphate production and so decreased mineralisation of the
collagenous matrix.
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Results
Acidosis inhibits mineralisation of the collagenous matrix by osteoblasts
Long term culture (14 days) of primary rat osteoblasts in acidotic medium (pH
6.9) prevents mineralisation of the collagenous matrix as demonstrated by lack
of alizarin red staining for calcium (Figs. 4.1C and 4.1D) compared to
osteoblasts cultured in medium at physiological pH (pH 7.4) (Figs 4.1A and
4.1B).
Figure 4.1 Acid inhibits mineralisation by primary rat
osteoblasts
Osteoblasts were cultured at pH 6.9 or pH 7.4 for 14 days.
Low power scans demonstrate a lack of alizarin red stained
bone nodules at pH 6.9 (C) compared to pH 7.4 (A). Phase
contrast micrographs (B) indicate the presence of collagenous
matrix but absence of alizarin red staining at pH 6.9 (D)
indicating that mineralisation did not occur. Scale bars: tissue
culture wells = 8.75mm, phase contrast micrographs = 800μm. 
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Osteoblasts express numerous E-NPPs and E-NTPdases but only E-NPP1
is up-regulated in osteoblasts cultured at pH 6.9
Osteoblasts were cultured for 14 days at pH 7.4 or pH 6.9. mRNA and protein
samples were taken at days 4, 7, 10 and 14 of culture. RT-PCR demonstrated
the presence of E-npp1, E-npp2 and E-npp3 and the E-ntpdases 2-6. Of these,
E-npp1 was up-regulated at all stages of differentiation when cells had been
cultured in acidosis compared to control (Fig. 4.2). Further analysis of E-NPP1
by Western blotting and immunocytochemistry revealed that protein levels of E-
NPP1 are also increased when cells had been cultured in acid conditions (Fig.
4.2). Multiple bands present are the result of different post-translational
modifications.
Figure 4.2 The effect of acid on expression of ecto-nucleotidases
RT-PCR revealed that expression of mRNA for E-NPP1 is up-
regulated when osteoblasts were cultured at pH 6.9. Alkaline
phosphatase, E-NPP2, E-NPP3 and E-NTPdase 2 mRNA
expression was decreased in acid. Expression of mRNA for E-
NTPdase 3─6 showed no difference between the two pH conditions. 
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Figure 4.3 Expression of E-NPP1 protein by osteoblasts cultured at pH 6.9 and pH 7.4
Western blotting (A) demonstrated that E-NPP1 expression was increased at all stages
of differentiation when osteoblasts were cultured at pH 6.9 compared with pH 7.4.
Immunocytochemistry at day 7 showed increased E-NPP1 expression (green) at pH
6.9 (C) compared to pH 7.4 (B). DAPI staining of cell nulcei is blue. Negative control =
(D). Scale bar = 50µm.
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Total E-NPP activity is significantly increased at days 7 and 10 of culture
in osteoblasts cultured at pH 6.9
An enzyme assay was performed to determine total E-NPP activity in
osteoblasts cultured at pH 6.9 compared to pH 7.4 at days 4, 7, 10 and 14 days
of culture. Total E-NPP activity was increased at all time points, but significantly
at days 7 and 10 (Fig. 4.4).
Figure 4.4 Total E-NPP activity is increased in
osteoblasts cultured at pH 6.9
Osteoblasts show increased E-NPP activity when
cultured at pH 6.9 at days 4, 7, 10 and 14. E-NPP
activity is increased by 50% at day 7 and 1.4-fold at
day 10 at pH 6.9 compared with pH 7.4 (n = 6, *** = p
<0.001, * = p<0.05).
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Exposure to acidotic medium effects phosphate and pyrophosphate
generation by osteoblasts
Osteoblasts were either cultured at pH 7.4 for the duration of the experiment
and then transferred to pH 6.9 one hour prior to the assays being performed or
were cultured for the entirety at pH 6.9. In both cases a control group at pH 7.4
was treated in the same way. Short term exposure resulted in significantly
increased generation of phosphate but no significant change in pyrophosphate
generation (Fig. 4.5 A). Long term culture at pH 6.9 caused significant
increases in both phosphate and pyrophosphate generation (Fig. 4.5 B).
Figure 4.5 Exposure to short term and long term acidosis affects
phosphate and pyrophosphate generation by primary rat osteoblasts
Osteoblasts were cultured for 10 days at pH 7.4 and then transferred to
pH 7.4 or pH 6.9 one hour (A). The amount of phosphate generated was
significantly increased, but pyrophosphate generation was reduced
slightly. When osteoblasts were cultured for 14 days at either pH 7.4 or
pH 6.9 (B), there were significant increases in amounts of both phosphate
and pyrophosphate generated. (n = 12, *** = p <0.001, ** = p<0.01 * =
p<0.05).
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Figure 4.6 Acidosis does not
affect ATP release by
osteoblasts
Osteoblasts were cultured for
between 4 and 14 days at either
pH 7.4 or pH 6.9. ATP release
was measured using a
luminometer. Acidosis did not
result in any significant changes
in ATP release at any stage of
culture. Cell viability assays were
performed alongside. (n = 12).
Acidosis does not affect ATP release by osteoblasts in vitro
ATP is a known inhibitor of mineralisation (Fig 1.3) (Orriss et al. 2007) and is
released by osteoblasts following exposure to stress; therefore it was
hypothesized that acidosis might stimulate ATP release by osteoblasts which
may in turn inhibit mineralisation. Osteoblasts were cultured for up to 14 days at
pH 7.4 or pH 6.9, a luminescent assay to detect ATP release was performed at
days 4, 7, 10 and 14 of culture. ATP release increased with osteoblast
differentiation, however, there was no significant differences in ATP release
between the two pH groups (Fig. 4.6). Quinacrine staining also showed no
differences in ATP containing vesicles in osteoblasts at pH 6.9 compared with
pH 7.4.
*
culture time (days)
4 7 10 14
AT
P
re
le
as
e
pe
ro
st
eo
bl
as
t(
fm
ol
es
)
0
1
2
3
4
5 pH 7.4
pH 6.9
Chapter 4 Osteoblasts and the regulatory role of acid
92
Figure 4.7 Quinacrine staining of osteoblasts
Osteoblasts were cultured for 10 days at either pH 7.4 or pH 6.9, they were then
transferred to DMEM containing the ATP-binding dye quinacrine, adjusted to the
correct pH for one hour before visualising. These images show no differences in
quinacrine binding to ATP between the two pH values.
Discussion
The deleterious effect of acid on the skeleton has been known for almost 100
years (Goto 1918). The skeleton provides a large store of base to buffer excess
acid that occurs in the body as a consequence of metabolic acidosis. Metabolic
acidosis is caused by kidney disease, respiratory acidosis by chronic respiratory
disease. Systemic acidosis can result from: a high protein diet, ingestion of
inorganic acid, aging and the menopause (Arnett 2010). More localised
acidosis occurs owing to reduced vascular supply, which is in turn a
consequence of inflammation, infection, tumours, diabetes and aging.
In addition to buffering these body-wide effects, it was observed that acid
had a direct effect on osteoblasts whereby acid prevented mineralisation of the
deposited collagenous matrix (Fig. 4.1). This effect is not simply a physico-
chemical instance of acid dissolving mineral (Brandao-Burch 2005a).
Mineralisation of collagenous bone matrix is regulated by the ratio of
phosphate to pyrophosphate within the bone microenvironment; inorganic
phosphate (Pi) is required as a component of the hydroxyapatite that comprises
the mineral matrix. Pyrophosphate (PPi) is a potent inhibitor of mineralisation
Chapter 4 Osteoblasts and the regulatory role of acid
93
(Fleish & Neuman 1961; Thouverey et al. 2009). Several enzymes produce
either Pi or PPi from nucleotides and these were investigated as potential
targets of the action of acid. Of the family of E-NPP and E-NTPdases tested,
the only enzyme up-regulated in osteoblasts grown in acidic conditions was E-
NPP1; this enzyme has also been reported to be the most highly expressed of
this family of enzymes in bone (Vaingankar et al. 2004). E-NPP1 has already
been shown to have a role in the regulation of mineralisation within the body; E-
NPP1 deficiency results in infantile arterial calcification (Rutsch et al. 2003)
The disease is characterised by calcification of muscular arteries, and
their abnormal narrowing owing to migration of cells from the muscle layer of
the arterial wall migrating to a sub-endothelial site and ‘organising’ deposits on
the vessel wall (Rutsch et al. 2003). Of twelve individuals identified with this
disease, all had mutations that resulted in inactive E-NPP1. Seven of these
individuals died within 45 days of birth, one died at 6 months of age, the
remaining four were still alive at two, three, 6 and 16 years of age (Rutsch et al.
2003). This analysis provides evidence that E-NPP1 is responsible for
generating PPi in order to maintain the Pi/PPi at levels to prevent mineralisation
of the soft tissue.
E-NPP1 protein was shown to be up-regulated at all stages of osteoblast
differentiation. In addition, total E-NPP activity was also up-regulated at all
stages of differentiation, though only significantly at days 7 and 10 but, in vitro,
this would be the stage at which osteoblasts are mineralising. E-npp1
expression appears to peak and then drop in mature osteoblasts, other E-npps
and E-ntpdases are either unaffected by stage of differentiation or later stages
of differentiation result in higher levels of gene expression, thus potentially
explaining the lack of significant effect in total E-NPP activity seen at day 14. To
date there is not a commercially available assay to determine E-NPP1 activity
alone, should one become available, this would provide a useful addition to this
work.
As E-NPP1 hydrolyses nucleotide triphosphates to generate a nucleotide
monophosphate and PPi, a logical deduction would be that acid would cause an
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increase in pyrophosphate generation and a decrease in phosphate generation;
however, results presented show something different, when exposed to acidic
medium for a period of one hour, there is no significant change in
pyrophosphate levels but phosphate generation is significantly increased by
approximately 40%. In osteoblasts cultured long term at pH 6.9, phosphate
generation is again increased by a similar amount; however, pyrophosphate is
also significantly increased, by 54%.
Where osteoblasts have been cultured for an extended period of time at
pH 6.9, pyrophosphate is increased as anticipated, this could account for the
decreased mineralisation observed. The increase in phosphate generation
however, does not appear to fit in with current understanding of the control of
mineralisation. It could be that there is a feedback mechanism at work whereby
the osteoblasts detect the extracellular acid and consequently generate
phosphate to buffer the decrease in pH. However, previous work has shown
that in osteoblasts cultured in acidic medium, alkaline phosphatase activity is
reduced (Brandao-Burch et al. 2005b), so that would imply the increases in
phosphate generation seen here are not due to alkaline phosphatase activity,
but rather another enzyme responsible for phosphate generation. RT-PCR
presented here has shown that E-NTPdase 5 and E-NTPdase 6 expression
(Fig. 4.1) is not affected by growing osteoblasts in culture that is slightly acidic.
these enzymes, however are currently thought to only be localised intracellularly
(Yegutkin 2008) so are unlikely to have a role in Pi generation in the extra
cellular environment.
The phosphate generating enzyme PHOSPHO 1 could be a potential
candidate responsible for the increased phosphate generation. The enzyme has
already been implicated in generating phosphate for matrix mineralisation
(Ciancaglini et al. 2010); Phospho1-/- animals have been generated, they are
smaller than age matched wildtype controls, show growth retardation and have
shorter bones (Yadav et al. 2011). These animals eat and drink less than
wildtype littermates and show reduced chewing, thought to be due to soft jaw
bones and incorrectly developed teeth. Thoracic scoliosis was present in
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approximately 30% of animals at day 10 and in 100% when they had reached
one month in age. This deformity progressively worsened. Histological analysis
demonstrated reduced alizarin red staining, indicative of a reduction in
mineralisation of the trabeculae. The femurs of these animals had increased
cortical porosity and decreased cortical thickness (Yadav et al. 2011).
These observations indicate that PHOSPHO1 has an important role in
mineralisation of the bone matrix. The pH optimum for this enzyme is reported
to be pH 6.7. (Roberts et al. 2004). PHOSPHO1 actually has two types of
activity: phosphocholine activity and phosphoethanolamine activity. Each has
separate pH dependent activity, however, both peak at pH 6.7. Interestingly, the
activity of PHOSPHO1 drops at pH levels above 7.2 (Roberts et al. 2004),
therefore suggesting that when pH is at normal physiological levels, activity is
not as important as at more acidic pHs. As the pH optimum of PHOSPHO 1 is
pH 6.7, it may have an important role as a homeostatic regulator of Pi
generation.
It is known that at acidic pH, alkaline phosphatase decreases (Brandao-
Burch et al. 2005b) resulting in decreased production of phosphate; E-NPP1
activity increases, and in theory should result in an increase in pyrophosphate
production. Pi and PPi assays, however, have not given the results expected,
so potentially, PHOSPHO 1 may function to correct the lack of phosphate as the
osteoblasts are able to detect that mineralisation is not occurring and this may
result in increased phosphate generation via PHOSPHO 1 to provide Pi for
incorporation into the hydroxyapatite. This provides a potential area for further
investigation.
Another protein that may be worth investigating is progressive ankylosis
protein (ANK). ANK spans the cell membrane and transports PPi from within the
cell to the extracellular space, it regulates the levels of PPi both intra- and extra-
cellularly, where it contributes to the ratio of Pi/PPi (Ho et al. 2000). Although E-
NPP1 is responsible for the majority of PPi in the extracellular bone
microenvironment, ANK does contribute to this store (Johnson et al. 2003). The
effect of acid on expression of this protein may account for the PPi levels being
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lower than expected if acid down-regulates expression. As PPi levels are lower
than anticipated I would hypothesise that ANK is down-regulated in acidotic
conditions and therefore less PPi is channelled into the extracellular space.
Our laboratory recently acquired E-npp1-/- mice and investigating the
responses to acid of osteoblasts from these animals may provide a clearer idea
of the exact role of E-NPP1 in the striking absence of matrix mineralisation
owing to acidosis. Work presented recently demonstrated that E-npp1 knockout
animals have reduced resistance to bending, hypomineralisation of the long
bones, reduced trabecular number at both 6 and 22 weeks of age, a decreased
percentage bone volume to tissue volume (%BV/TV) ratio, an increased cortical
thickness but increased bone mineral density. The researchers propose that
this paradox is due to the smaller size of the E-npp1 deficient animals
compared to the wildtype animals. Osteocalcin is decreased when animals are
6 weeks of age but by 22 weeks levels are comparable. The resorption marker
C-terminal telopeptide (CTx) is the same at 6 weeks but by 22 weeks is
significantly reduced. Alkaline phosphatase is increased, as are levels of the
phosphate regulator FGF23 (Mackenzie et al. 2011). Preliminary micro X-ray
computed tomography (micro-CT) scans from our laboratory of spines from E-
npp1 knockout animals compared with wildtype show ectopic mineralisation of
the intervertebral discs (unpublished data).
Adenosine triphosphate (ATP) is well documented as an inhibitor of
mineralisation (Boskey et al. 1992; Zhang et al. 2005; Orriss et al. 2007). Cell
stress has been reported to cause ATP release for example, hypoxia causes
ATP release from primary rat osteoblasts (Orriss et al. 2009) and fluid shear
stress has been reported to cause ATP release from MC3T3-E1 mouse-derived
osteoblast-like cells (Genetos et al. 2005). Additionally, mechanical loading of
the human osteoblastic cell line Te85 and the human osteosarcoma cell line
with osteoblastic properties, SaOS-2, has been reported to increase ATP
release from these cells (Rumney et al. 2008a; Rumney et al. 2008b).
As a consequence, it was investigated whether acidosis could cause
ATP release from osteoblasts; this ATP could then act upon the very
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osteoblasts it was released from in a feedback loop via P2 receptors to inhibit
bone formation (Orriss et al. 2007). Results presented here, however, show that
osteoblasts exposed to acidosis within the physiological range demonstrate no
changes in ATP release and, thus, the decreased mineralisation observed
under acidotic condition is not due to increases in ATP release. Certainly more
acidic conditions may result in ATP release from osteoblasts but levels of acid
needed will be on at least near the borderline of being physiologically relevant
and so this has not been investigated further.
There are several animal models of pathological mineralisation states
and genes and proteins implicated in these processes may also be affected by
changes in pH. The focus of future work could move to these.
The actions of E-NPP1, TNAP, PHOSPHO 1 and ANK are intrinsically
linked. In order to understand the exact mechanism by which acid inhibits
mineralisation, the actions of both PHOSPHO 1 and ANK under acidic
conditions need to be determined in addition to those of E-NPP1 and TNAP.
Chapter 5 TRP channels and bone cell function
98
Chapter 5
TRP channels and bone cell function
Introduction
The mechanisms by which small pH drops within the normal physiological range
are detected and transduced to the cells are still unknown. The TRP group of
ion channels have been identified as potential sensors of changes in pH by
bone cells. The aims of this chapter were to determine the roles of TRPV1 and
other TRP channels in mediating the responses of osteoclasts and osteoblasts
to the stimuli of extracellular pH.
Hypothesis – TRPV1 will act as the acid-sensor in osteoclasts and osteoblasts,
demonstrated by the TRPV1 agonist, capsaicin, (1) stimulating osteoclastic
resorption at physiological pH; (2) preventing matrix mineralisation by
osteoblasts cultured at pH 7.4. Osteoclasts isolated from TRPV1-/- will not
resorb when culture medium is acidified.
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Results
TRPV1 protein is expressed by mouse and human osteoclasts
TRPV1 expression on osteoclasts was investigated using immunofluorescence.
Clear expression of TRPV1 protein was evident on both mouse (Fig. 5.1 A) and
human (Fig. 5.1 C) osteoclasts.
Figure 5.1 TRPV1 expression by mouse and human osteoclasts
TRPV1 expression in osteoclasts was studied by immunofluorescence
using specific primary polyclonal antibodies, a Cy3-labelled anti-rabbit
secondary antibody (red) and DAPI nuclear stain (blue). The image in (A)
shows TRPV1 expression on a mouse osteoclast at day 10 of culture and
(B) the negative control. (C) Human osteoclasts also express TRPV1
channels. (D) Negative control image. Scale bar = 150μm.
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TRPV1 protein is up-regulated in mouse osteoclasts cultured at pH 6.9
Mouse osteoclasts were grown at pH 7.4 continuously or pH 7.4 and then pH
6.9 for the 48 hours prior to protein collection. Western blotting demonstrated an
increase in amount of TRPV1 detected in osteoclasts that were subject to pH
6.9 medium (Fig. 5.2).
Capsaicin does not affect mouse osteoclast formation or resorption
Osteoclasts were grown for 7 days at pH 7.4 and then 7.4, 7.2 or 6.9 for the
final 48 hours. To determine capsaicin’s effect on osteoclast formation,
capsaicin at concentrations of 5nM–5µM were added at the same time as
RANKL. In order to determine effects on osteoclast resorption, capsaicin was
added at the same time as acidification. If TRPV1 was the acid sensor, agonists
of this channel would be expected to mimic the effects of acid at physiological
pH. Capsaicin had no effect on formation of osteoclasts or osteoclastic
resorption in contrast to the profound stimulatory effects of acid (Figs. 5.3 and
5.4).
Figure 5.2 TRPV1 protein expression is
increased in mouse osteoclasts cultured at
pH 6.9 compared to pH 7.4
Mouse osteoclasts were cultured for either
12 days at pH 7.4 or 10 days at pH 7.4
followed by two days at pH 6.9. Western
blotting detected the TRPV1 protein which,
has a size of approximately 100kDa, is up-
regulated when osteoclasts were acid
activated.
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Figure 5.3 Capsaicin does not affect osteoclast formation or activation
Osteoclasts were cultured for 8 days at pH 7.4, for the final 48 hours pH was
either kept at pH 7.40 or adjusted to 7.23 or 6.96. To investigate the effect of
capsaicin on osteoclast activation, capsaicin was added for the final 48 hours of
culture at concentrations of 5nM─5µM (ethanol vehicle was added to control 
groups); capsaicin had no effect on osteoclast activation when compared to
control groups. (A) pH 7.40 control, (B) pH 7.40 5µM capsaicin, (C) pH 7.23
control, (D) pH 7.23 5µM capsaicin, (E) pH 6.96 control, (F) pH 6.96 5µM
capsaicin. (Red/purple = TRAP stained osteoclasts, orange = resorption
pits/trails.) Scale bar = 150µm.
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Figure 5.4 Lack of effect of capsaicin on osteoclast formation or activation
Osteoclasts were cultured for 8 days at pH 7.4, then at pH 7.4, 7.2 or 6.9
for the final 48 hours. Capsaicin was added at 5nm-5µM, at the same time
as RANKL to determine effects on osteoclast formation, or 48 hours prior to
termination to determine effects on resorption. Capsaicin had no effect on
the number of osteoclasts formed (A) or on osteoclast activation (B). (n =
8).
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TRPV1-/- osteoclasts show no differences in their ability to resorb
dentine when compared to wildtype osteoclasts
In order to ascertain whether TRPV1 was the ‘acid sensor’ in bone cells,
knockout osteoclasts were cultured to determine responses to acid. Trpv1-/-
mouse marrow was kindly donated by Prof. Bernd Nilius (Catholic University of
Leuven, Belgium) and results show that resorption per osteoclast was
comparable to wildtype osteoclasts at pH 6.9 (Fig. 5.5).
Figure 5.5 TRPV1-/- osteoclasts are stimulated to resorb by acid
Wildtype (A) and Trpv1-/- (B) osteoclasts (black arrows) show
characteristic resorption pits (red arrows) when they have been
stimulated to resorb by culture at pH 6.9. Osteoclasts from
Trpv1-/- mice resorb a comparable amount to those isolated from
wildtype animals (C). Scale bar = 50µm. (n = 8).
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TRPM8 agonists have no effect on osteoclast formation and activity
Menthol has previously been shown to inhibit osteoclastic bone resorption in
vivo (Muhlbauer et al. 2003). Icilin and menthol were tested to determine
whether they influenced osteoclast formation and activity. Both agonists failed
to affect either the formation or activation of human osteoclasts from peripheral
blood mononuclear cells (Fig. 5.6).
Figure 5.6 Icilin has no effect on osteoclast formation or activation
(A) Osteoclasts (black arrows) under control conditions and (B)
associated image under reflected light to visualise resorption (red
arrows). (C) Osteoclasts exposed to 10μM icilin and (D)
corresponding reflected light image. Icilin at 1nM–10µM does not
affect osteoclast formation (E) or activation (F). Treatment with
menthol at the same concentrations was similarly without effect (data
not shown). Scale bar = 150μm. (n = 8).
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Murine osteoclasts express Trpv4 but not Trpv3 mRNA
RT-PCR was performed on mRNA isolated from mature osteoclasts. Levels of
mRNA were normalised using the housekeeping gene, Gapdh. Trpv4 mRNA
was clearly expressed by mature osteoclasts, whereas Trpv3 mRNA was
absent (Fig. 5.7).
TRPV1 protein is expressed by rat osteoblasts
Immunofluorescence demonstrated TRPV1 expression by mature bone forming
osteoblasts (Fig. 5.8).
Figure 5.8 Primary rat osteoblasts express TRPV1
TRPV1 expression in osteoblasts was studied by immunofluorescence using
specific primary polyclonal antibodies, Cy3-labelled anti-rabbit secondary
antibody (red) and DAPI nuclear stain (blue). TRPV1 expression was evident
in mature osteoblasts and appeared to be localised intracellularly (A);
corresponding negative staining in (B). Scale bar = 150μm. 
Figure 5.7 Mouse osteoclasts express Trpv4
but not Trpv3 mRNA
RNA was extracted from osteoclasts cultured for 10
days at pH 7.4. Trpv4 mRNA was strongly expressed
on mouse osteoclasts; however, Trpv3 mRNA was
not detected. Samples were normalised with mRNA
for the housekeeping gene Gapdh.
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The TRPV1 agonist capsaicin does not affect bone formation by
osteoblasts or their proliferation
Acid inhibits bone mineralisation by osteoblasts (Fig. 4.2) and, thus, the TRPV1
agonist capsaicin was added to osteoblast cultures to determine whether it
could also mimic the effect of acid and inhibit mineralisation in osteoclasts
cultured at physiological pH (pH 7.4). Capsaicin was also added to cells at pH
6.9 to provide an ‘acid’ reference group. Results obtained indicate that long
term culture with capsaicin at concentrations between 2nM-20µM have no effect
on bone formation in vitro, nor does capsaicin affect the proliferation of
osteoblasts at either pH 7.4 or pH 6.9 (Figs. 5.9, 5.10 and 5.11).
Figure 5.9 Capsaicin does not affect bone nodule formation by
osteoblasts
Long term culture of primary rat osteoblasts with 20μM capsaicin 
does affect the number or appearance of alizarin red stained bone
nodules formed by primary rat osteoblasts (C and D) when
compared to bone nodules grown under control conditions (A and
B). White scale bar = 800μm, black scale bar = 3.75mm.
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Figure 5.10 Capsaicin has no effect on the bone forming
capacity of osteoblasts.
Primary rat osteoblasts were cultured for 14 days at pH 7.4 or pH
6.9 with 2nM-20µM capsaicin. Cultures were terminated at day
14. Capsaicin has no reproducible effects on bone formation by
osteoblasts (n= 6).
Figure 5.11 Capsaicin does not affect the proliferation of
osteoblasts.
Capsaicin at 2nM─20µM had no effect on proliferation of rat 
osteoblasts cultured at pH 7.4 or pH 6.9 for 15 days (n = 6).
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The TRPV1 antagonists’ capsazepine and N-(3-methoxyphenyl)-4-
chlorocinnamide (SB 366791) do not affect bone formation by primary rat
osteoblasts.
Capsazepine is a synthetic TRPV1 antagonist, generated by altering the side
chain region of capsaicin (Walpole et al. 1994). Osteoblasts were cultured for
14 days in the presence of capsazepine or SB 366791 at pH 7.4 or 6.9. Both
capsazepine and SB 366791 had no effect on primary osteoblasts’ ability to
form bone nodules in vitro. (Figs. 5.12, 5.13 and 5.14). If TRPV1 was the only
acid-sensing receptor, adding these antagonists to osteoblasts cultured at pH
6.9 would be expected to block the acid-sensing part of the receptor and so
osteoblasts would produce the classic bony nodules made by osteoblasts in
vitro.
Figure 5.12 The TRPV1 antagonists capsazepine and SB366791 do not affect bone
nodule formation by primary rat osteoblasts in vitro.
2nM–2µM capsazepine or SB366791 did not affect alizarin red stained bone nodule
formation by osteoblasts at either pH 7.4 or pH 6.9. Well width = 1.5mm.
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Figure 5.13 Capsazepine does not affect bone nodule formation
Capsazepine at concentrations between 2nM─20µM had no effect 
on bone nodule formation by primary rat osteoblasts at either pH
7.4 or 6.9. (n = 6).
Figure 5.14 SB366791 does not affect bone nodule formation
Bone nodule formation by osteoblasts at pH 7.4 is decreased following
additions of SB 366791 at concentrations of up 20µM though this is not
statistically significant. At pH 6.9, bone nodule formation is unaffected at
all concentrations of SB 366791 tested. (n = 6).
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Rat osteoblasts express Trpv3 and Trpv4 mRNA
In addition to TRPV1, there are a number of other TRP channels which are
reported to detect protons, these include TRPV3 and TRPV4 (Bandell et al.
2007; Holzer 2009). Both Trpv3 and Trpv4 mRNA were expressed on
osteoblasts at both 7 and 14 days of culture (Fig. 5.15).
The TRPV4 agonist, 4 α-phorbol 12,13-didecanoate (4αPDD) is cytotoxic to 
osteoblasts at concentrations above 1µM
As TRPV4 has a similar structure and has been reported to work in a similar
way to TRPV1, it was investigated as a potential acid-sensor. To determine if
4αPDD was able to mimic acid, it was added to osteoblast cultures at 
concentrations between 1nM and 10µM at pH 7.4 and also at pH 6.9 to provide
an acid control. Bone formation was inhibited at concentrations of 1µM and
above (Fig 5.16); however, a viability assay performed on osteoblasts showed
that at concentrations of above 1µM 4αPDD was cytotoxic to osteoblasts (Fig.
5.17).
Figure 5.15 TRPV3 and TRPV4 mRNA is
expressed by primary rat osteoblasts
RNA was extracted from osteoblasts cultured
for 7 or 14 days at pH 7.4. Trpv3 and Trpv4
mRNA was expressed at both time points
Samples were normalised with mRNA for the
housekeeping gene, β-actin.
Figure 5.16 TRPV4 agonist
4αPDD is cytotoxic at 
concentrations >1µM
Bony nodule formation at pH
7.4 was inhibited at
concentrations of 1µM
4αPDD and above because 
long term culture results in
cytotoxicity.
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Figure 5.17 TRPV4 agonist 4αPDD is cytotoxic to osteoblasts at 
concentrations of 1µM and above
1nM─100nM 4αPDD did not affect bone formation (A); however, at
concentrations of 1 and 10µM significant decreases in bone nodule
formation were observed. Viability assays demonstrated that 4αPDD 
(1nM─10μM) is cytotoxic to osteoblasts, at pH 7.4, 10µM was cytotoxic 
from day 7 and 1µM from day 10 (B). At pH 6.9 (C), 4αPDD was 
cytotoxic at 10µM day 4 and 1µM from day 10 of exposure. (n = 6, * = p
<0.05, ** = p <0.001 *** = p <0.001).
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Figure 5.19 The effect
of ruthenium red on
bone formation by
osteoblasts in vitro.
Ruthenium red
significantly inhibited
bone nodule formation
by primary rat
osteoblasts at
concentrations above
100nM at physiological
pH. At pH 6.9,
ruthenium red did not
affect bone formation.
(n = 6, ** = p <0.001).
Ruthenium red inhibits bony nodule formation at concentrations
greater than 100nM at physiological pH
Ruthenium red (RR) is an antagonist of several TRP channels including TRPV4.
Osteoblasts were cultured for 14 days in the presence of ruthenium red at
1nM─10µM at pH 7.4 or pH 6.9. At physiological pH, bone nodule formation 
was inhibited in osteoblasts cultured at pH 7.4 (Fig. 5.18, 5.19 and 5.20).
Ruthenium red had no effect on osteoblastic bone formation in cells cultured in
acidic medium.
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Figure 5.18 The
effect of ruthenium
red on bone
formation by
osteoblasts in vitro
Ruthenium red at
concentrations >1µM
inhibited osteoblastic
bone nodule
formation when
cultured for 14 days
at pH 7.4. (Well width
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Gadolinium chloride, a TRPV4 antagonist, does not affect bone nodule
formation by osteoblasts
Primary rat osteoblasts were cultured for 14 days in the presence of the TRPV4
antagonist gadolinium chloride at both pH 7.4 and pH 6.9. There was no effect
on bone nodule formation at either pH (Fig. 5.21).
Figure 5.21 Gadolinium
chloride does not affect the
bone forming capacity of
primary rat osteoblasts
At pH 7.4 and 6.9, long-term
culture of osteoblasts with
1nM–10µM gadolinium
chloride does not affect bone
nodule formation in vitro. Well
width = 1.5cm.
Figure 5.20 Ruthenium red
is cytotoxic to osteoblasts
Osteoblasts cultured for 14
days at pH 7.4 and with
ruthenium red (RR) for 14
days. Concentrations of
100nM and above resulted in
cell death. 10µM ruthenium
red caused significant
decreases in cell viability
from day 7. (n = 6, * = p
<0.05, ** = p <0.001 *** = p
<0.001).
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Figure 5.22 Gadolinium chloride has no effect on bone nodule
formation in vitro
At concentrations of 1nM─10µM gadolinium did not affect the bone 
forming capacity of primary rat osteoblasts in vitro when cultured at
pH 7.4 or pH 6.9 (n = 6).
TRPM8 mRNA is not expressed by primary rat osteoblasts
RT-PCR was used to investigate the expression of Trpm8 mRNA by osteoblasts
after 7 and 14 days of culture. Levels of mRNA were normalised using the
housekeeping gene, β-actin. Trpm8 mRNA was not detected in osteoblasts at
either day 7 or 14 (Fig. 5.23), in agreement with the lack of effect of both icilin
and menthol.
Figure 5.23 Lack of Trpm8 mRNA
expression by primary rat osteoblasts
Osteoblasts cultured were for 7 or 14
days at pH 7.4 or 6.9; TRPM8 mRNA
expression was not detected at either
time point or temperature. Rat brain
was used as a positive control.
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TRPM8 agonists do not affect osteoblast proliferation and function
The effects of the TRPM8 agonists’ menthol and icilin were investigated on both
osteoblast and osteoclast formation and activity. Menthol is the natural agonist
of TRPM8 and icilin is a higher potency synthetic agonist. Initially, menthol and
icilin were investigated at concentrations between 1nM─10µM on bone nodule 
formation by primary rat osteoblasts. At all concentrations tested, menthol and
icilin failed to have any effect on bone formation at either pH 7.4 or pH 6.9.
Furthermore, neither agonist affected osteoblast proliferation, assessed using
the LDH assay (Figs. 5.25 B and 5.25 D). The medium pH was maintained at
either physiological (pH 7.4) or acid (pH 6.9) levels throughout the duration of
the culture. Bone matrix mineralisation was inhibited by the acid conditions
(Figs. 5.24, 5.25 A and 5.25 C), in agreement with published results (Brandao-
Burch et al. 2005b).
Figure 5.24 The TRPM8
agonists’ icilin and menthol
do not affect the bone
forming capacity of primary
rat osteoblasts
At pH 7.4 and 6.9, long term
culture of osteoblasts with 1–
100nM icilin or menthol do
not affect bone nodule
formation in vitro. Well width
= 1.5cm.
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Figure 5.25 TRPM8 agonists icilin and menthol do not affect the bone forming
capacity of osteoblasts or their proliferation
Icilin at 1nM─10µM had no effect on bone nodule formation by osteoblasts  (A) or on
their proliferation at pH 7.4 (B). (C) Menthol at 1nM─10µM did not effect on bone 
nodule formation by osteoblasts (D); osteoblast proliferation was unaffected by
menthol in the range 1nM─10μM at pH 7.4. (n = 6).
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Discussion
The negative effect of acid on the skeleton has been known for many years;
more recently it was shown that in addition to acting as a fail-safe store of base
to buffer low pH during times of acidosis, acid is actually able to elicit direct
effects on bone cells themselves (Arnett & Dempster 1986; Brandao-Burch et
al. 2005b). Currently the mechanism by which osteoclasts and osteoblasts
detect low pH is unknown. Experimental work carried out in this chapter set out
to determine whether proton-sensing members of the TRP family of ion
channels may be responsible for acid-sensing by bone cells.
Work presented in this chapter has demonstrated the presence of
several TRP channels on both osteoclasts and osteoblasts. TRPV1 is
expressed by both murine and human osteoclasts. TRPV1 protein levels are
increased in murine osteoclasts cultured in acidic conditions. TRPV1 has also
been shown to be expressed by primary rat osteoblasts. This is in agreement
with Idris et al, who are the first to have published this (Idris et al. 2010). TRPV1
expression however appears to be localised intracellularly within osteoblasts
(Fig. 5.8) rather than on the cell membrane where it would be expected to be
present. Further immunofluorescence could be performed ensuring the cell
membrane is not lysed to reveal whether TRPV1 is expressed at the cell
membrane of osteoblasts. TRPV4 mRNA was expressed by murine osteoclasts
and rat osteoblasts. TRPV3 mRNA was expressed by rat osteoblasts but could
not be detected on osteoclasts. TRPM8 could not be detected on osteoblasts.
Capsaicin, a TRPV1 agonist, was added to cultures of pre-osteoclasts
and mature osteoclasts to determine if it had an effect on osteoclast formation
or activity, respectively. Osteoclasts are known to be stimulated to resorb by
drops in pH within the physiological range (Arnett & Dempster 1986). It was
hypothesised that if TRPV1 was functioning as the acid-sensor in osteoclasts,
then even when cultured at physiological pH, capsaicin may be able to stimulate
osteoclasts to resorb. However, the foregoing examples show that this was not
the case. TRPV1 activation is complex as it can occur in two distinct ways,
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either the channel is stimulated purely by protons which act via several key
amino acid residues (Val-538, Thr-633, Glu-648). Alternatively TRPV1 can be
initially sensitised by mild acidosis, whereby protons act via the Glu-600 amino,
TRPV1 is then activated fully following detection of capsaicin or heat (Ryu et al.
2007). Due to the nature of TRPV1 activation, a pH in between physiological
(pH 7.4) and acidotic (pH 6.9) was also tested in case the mild acidosis (pH 7.2)
was required for capsaicin activation. However, at pH 7.4 no resorption was
detected and at pH 7.2 no more resorption was observed in osteoclasts treated
with capsaicin compared with those in the control groups. This led to the
conclusion that capsaicin could not stimulate osteoclasts to resorb. This is in
agreement with results presented by Idris et al, who reported that at
concentrations of three µM and above, capsaicin has no effect on osteoclasts
(Idris et al. 2010). In order to confirm this, osteoclasts were obtained from
Trpv1-/- mice. Osteoclasts from these animals were still able to resorb when the
medium was acidified to pH 6.9. The knockout osteoclasts did however resorb
less than those from wildtype animals therefore indicating that TRPV1 may
contribute to acid-sensing. These results suggest that in osteoclasts, TRPV1
does not act as the sole acid-sensor. Capsaicin also had no effect on the bone
forming capacity of primary rat osteoblasts when cultured at either pH 7.4 or pH
6.9.
The TRPV1 antagonists tested in this study, capsazepine and N-(3-
methoxyphenyl)-4-chlorocinnamide (SB366791), also had no effect on the bone
forming abilities of primary rat osteoblasts cultured in vitro. Capsazepine and
SB366791 are both selective antagonists for TRPV1, and it is thought that they
act competitively against capsaicin for the same binding site. SB366791,
although a potent antagonist of TRPV1 when the channel has been stimulated
with TRPV1 agonists or noxious heat, is not able to antagonise the channel
when it has been stimulated with protons. It is proposed that all TRPV1
antagonists identified to date function by competing with capsaicin for the
capsaicin binding site, this causes a conformational change in TRPV1 that
keeps the channel closed when it is stimulated by capsaicin. However, when
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TRPV1 is stimulated by protons, certain antagonists, including SB366791 are
unable to generate the conformational change needed to close the channel.
Therefore, Ca2+ is still able to pass through TRPV1 and the channel is still
active (Gavva et al. 2005). The following TRPV1 antagonists, which were not
commercially available at the time the work was carried out, inhibit the channel
allosterically when it is stimulated by protons and are able to close the channel:
AMG 7472; BCTC, AMG 6880 and AMG 9810 (Gavva et al. 2005).
Of the other members of the TRPV family, TRPV4 was also investigated.
It has been reported to respond to acid in a similar way to TRPV1, although how
important its role as an acid-sensing receptor is remains to be determined given
that it also functions as both a mechano- and osmo-sensor (Holzer 2009).
mRNA for this channel was detected on both osteoblasts and osteoclasts. The
specific TRPV4 agonist 4αPDD was added to in vitro osteoblast cultures. At
concentrations of 1µM and above bone nodule formation was decreased,
however, further investigation revealed that at concentrations of 1µM and
above, 4αPDD was cytotoxic to osteoblasts in vitro. Assessment of viability in
this case was important as the results could have easily been misinterpreted as
an inhibition of bone formation. The assays used to assess bone formation
mimic a chronic system, whereby the cells are exposed to the agonist or
antagonist of interest for a sustained period of time thus providing an in vitro
system akin to the physiological situation.  If 4αPDD was able to stimulate 
TRPV4 and function as an acid-sensor, it would be expected that at
physiological pH, bone nodule formation would be inhibited. As this is not the
case, it would appear that TRPV4 is not acting as an acid-sensing receptor in
osteoblasts.
The effect of two TRPV4 antagonists, gadolinium chloride and ruthenium
red, on bone nodule formation was also tested. Given that they are
antagonists, it would be anticipated that if osteoblasts were detecting acid via
the TRPV4 channel, blocking it would result in a lack of an acid effect and, thus,
bone nodules would be made in vitro by osteoblasts that were cultured at pH
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6.9. For both ruthenium red and gadolinium chloride this was not the case and
bone nodule formation was inhibited when osteoblasts were cultured at pH 6.9
at all concentrations tested.
In addition to sensing pH, TRPV4 is more commonly associated with
temperature sensing; it detects temperatures between 27 and 34˚C and osmotic 
cell swelling (Venkatachalam & Montell 2007) and, therefore, it may not have a
role in acid sensing in bone cells, as evidence presented in this chapter would
suggest. Additionally, the TRPV antagonist, ruthenium red, has been reported
to block heat activation of TRPV4 (Watanabe et al. 2002) therefore ruthenium
red may not inhibit pH sensing. Also, some reports state that TRPV4 is not able
to detect acid until pH reaches levels of 6.0 and below (Holzer 2007). As a
consequence, TRPV4 may not function as an acid-sensor in bone cells because
it is unlikely that pH will drop to such levels in the bone microenvironment in a
healthy individual. Furthermore, although I detected mRNA for Trpv4 on cells,
this does not necessarily mean the protein has been translated; therefore it may
be that a functional TRPV4 channel is not expressed by bone cells.
Finally, TRPM8 was investigated. TRPM8 was investigated because it is
a ‘sister’ channel of TRPV1; although it has not been reported as an acid
sensor, it is stimulated by temperatures in the range 23─28˚C and functions as 
the ‘cool’ sensor. It is also stimulated by menthol and icilin. Icilin is a super-
agonist of TRPM8 and is 200 times more potent (Montell 2005). Both icilin and
menthol at the concentrations tested had no effect on either osteoclasts or
osteoblasts. RT-PCR revealed a lack of mRNA for TRPM8 and, therefore, it is
likely that the lack of effect seen is because TRPM8 is not expressed by bone
cells.
Although numerous TRP channels are expressed by bone cells,
evidence presented in this chapter would suggest that they do not act as the
acid-sensing receptor. Work published recently has shown TRP channels
working cooperatively with cannabinoid receptors in bone cells, where this
combination of receptors has been implicated as a potential target of
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osteoporosis treatments. TRP channels have also been hypothesised to work
with purinergic receptors. Both of these provide areas for further investigation.
The question remains, however, as to role TRP channels may play in
bone cell function. In addition to the TRP channels detected on bone cells
during this study, other TRP channels have also been detected. TRPC1,
TRPC3, TRPC4, TRPC6, TRPM4, TRPM6, TRPM7, TRPM8, TRPV2 and
TRPV4 mRNA has been detected on human osteoblast-like cells (Abed et al.
2009; Suzuki et al. 2011), murine osteoblast cell-lines additionally express
TRPC7 and TRPM1 but not TRPC3, TRPV2 or TRPV4 (Abed et al. 2009).
Furthermore the Trpv5-/- mouse is reported to have a bone phenotype, whereby
bone thickness is increased and bone resorption is defective (Hoenderop et al.
2003; van der Eerden et al. 2005). TRPV4 has already been shown to play a
part in mechanosensation in bone cells (Suzuki et al. 2003).
Some members of the TRP channel superfamily are able to act as
thermosensors; TRV1–4, TRPM8 and TRPA1 are all activated at varying
temperature ranges (Clapham 2003). Work performed at the beginning of this
PhD (not presented here) showed that human osteoclast formation was
increased 3-fold when osteoclasts were cultured at 34ºC compared to 37ºC; the
effect on murine osteoclast formation was similar (Patel et al. 2009).
Furthermore in vitro bone formation was decreased by 95% when cultured for
16 days at 34ºC in comparison to 37ºC (Patel et al. 2009). The mechanism by
which osteoclasts and osteoblasts detect and respond to changes in
temperature is currently unknown, but TRP channels may be involved in this
temperature detection.
Previous work in our laboratory has shown that the acid-sensing receptor
ovarian cancer G-protein coupled receptor 1 (OGR1) is expressed by primary
rat osteoblasts and human osteoclasts and is up-regulated in both when cells
are cultured in acidotic conditions. Similar up-regulation was reported for T cell
death-associated gene 8 (TDAG8). mRNA for GPR4 could not be detected
(Brandao-Burch 2005a). Osteoclasts isolated from Ogr1-/- and Tdag8-/- mice
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were able to respond to acidosis in the same way as wildtype, thus ruling these
receptors out as the acid sensor (Gasser et al. 2006).
Another set of acid-sensors that may have a role are the acid-sensing ion
channels (ASICs); these proteins are encoded by three genes: amiloride-
sensitive cation channel (ACCN) -1, - 2 and -3. Alternative splicing gives rise to
at least five subunits, these then assemble to generate to the different ASICs,
some of which have already been detected on bone cells. Human osteoblasts
express mRNA for ASIC1, 2 and 3 and human osteoclasts express mRNA for
ASIC1, 2, 3 and 4 (Jahr et al. 2005). Previous work in the laboratory has shown
that mRNA for ASIC1a was expressed by human osteoclasts, however this was
down-regulated when osteoclasts had been acid-activated (Brandao-Burch
2005a). ASIC3 is the most sensitive of the ASICs when pH drops within the
pathophysiological range, metabolic acidosis can reach a pH of 7.0 and, ASIC3
begins to open at pH 7.1 and fully activated at pH 6.5 (Birdsong et al. 2010).
Therefore the role of ASIC3 on bone cells is worth investigating.
TRPC5 detects decreases in pH from 7.4 to 7.0, however, because all
other TRP channels studied to date do not affect bone cell function, this may
not have a role on these cells either. There are many other families of acid-
sensing receptors that may have a role in acid sensing by osteoblasts and
osteoclasts (Holzer 2009) including TWIK (tandem of pore domains in weak
inward rectifier (K+) channels, TALK (TWIK-related alkaline pH-activated K+)
channels, TASK (TWIK-related acid-sensitive K+) and TRESK (TWIK-related
spinal cord K+) channels. Of these I have identified the following as the most
likely to be physiologically relevant in osteoclasts and osteoblasts because they
respond to small decreases in acidosis within the pathophysiological range:
TWIK-1, TALK-1 and -2, TASK-1, -2 and -3 (Duprat et al. 1997; Holzer 2009).
There is substantial evidence that clearly demonstrates the importance of
acid in regulating both osteoblastic bone formation and osteoclastic bone
resorption however, it seems likely that that deducing the mechanisms of pH
detection and signal transduction is likely to be a multi-factorial problem. Acid-
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sensing is one of the most tightly regulated of all the homeostatic mechanisms
(Frassetto et al. 1996) and it is probable that a degenerate system for acid
detection evolved. As a consequence, elucidating the receptor(s) that function
as the acid sensor in bone will prove a significant challenge for the future.
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Chapter 6
The role of acid in breast cancer-induced
osteolytic bone disease
Introduction
The damaging effects that breast cancer metastases have on bone are well
documented. Much work has been undertaken to understand the mechanisms
involved and to identify growth factors and cytokines that might contribute to the
destructive effect of osteolytic bone disease. The cancer microenvironment is
known to be acidic, and acid is known to stimulate osteoclastic resorption,
however little attention has been paid to the direct effect protons at this location
may have on resorption by osteoclasts. The aims of this chapter were to
determine the role acid has in stimulating osteoclastic resorption in the vicious
cycle model of cancer metastasis to bone. Additionally, cytokines implicated in
this model were investigated to determine their ability to stimulate osteoclast
formation and activation.
Hypothesis – (1) Activin A and BAFF will only be able to augment osteoclastic
resorption when they are first stimulated to resorb by acid; (2) co-culture of
breast cancer cells with osteoclast precursors will result in increased osteoclast
formation; (3) acid produced by the breast cancer cells will stimulate osteoclast
resorption.
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Materials and methods
Methods used were as described in chapter 2. A novel system was devised to
investigate the effects of acid produced by cancer cells on osteoclast activity.
These are outlined below.
Co-culture of breast cancer cells and osteoclasts – without cell-to-cell
contact
Osteoclasts were isolated and seeded onto dentine discs (5mm diameter) as
described in Chapter 2. Osteoclasts were allowed to adhere to the dentine for 24
hours. On the same day, cancer cells were trypsinised, collected and seeded
onto dentine discs, (1cm diameter) at 106 cells/disc for long-term culture or 5x106
cells/disc for short term culture in 1ml of MEM (without M-CSF or RANKL) and
allowed to adhere for 24 hours. Two dentine discs (5mm diameter) on which
osteoclasts had adhered were placed in the bottom of one well of a 24-well plate
in 2ml MEM, followed by a 1cm2 stainless steel grid on which a large dentine disc
(diameter = 1cm) on which cancer cells had been seeded was placed (Fig. 6.1).
To investigate either long- or short-term exposure to acid produced by
MCF-7 and MDA-MB-231 cells on osteoclasts, cells were cultured for 5 days or
48 hours, respectively. Half of the medium was replaced on day three. Culture
medium pH, pCO2 and pO2 were monitored daily, as described previously in
Chapter 2. Upon termination of the culture, large dentine discs were removed,
washed with PBS, trypsinised and a cell count performed. Some from each group
were fixed with 2.5% glutaraldehyde and stained with toluidine blue. Small
dentine discs were washed with PBS and then fixed in 2.5% glutaraldehyde for 5
minutes and stained for tartrate resistant acid phosphatase (TRAP) using the
leukocyte acid phosphatase kit according to the manufacturer’s instructions and
analysed as outlined in Chapter 2.
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Figure 6.1 Experimental set up for culture of osteoclasts and breast cancer cells without
cell-to-cell contact
Osteoclasts were seeded onto small dentine discs (5mm diameter), two were placed in
the bottom of a well in a 24-well plate, a 1cm2 stainless steel grid (B) was placed above
these discs, on top of this a large dentine disc (1cm diameter) on which the breast
cancer cells had been seeded was placed in 2ml MEM (D). Components of this
experimental set up (A) were two small dentine discs, a 1cm2 stainless steel grid, one
large dentine disc and in situ, without any culture medium (C).
Co-culture of breast cancer cells and osteoclasts – allowing cell-to-cell
contact
Osteoclasts were isolated as described previously and allowed to adhere to
dentine discs (5mm diameter) for 24 hours. Dentine discs were then transferred
into 6-well trays in 4 ml MEM/well. In order to determine long-term effects of co-
culture with MCF-7 or MDA-MB-231 cells, they were seeded directly into the
wells at a 106 cells/well. In order to determine short term effects of co-cultures,
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cancer cells were added 48 hours prior to the termination of the culture at a
density of 5x106/well. Upon termination of the culture, cells were fixed as
previously described. Discs were then stained with TRAP to demonstrate
osteoclasts; these were counted, and resorption analysed, as previously outlined.
Discs were then additionally stained with toluidine blue to identify the cancer
cells.
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Results
Activin A does not stimulate osteoclasts to resorb at physiological pH
Osteoclasts were cultured for up to 9 days in the presence of activin A at
concentrations of 0, 10 and 100 ng/ml. Osteoclasts were maintained at
physiological pH (7.4) for 7 days, then half the cells were transferred to medium
adjusted to pH 6.9 by addition of 10 meq/L H+ (as HCl). After 48 hours, pH was
recorded using a blood gas analyser, cells were fixed and TRAP stained.
Osteoclast cell number and resorption was analysed as outlined in Chapter 2.
Figures 6.2 and 6.3 show that activin A did not affect osteoclast formation nor
was it able to stimulate osteoclasts to resorb when cultured at physiological pH.
Figure 6.2. Effect of activin A on osteoclastic resorption
(A) Mouse osteoclasts (black arrows) resorb (red arrows) a small
amount when maintained at pH 7.4 for the duration of the experiment;
addition of activin A 100ng/ml (B) has no effect on osteoclast formation
or resorption. (C) Resorption by osteoclasts was increased when
medium was acidified to pH 6.91 for the final 48 hours in culture.
Addition of 100ng/ml activin A to acidified culture medium did not affect
resorption by osteoclasts (D). Scale bar = 100µM.
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Figure 6.3 Activin A does not affect osteoclast formation or resorptive
activity.
At concentrations of 10 and 100ng/ml, the cytokine activin A does not
affect osteoclast formation. Additionally, activin A does not stimulate
osteoclasts to resorb when cultured at physiological pH. Activin A is
unable to augment osteoclast resorptive activity when they are already
stimulated to resorb by addition of protons. (n = 8).
BAFF does not stimulate osteoclasts to resorb at physiological pH.
BAFF was added to osteoclast cultures 48 hours prior to their termination at
concentrations of two, 20 and 200 ng/ml in order to determine the effect on
osteoclastic resorption. Osteoclasts were maintained at either pH 7.4 for the
duration of the experiment or stimulated to resorb by adjusting the pH from 7.41
to 6.93 for the final 48 hours. BAFF was unable to stimulate osteoclasts to resorb
when they were maintained at physiological pH. Additionally, when osteoclasts
were stimulated by the addition of H+ to the culture medium, BAFF did not
augment resorption (Figs. 6.4). Additionally, BAFF had no effect on osteoclast
formation.
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Figure 6.4 BAFF does not affect osteoclast activation.
At concentrations of two, 20 and 200ng/ml, BAFF did not stimulate osteoclasts
to resorb at physiological pH. When osteoclasts had first been stimulated to
resorb by the addition of protons, BAFF is unable to alter the resorptive activity
of these osteoclasts. (n = 8).
Acidification of culture medium by MDA-MB-231 and MCF-7 human breast
cancer cells.
Cancer cells were seeded at different densities onto large dentine discs, (1cm
diameter) and placed in 2ml of MEM. Cells were half media changed at day
three of culture; medium pH was measured at this point and also at termination
on day 5, using a blood gas analyser. MDA-MB-231 and MCF-7, initially seeded
at 106 cells reduced the pH by 0.18 and 0.21 pH units, respectively (Figs. 6.5A
and 6.5B)
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Figure 6.5 Effect of seeding density of human breast cancer cells on culture
medium pH.
Cells were seeded at 106 / 1cm diameter dentine disc. (A) MDA-MB-231 cells
caused a maximum medium pH decrease of 0.17 units. (B) MCF-7 cells
caused a maximum pH decrease of 0.21 units.
MDA-MB-231 and MCF-7 human breast cancer cells inhibit osteoclast
formation when co-cultured without cell-to-cell contact
Mouse marrow derived osteoclasts were cultured in the presence of MDA-MB-
231 or MCF-7 cells for 5 days, medium had either 10meq/l OH- added in order to
maintain pH at ~7.3 for the duration of the experiment, or, 5meq/l OH- was added
to enable cancer cells to self-acidify the medium to approximately pH 7.1
Surprisingly for both cell types, culture with cancer cells resulted in highly
significant reductions in numbers of osteoclasts formed (Fig. 6.6 A).
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Figure 6.6 A Effect of pH and co-culture with human breast cancer cells
on osteoclast formation in mouse marrow cultures
Mouse marrow derived osteoclasts were cultured in the presence of M-
CSF and RANKL and human breast cancer cells. Co-culture with MDA-
MB-231 or MCF-7 resulted in significant decreases in numbers of
osteoclasts formed compared to osteoclast only controls regardless of
pH.
A, osteoclast formation at pH 7.31 (days 1-7).
B, osteoclast formation at pH 7.31 (days 1-5); resorption stimulated
(days 5-7) by acidification with 10meq/L H+ to pH 7.12.
C, osteoclast formation at pH 7.31 (days 1-5), resorption stimulated
(days 5-7) by acidification with 15meq/L H+ to 6.82.
D, osteoclast formation with MDA-MB-231 cells at pH 7.33 (days 1-7).
E, osteoclast formation with MDA-MB-231 cells at pH 7.33 (1-5 days); self-
acidification by MDA-MB-231 cells (days 5-7) to pH 7.14.
F, osteoclast formation with MCF-7 cells pH 7.37 (days 1-7).
G, osteoclasts formation with MCF-7 cells at pH 7.37 (1-5 days); self-
acidification by MCF-7 cells (days 5-7) to pH 7.
(n = 10, *** = p <0.001).
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MDA-MB-231 and MCF-7 human breast cancer cells significantly inhibit
osteoclastic resorption
Mouse marrow derived osteoclasts were cultured in the presence of M-CSF and
RANKL for 5 days before addition of MDA-MB-231 or MCF-7 cells for two days.
Culture medium had either 10meq/l OH- added in order to maintain pH at 7.3 for
the duration of the experiment, or 5meq/l OH- was added to allow cancer cells to
self-acidify the medium to approximately pH 7.00. For both cell types, culture
with cancer cells resulted in significant reductions in both the amount of
resorption carried out per osteoclast and, as osteoclast number was not affected
by addition of cancer cells for only two days, total resorption was also
significantly reduced. (Fig. 6.6 B).
Osteoclastic resorption is significantly increased when cultures are
allowed to self-acidify
Mouse marrow derived osteoclasts were cultured in the presence of M-CSF and
RANKL for 5 days. Human breast cancer cells without contact with the
osteoclasts were added for the final 48 hours of culture to determine the effect on
resorption. One group was maintained at approximately physiological pH by
addition of OH-, the other system was allowed to self-acidify via the metabolic
activity of the cancer cells. This self-acidification resulted in a decrease in pH
large enough to significantly increase the resorption carried out by osteoclasts,
as expected, without affecting their number (Fig. 6.6 C).
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Figure 6.6 B Effect of pH and co-culture with human breast cancer cells on osteoclastic
resorption
Osteoclasts were generated for 5 days at pH >7.3 from mouse marrow using M-CSF and
RANKL. Human breast cancer cells were then added for a further two days, without
direct contact with the osteoclasts, to determine their effects on acidification and
resorption. Co-culture of osteoclasts with either MDA-MB-231 or MCF-7 breast cancer
cells significantly decreased resorption.
A, osteoclast formation at pH 7.34 (days 1-7).
B, osteoclast formation at pH 7.34 (days 1-5); resorption stimulated (days 5-7) by
acidification with 10meq/L H+ to pH 7.17.
C, osteoclast formation at pH 7.32 (days 1-5); co-culture with MDA-MB-231 cells (days
5-7), with addition of 10meq/L OH- to prevent self-acidification (pH maintained at 7.29).
D, osteoclast formation at pH 7.32 (days 1-5); co-cultured with MDA-MB-231 cells (days
5-7), resulting in self-acidification to pH 6.98.
E, osteoclast formation at pH 7.31 (days 1-5); co-culture with MCF-7 cells (days 5-7),
with addition of 10meq/L OH- to prevent self-acidification (pH maintained at 7.30).
F, osteoclasts allowed to form at pH 7.31 (days 1-5), then co-cultured with MCF-7 cells
(days 5-7), resulting in self-acidification to pH 7.02.
(statistics: * compared to osteoclasts at pH 7.34 in column A, + compared to osteoclasts
at pH 7.17 upon termination of culture in column B. (n = 10, * = p <0.05, ** = p <0.001 ***
= p <0.001).
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Figure 6.6 C Acid activation of
osteoclasts when co-cultured with
human breast cancer cells.
Osteoclasts in co-culture with breast
cancer cells resorb significantly
more when the system was allowed
to self-acidify when compared to
those at physiological pH.
A, osteoclast formation at pH 7.32
(days 1-5); co-culture with MDA-
MB-231 cells (days 5-7), with
addition of 10meq/L OH-to prevent
self-acidification. (pH maintained at
7.32).
B, osteoclast formation at pH 7.32
(days 1-5); co-culture with MDA-
MB-231 cells (days 5-7), resulting in
self-acidification to pH 6.98.
C, osteoclast formation at pH 7.31
(days 1-5); co-culture with MCF-7
cells (days 5-7), with addition of
10meq/L OH- to prevent self-
acidification. (pH maintained at
7.31).
D, osteoclast formation at pH 7.31
(days 1-5); co-culture with MCF-7
cells (days 5-7), resulting in self-
acidification to 7.12.
(n = 10, * = p <0.05, ** = p <0.001)
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Figure 6.7 Formation of and resorption by osteoclasts is reduced when
co-cultured with MDA-MB-231 or MCF-7 cells
A, osteoclast formation at pH 7.34 (days 1-7).
B, osteoclast formation at pH 7.34 (days 1-5); resorption stimulated
(days 5-7) by acidification with 10meq/L H+ to pH 7.17.
C, osteoclast formation at pH 7.32 (days 1-5); co-culture with MDA-MB-
231 cells (days 5-7), with addition of 10meq/L OH- to prevent self-
acidification (pH maintained at 7.29).
D, osteoclast formation at pH 7.32 (days 1-5); co-cultured with MDA-MB-
231 cells (days 5-7), resulting in self-acidification to pH 6.98.
E, osteoclast formation at pH 7.31 (days 1-5); co-culture with MCF-7
cells (days 5-7), with addition of 10meq/L OH- to prevent self-acidification
(pH maintained at 7.30).
F, osteoclasts allowed to form at pH 7.31 (days 1-5), then co-cultured
with MCF-7 cells (days 5-7), resulting in self-acidification to pH 7.02.
Osteoclasts: purple/red; resorption trails/pits: orange. Red arrows
highlight some of the smaller resorption pits. Scale bar = 100µm.
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Figure 6.8 Cancer cell
control discs
MDA-MB-231 cells (A) and
MCF-7 cells (B) were
cultured on dentine discs for
7 days then fixed with
glutaraldehyde and stained
with toluidine blue.
Scale bar = 100µm.
Direct co-culture of MDA-MB-231 and MCF-7 human breast cancer cells
with marrow derived mouse osteoclasts
Osteoclasts were cultured directly with cancer cells to determine if cell-to-cell
contact between the two cell types affected osteoclast formation or resorption.
The cancer cells were able to out-compete the osteoclasts for space on the
dentine so barely any osteoclasts formed. (Fig. 6.9)
Figure 6.9 Direct co-culture of
osteoclasts with breast cancer
cells
Murine marrow derived cells were
cultured in the presence of M-CSF
and RANKL for 7 days, and with
MDA-MB-231 or MCF-7 breast
cancer cells. TRAP staining
(red/purple) revealed barely any
TRAP positive cells when co-
cultured directly with MDA-MB-231
cells (C) and none when co-
cultured directly with MCF-7 cells
(D). Staining with toluidine blue
demonstrated MDA-MB-231 cells
(E) and MCF-7 cells (F).
Osteoclast only controls under
transmitted light (A) and reflected
light to view resorption trails
(orange) (B). Scale bar = 100µm.
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Expression of genes, important in osteoclastogenesis and resorption, by
MCF-7 and MDA-MB-231 breast cancer cells
qRT-PCR was performed on cDNA generated from RNA extracted from MCF-7
and MDA-MB-231 cells. Cells were investigated for RANKL, M-CSF, OPG, IL-6,
TNFα, TGFβ1 and TGFβ2. RANKL expression was not detected in either cell
type. Results revealed that M-CSF was only expressed by MDA-MB-231 cells. As
such, the relative amounts compared between cell types cannot be carried out,
therefore the PCR products were run on a gel and visualised using ethidium
bromide and UV (Fig. 6.10). Additionally, IL-6 was shown to be expressed only
by MDA-MB-231.
Other genes investigated all demonstrated differences in expression levels
between the two cell types. OPG was expressed 10.95-fold higher in MDA-MB-
231 cells compared to MCF-7 cells. TNFα was decreased in MDA-MB-231 cells
by 16% compared to MCF-7. Both TGFβ1 and TGFβ2 were increased in MDA-
MB-231 cells compared to MCF-7s, 4.89- and 49.51-fold, respectively (Fig. 6.11).
Figure 6.10 Expression of M-CSF
and IL-6 by MCF-7 and MDA-MB-
231 cells
qRT-PCR revealed that MCF-7
cells do not express mRNA for M-
CSF or IL-6, in comparison; MDA-
MD-231 cells did express both M-
CSF and IL-6, as shown by bands
present at 100bp and 99bp.
Chapter 6 The role of acid in cancer-induced osteolytic bone disease
139
Figure 6.11 Expression of genes involved in osteoclastogenesis by MDA-
MB-231 and MCF-7 cells
qRT-PCR revealed that OPG, TGFβ1 and TGFβ2 expression is 10.95-, 4.89-
and 49.51-fold higher, respectively, in MDA-MB-231 cells compared to MCF-
7s. It also demonstrated that TNFα expression is decreased by 16% in MDA-
MB-231 compared to MCF-7s.
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Discussion
Breast cancer is the most common type of cancer in the UK (Key et al. 2001),
and the second most common in Europe (Ferlay et al. 2010), although survival
rates are increasing year on year (Peto et al. 2000; Jemal et al. 2010). This,
however, means that more people are living with the complications that
accompany breast cancer. A common consequence of breast cancer is
metastasis, particularly to bone, where osteolytic bone disease occurs. Osteolytic
bone disease results in increased osteoclast activation and therefore greater
bone resorption, and localised bone destruction.
The current model of cancer metastasis and subsequent bone destruction
is known as the ‘vicious cycle of bone metastases’. The model proposes that
once cancer cells have metastasised to bone, they produce a large number of
growth factors and cytokines including PTHrp, TGFβ and IL-11. The model states 
that these growth factors and cytokines are able to stimulate osteoclastic
resorption of bone, therefore resulting in release of growth factors ordinarily
trapped within the bone matrix. Once released into the bone/cancer
microenvironment, they stimulate the growth of further cancer cells and hence
the cycle continues (Kingsley et al. 2007).
This model, however, fails to take into account the effect of acid on bone
cells. Acid has been known to have a detrimental effect on bone for many years;
it prevents bone formation (mineralisation) by osteoblasts and causes done
destruction by stimulating osteoclast activity. Some authors are now beginning to
take account of acidic microenvironment in which the vicious cycle of bone
metastases takes place (Kingsley et al. 2007) but rarely consider the direct action
of low pH on osteoclasts in this location, instead placing more significance on the
many growth factors and cytokines found in this locale.
One of the initial aims of this thesis set out to examine whether two of the
key cytokines implicated in this model (activin A and BAFF) could stimulate
osteoclasts to resorb at physiological pH. Activin A recently came to attention as
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a cytokine of interest following cytokine profiling of patients suffering from
multiple myeloma and associated osteolysis. Activin A was the only cytokine
found to be significantly increased in patients with osteolysis compared to those
who had no osteolytic lesions (Vallet et al. 2010). It was found that activin A at
concentrations up to 100ng/ml was unable to stimulate osteoclastic resorption at
physiological pH; furthermore it was unable to increase the amount of resorption
carried out when osteoclasts had been initially stimulated with exogenous H+
(Figs. 6.2 and 6.3).
Currently, the precise role of activin A is unknown, with many laboratories
reporting contradictory stimulatory and inhibitory effects of activin A on osteoclast
activity (Fuller et al. 2000; Gaddy-Kurten et al. 2002; Nicks et al. 2009; Leto
2010; Vallet et al. 2010); interestingly, none of these groups reported the pH of
cultures, so increased resorptive activity as a result of acid activation cannot be
ruled out. Recent work by our collaborators has shown that activin A actually
inhibits osteoblastic differentiation and tumour burden (Chantry et al. 2010). In
animals in which activin A activity was blocked, bone mass was increased in vivo;
in vitro, blocking activin A resulted in increased osteoblast differentiation and
mineralisation. Moreover, osteoclasts from these animals in which activin A was
blocked were unaffected, both in number and activity (Chantry et al. 2010); these
data are consistent with the results presented in this thesis. However as stated,
other groups have reported contradictory results in which in vivo mouse studies
using an activin A soluble decoy receptor show decreased osteoclast number
(Vallet et al. 2010); additionally, human trials with a similar activin A decoy
receptor resulted in decreased serum levels of C-terminal type 1 collagen
telopeptide (CTX) and TRAPC-5b levels (Ruckle et al. 2009), both indicative of
decreased resorption levels. Taken together these results indicate that in vivo,
activin A can affect osteoclast formation and resorption, though neither study
reveals the mechanism by which this may be occurring.
B-cell activating factor (BAFF) is often produced by cancer cells that go on
to cause osteolytic bone disease, including multiple myeloma. (Tai et al. 2006);
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(Podar et al. 2009). BAFF also supports the growth of cancer cells within the
bone marrow microenvironment (Breitkreutz et al. 2008). Patients with multiple
myeloma have serum levels of BAFF approximately 4-fold higher than healthy
individuals (Moreaux et al. 2004). It was found that BAFF at concentrations up to
200ng/ml was unable to stimulate osteoclasts to resorb when at physiological pH
(Fig. 6.4). Furthermore, BAFF did not cause any change in the amount of
resorption carried out by osteoclasts which had already been stimulated to resorb
by the addition of exogenous H+ (as HCl) to the system.
It has been reported that within the bone microenvironment, BAFF acts to
promote survival of cancer cells themselves via a paracrine action (Neri et al.
2007; Baud & Karin 2009). Hemingway et al. have demonstrated that BAFF could
stimulate osteoclastic resorption via a RANKL-independent mechanism;
however, osteoclasts treated with M-CSF and BAFF only resorbed 0.2% the area
of osteoclasts treated with both M-CSF and RANKL and the authors
acknowledge that BAFF is not an efficient inducer of osteoclast generation
(Hemingway et al. 2011). If BAFF only accounts for 0.2% of the normal amount
of resorption that occurs it is unlikely that blocking it would have been responsible
for the large changes in resorption reported by other groups. Furthermore, the
pH of these cultures was not controlled and osteoclasts are able to self-acidify
their medium in vitro, so resorption might have been a consequence of acid
stimulation. The in vivo effects of BAFF are less clear; it has been shown that a
mouse model of multiple myeloma administered with an anti-BAFF neutralising
antibody had decreased osteoclast recruitment and activity (Neri et al. 2007).
Results I have presented indicate that any effects that activin A and BAFF
might have on osteoclasts must occur via indirect means. Thus, future work
could involve co-culturing osteoclasts with osteoblasts or stromal cells in order to
determine whether activin A or BAFF are able to mediate effects on osteoclasts
via these cell types and therefore an indirect mechanism. The murine osteoclast
isolation method used to investigate the effects of activin A and BAFF involved
removal of the majority of stromal cells and isolating just the haematopoietic cells
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of the mouse marrow. These are the cells which gave rise to osteoclasts
following addition of M-CSF and RANKL, thus providing a means to determine
direct effects of test compounds on osteoclasts.
The rest of the work presented in this chapter involved the co-culture of
osteoclasts with breast cancer cells. My results show that when osteoclasts were
co-cultured with either MDA-MB-231 or MCF-7 human breast cancer cells for 5
days, osteoclast formation was significantly reduced in both cases (Fig. 6.6 A).
This was surprising, as it was hypothesised that cancer cells would stimulate
osteoclast formation. There are two possible explanations for the decreased
osteoclast number firstly that the decreased number of osteoclasts were the
result of the cancer cells using up the nutrients and therefore inhibiting osteoclast
formation; a second more likely explanation is due to the increased levels of OPG
produced by both of the cancer cell lines. Effects of co-culture on osteoclast
activity are discussed later.
qRT-PCR revealed that, although neither of the breast cancer cell types
express RANKL, both express OPG (Fig. 6.10). OPG mRNA was expressed 11-
fold higher in MDA-MB-231 cells compared to MCF-7 cells, which correlates with
the greater reduction in osteoclast number formed when co-cultured with MDA-
MB-231 cells compared to MCF-7 cells. Expression of OPG by these cancer cell
lines is in agreement with work published by (Holen et al. 2005; Rachner et al.
2009). It should be noted that the MDA-MB-231 and MCF-7 cells were grown in
RPMI, the qRT-PCR should be repeated on cells that have been grown in MEM
as the co-culture experiments in order to confirm that the effects are the same.
In patients with breast or prostate cancer that has metastasised to the
bones, higher levels of serum OPG have been recorded in comparison to those
without metastases (Dougall & Chaisson 2006). In mice injected with cancer
cells, immediately followed by administration with OPG, reduced numbers of
osteoclasts resulted and osteolytic lesions did not form unlike animals injected
with cancer cells only (Zhang et al, 2001). Given that neither MDA-MB-231 cells
nor MCF-7 cells produced RANKL but did produce OPG, the
Chapter 6 The role of acid in cancer-induced osteolytic bone disease
144
(exogenous)RANKL:OPG ratio would have been altered. This would have
prevented differentiation of pre-osteoclasts into mature bone resorbing
osteoclasts. This could account for the decrease in osteoclast numbers recorded
compared to osteoclast-only control groups.
Correspondingly, when cancer cells were added for only the final 48 hours
of culture (i.e., to determine their effect on osteoclast activation rather than
formation), no reduction in osteoclast number was observed, which adds further
weight to the theory that the OPG produced by the cancer cells themselves is
responsible for inhibition of osteoclast formation. These data show that the in vivo
effects of cancer on bone cells are likely to be a complex system of inhibitory and
stimulatory factors.
The effect of co-culture on osteoclast activity (i.e., resorption) was also
investigated. Osteoclasts co-cultured with MDA-MB-231 cells and MCF-7 cells
resorbed significantly less at both physiological and acidic pHs when compared
to osteoclast only controls at the equivalent pH (Fig. 6.6 B). Within the ‘vicious
cycle’ model, much emphasis has been placed on growth factors and cytokines
produced by cancer cells that go on to stimulate osteoclast activity (Guise 2000;
Roodman 2004; Rose & Siegel 2006; Kingsley et al. 2007; Clezardin 2011).
qRT-PCR has demonstrated that MDA-MB 231 cells express IL-6, TGFβ1,
TGFβ2 and TNFα and MCF-7 cells express TGFβ1, TGFβ2 and TNFα (Figs.
6.10 and 6.11). Results presented in this chapter however, suggest that these
factors have not stimulated osteoclasts to resorb to the same extent that acid can
(Fig. 6.6 C), however, when osteoclasts were co-cultured with MDA-MB-231
cancer cells at physiological pH, there was 10 times the amount of resorption
than MCF-7 cells. This provides evidence that the different combination of growth
factors produced by each cell type in addition to the acid produced by these cells
contributes to the overall stimulatory effect of osteoclast activity.
Owing to the high metabolic activity of osteoclasts, they are able to self-
acidify their own culture medium. This therefore means that the cytokines and
growth factors implicated in the ‘vicious cycle’ may not be solely responsible for
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stimulating osteoclasts to resorb but rather, they augment resorption when
osteoclasts were stimulated to resorb by acid. This is true of RANKL; acid
potentiated the small stimulatory effect of RANKL at pH 7.41 to cause a ~20-fold
increase in resorption in osteoclasts treated with 100ng/ml RANKL at pH 6.98
(Orriss & Arnett 2012).
It should be noted that only mRNA expression has so far been
investigated, and any effect on protein would need to be determined to confirm
these findings. Additionally, there are some differences in expression of cytokines
detected compared with reports in the literature. MCF-7, MDA-MB-231 and
another breast cancer cell line, T-47D, account for more than two thirds of all
breast cancer research listed in PubMed (Lacroix & Leclercq 2004). It is
proposed that the very nature of cancer cells means that these cell lines in vitro
are likely to undergo genotypic and phenotypic alterations resulting from long
term cell culture (Lacroix & Leclercq 2004). Given that individual laboratories use
slightly different conditions to maintain cell lines and to conduct experiments, cell
lines evolve differently, characteristics diverge and as such become a distinct
sub-population of the original cell line result (Lacroix & Leclercq 2004).
Differences in expression I have reported here may be a result of this divergence.
As previously stated, qRT-PCR revealed a lack of RANKL but the
presence of OPG expression by both of the cell lines investigated. In addition to
the clear inhibitory effect that OPG has on osteoclast formation, as discussed
previously, it is also an important regulator of resorption. OPG has been found to
block cancer induced skeletal destruction (Honore et al. 2000; Zhang et al. 2001;
Theoleyre et al. 2004). Therefore the lack of resorption I saw when osteoclasts
were cultured with breast cancer cells may be a result of increased OPG levels. If
this is the case, it would indicate the ‘vicious cycle’ model might not take into
account other inhibitory factors that might be present in the micro-environment.
Other factors known to be inhibitory to osteoclasts and therefore provide
opportunities for further work include IFN-γ, which inhibits bone resorption in vitro
(Gowen & Mundy 1986). Additionally IL-4 has been shown to inhibit both
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osteoclast formation and resorption (Shioi et al. 1991; Bendixen et al. 2001;
Mangashetti et al. 2005). Oestrogen, as outlined in Chapter 1, is a major inhibitor
of osteoclast formation (Roodman 2004).
An important observation made when analysing the results of the co-
culture experiments independently of osteoclast-only control groups was that
more resorption was carried out by the osteoclasts when the pH of the medium
was allowed to drop compared to those that had been maintained at a
physiological pH (Fig. 6.6 C), highlighting the role of low pH as a stimulator of
osteoclastic resorption. Importantly the pH values at which resorption occurred
for MDA-MB-231 cells and MCF-7 cells (6.98 and 7.12) were both within the
pathophysiological range. pHs of cancer in vivo have been measured in a 27
day tumour where hypoxia or anoxia were also present and pH was consistently
found to be below 7.0. Distance from the nearest blood vessel also influenced
the interstitial pH within the tumour; 20µm from the blood vessel gave a pH of
7.2, 50µm gave a pH of 7.04, at 150µm from the blood vessel the pH was
recorded as 6.9, and at 300µm the pH was 6.7. In some large tumours in which
some areas had become avascular, interstitial pH was recorded as low as 6.6
(Helmlinger et al. 1997). This indicates that pH values generated by the co-
culture system in vitro are comparable to those achieved in the in vivo disease
situations which are being investigated.
Work presented in this chapter was dependent on in vitro modelling of a
disease state. One of the most obvious challenges of in vitro modelling is that
cell culture provides conditions are optimised for growth, whereas in vivo
conditions are dictated by a particular person’s physiology. Environmental
changes to which the cancer cells are exposed to in vivo may well result in both
phenotypic and genotypic changes to the cancer cells which in vitro modelling
cannot replicate (van Staveren et al. 2009). The model I have developed to co-
culture breast cancer cells with osteoclasts has some advantages, most notably,
that the model allows osteoclasts to be cultured on dentine, on which they are
able to resorb and therefore behave as they would in vivo; this is clearly more
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realistic than using plastic tissue culture dishes, which osteoclasts cannot resorb.
Furthermore, in this model, the pH was closely monitored, whereas in current
systems, this important modulator of osteoclast activity is not considered.
Achieving the desired pH without altering it artificially did require a careful
balance between amount of medium used to keep the cells alive and functioning
normally and seeding enough cancer cells to allow these cells to acidify the
medium themselves as they would in vivo. Repeating the experiments with
increased culture volumes and artificially altering the pH might yield different
results but this would mean that cells are further removed from conditions
comparable to those within the body.
In vivo, tumours are often hypoxic, which in some cases can promote
tumour growth (Knowles & Harris 2001; Harris 2002), and this model has not
accounted for this. Different results may have been obtained if a hypoxic
environment had been established. Hypoxia has well documented effects on
osteoclasts; in vitro, hypoxia has been reported to double osteoclast formation
from human peripheral blood mononuclear cells and increase their resorption 10-
fold (Utting et al. 2010). Incorporating hypoxia experimentally provides an
opportunity to build upon and improve this model. It is also worth noting that this
work has only been carried out on two human breast cancer cell lines: MDA-MB-
231 and MCF-7; however, the majority of all breast cancer research carried out
worldwide is carried out on these cells lines (in addition to one other) (Lacroix &
Leclercq 2004). This work should be repeated on additional breast cancer cell
lines to determine whether this effect is universal or not. It would also be
advantageous to repeat this on other cancer cell types that metastasise to bone
i.e., prostate cancer (Langley & Fidler 2011) and lung adenocarcinoma (non-
small cell lung cancer) (Nguyen et al. 2009; Yamashita et al. 2012).
Finally, it must be noted that this system was heterologous; using human
breast cancer cell lines and primary murine osteoclasts. This work should be
repeated in a homologous system using primary human osteoclasts, derived from
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peripheral blood mononuclear cells in order to confirm that results presented here
are the same.
In conclusion, it has been shown that many of the intricacies of the vicious
cycle model of cancer metastases to bone may not be fully appreciated and,
although simplifications and modelling need to be made to study these systems
in vitro, the actual in vivo system should always be considered. I have also
highlighted the importance of monitoring pH of in vitro experiments as acidosis
has profound effects on osteoclast activity.
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Chapter 7
General discussion and future work
The negative effects of acid on the skeleton have been known for many years
(Goto 1918). For a long time it was thought that the negative effects were a
simple physico-chemical effect, whereby excess acid in the body dissolved the
bone which is a large store of base in order to balance pH within the body. This
would function to maintain pH within the narrow physiological limits (normal
blood pH 7.34-7.45) that are required to support life. However in 1986 an
important observation was made, whereby it was noted that osteoclasts were
actually stimulated to resorb bone when the pH dropped slightly but was still
within normal physiological limits (Arnett & Dempster 1986). This indicated that
drops in pH had a direct effect on osteoclasts.
It was another nineteen years before it was reported that acidosis also
had a direct negative functional effect on osteoblasts. Acid prevents
mineralisation both physico-chemically and by suppressing alkaline
phosphatase expression. The effect is selective as the growth of cells and
collagen production are not affected (Brandao-Burch et al. 2005b).
The above observations led to attempts to elucidate the mechanisms by
which osteoclasts and osteoblasts were able to detect acidosis; this has been
one of the key focuses of this thesis. pH within the body is one of the most
tightly controlled of all the homeostatic mechanisms (Frassetto et al. 1996).
Acidosis will typically result in impaired cellular function. One of the
consequences of severe changes in pH is to amino acids and therefore
proteins. Fluctuations away from the physiological norm result in protein
denaturation (Dzakula et al. 1991) and as a consequence reactions would
cease and life would not continue. Presumably this has been the case since
the beginning of cellular life, therefore even the most primitive cells would have
needed a way to sense the pH (Johnson 1998; Padan 2011). As cells evolved
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into multicellular organisms it is likely that various different single celled
organisms that were absorbed into the larger organism each had their own acid
sensing receptor(s) (Padan 2011). This may help account for the many
different types of acid sensing receptor expressed by mammalian cells. Thus,
understanding the mechanisms by which bone cells sense acid is a potentially
difficult task. It is worth pursuing however, as it may be possible to design a
drug to the particular acid-sensor on osteoclasts for example, in order to block
the receptor so that protons cannot be detected and therefore the osteoclasts
are not stimulated to resorb bone. This approach could potentially offer new
therapeutic targets for bone loss disorders such as osteoporosis.
Work by past members of the Arnett laboratory investigated the acid-
sensing receptors OGR1, TDAG8, GPR4 and ASIC1a. Osteoclasts isolated
from Ogr1-/- and Tdag8-/- mice had the same response to acid as those from
wildtype animals and from that it is inferred that they are able to sense protons
in the extracellular environment (Gasser et al. 2006). mRNA from GPR4 could
not be detected on osteoclasts, and mRNA for ASIC1a was down-regulated in
acid activated osteoclasts (Brandao-Burch 2005a), suggesting that these
proteins are unlikely to act as acid-sensors in osteoclasts.
The focus of work presented in Chapter 5 was the TRP family of ion
channels. TRPV1 is well a well-documented acid-sensing receptor which also
detects the hot ingredient in chilli peppers, capsaicin, as well as temperatures
above 43ºC (Benham et al. 2003; Clapham 2003; Desai & Clapham 2005;
Montell 2005; Voets et al. 2005; Nilius et al. 2007; Venkatachalam & Montell
2007). As described in Chapter 5, I found that both osteoclasts and osteoblasts
express TRPV1. I therefore tested the hypothesis that capsaicin might
stimulate bone resorption by cultured osteoclasts, including in non-acidified
conditions. However, this was not the case. Capsaicin was similarly without
effect on osteoblast function. Immunofluorescence appeared to show that
TRPV1 expressed by osteoclasts was located intracellularly; therefore, the lack
of effect could be a result of capsaicin being unable to interact with TRPV1 at
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the cell membrane. This immunofluorescence needs to be repeated, ensuring
that the osteoblast cell membrane is intact to confirm the cellular location of
TRPV1 by osteoblasts. The TRPV1 antagonist SB366791 inhibited bone nodule
formation up to concentrations of 2µM, although not significantly. It is possible
that there is a biphasic effect, and a wider concentration range would need to
be tested to investigate this further. Given that SB366791 is an antagonist of
TRPV1, it is unexpected that it would inhibit bone formation at pH 7.4, rather it
was expected to antagonise the effect of acid and, therefore, bone nodule
formation would happen at pH 6.9. The effect of SB366791 on bone nodule
formation at physiological pH warrants further investigation.
Agonists and antagonists for the channels TRPV4, TRPV3 and
TRPM8 were either without effect or cytotoxic; therefore leading to the
conclusion that the TRP family of ion channels are probably not acting as the
sole acid-sensing receptors in osteoclasts or osteoblasts.
It should, however, be taken into consideration that the system used for
this investigation was optimised to result in maximal osteoclast formation and
activity with RANKL. Lack of stimulatory effects seen may be because maximal
stimulation had already been reached and, therefore, any additional effects that
might have been observed may have been masked. To clarify whether TRP
agonists have a stimulatory affect it would be prudent to repeat these
investigations using a lower concentration of RANKL.
Osteoclasts obtained from Trpv1-/- null mice were still able to resorb and
therefore respond to acid, indicating that protons must have been sensed by
another acid-sensing receptor. Resorption by osteoclasts, however, was
reduced by approximately 31% compared to osteoclasts isolated from wildtype
animals. This might provide evidence that TRPV1 does contribute in part to
acid-sensing by osteoclasts.
Work carried out by other groups investigating the role of the TRP
receptors on bone cells have presented contradictory results, whereby
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capsaicin has inhibited resorption by osteoclasts (Takita et al. 2007; Kobayashi
et al. 2012). In both cases it is proposed that capsaicin is able to attenuate
osteoclastic resorption by signalling through TRPV1 on osteoblasts which in
turn down-regulates production of RANKL (Takita et al. 2007; Kobayashi et al.
2012). Co-culture experiments of osteoblasts with osteoclast precursor cells
could be performed in order to determine if the lack of effect seen in this study
was due to capsaicin exerting its effects via TRPV1 on osteoblasts rather than
on osteoclasts directly.
The functions of several other classes of acid sensing proteins in bone
cells may also be worth investigating further. Of the ASICs, ASIC3 is activated
within the physiological range that osteoclasts are activated (Birdsong et al.
2010) and it is expressed by human osteoclasts (Jahr et al. 2005). Additionally
TWIK-1, TALK-1, TASK-1, -2 and -3 are all activated within the physiological
range (Duprat et al. 1997; Holzer 2009). Any of these may be a candidate
proton sensor in osteoclasts or osteoblasts.
Since pH sensing is critical to cell survival (Frassetto et al. 1996; Padan
2011), it may be that bone cells have evolved ‘degenerate’ acid sensing
mechanisms, involving many different pH cell surface sensors. Protons are also
able to enter the cell; extracellular decreases in pH resulted in fast drops in
intracellular pH when cultured in bicarbonate/CO2 buffer (Arnett, personal
communication). Such redundancy may suggest that it will be a difficult problem
to solve. Blocking or knocking out a single channel may have limited effects.
Chapter 4 demonstrated that acid has additional direct effects on
osteoblasts, whereby it prevents mineralisation of the organic matrix in a
manner that is not physico-chemical. The focus of work in this chapter was to
elucidate the mechanism by which osteoblasts were prevented from
mineralising the matrix. It is known that the key regulator of mineralisation
anywhere in the body is the ratio of phosphate to pyrophosphate (Fleisch et al.
1966). Pyrophosphate as a by-product of many cellular reactions is present,
and acts to inhibit mineralisation of the soft tissue. In mineralised tissues,
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however, pyrophosphate is hydrolysed by the actions of enzymes including
alkaline phosphatase to generate phosphate (Fleisch et al. 1966; Meyer &
Nancollas 1973; Addison et al. 2007). Under acidotic conditions, alkaline
phosphatase activity was significantly decreased (Brandao-Burch et al. 2005b),
which would be expected to shift the balance in favour of more pyrophosphate
in the extracellular fluid surrounding the osteoblasts.
The investigations in Chapter 4 focussed on other enzymes that
generate pyrophosphate and phosphate, and of those examined, the
pyrophosphate producing E-NPP1 was found to be up-regulated in osteoblasts
that had been cultured in acidotic conditions. However, I found that long term
acidosis, in addition to causing an increase in pyrophosphate generation, also
resulted in significantly increased phosphate generation. Thus, the overall
Pi:PPi ratio remained the same; indicating that acidosis was not preventing
mineralisation by ultimately altering the critical Pi:PPi ratio. As other members of
the E-NPP and E-NTPdase families were either unaffected or down-regulated in
osteoblasts cultured at pH 6.9, it may be that another phosphate producing
enzyme was responsible for the increases in phosphate generation.
In order to understand further the mechanism by which acid inhibits
mineralisation by osteoblasts, it would be worth determining whether
PHOSPHO 1 is affected by acid conditions, especially given that the optimum
activity of PHOSPHO 1 is reported to occur around pH 6.7 (Roberts et al. 2004).
In Phospho 1-/- animals, bones are negatively affected; there is reduced
mineralisation of the trabecular bones and an absence of secondary ossification
centres in some animals (Yadav et al. 2011). Furthermore, TNAP activity in
hypertrophic chondrocytes is reduced. These observations suggest that
PHOSPHO 1 has a role in producing phosphate for proper bone production
(Yadav et al. 2011). pH regulation of the function of the enzyme ANK, which
additionally contributes to maintaining levels of PPi both intra- and extra-
cellularly (Ho et al. 2000) would also be worthwhile.
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It would appear that the activities of E-NPP1, TNAP, PHOSPHO 1 and
ANK are intrinsically linked in order to regulate mineralisation in vivo (Yadav et
al. 2011). Investigating the more specific effects of acid on PHOSPHO 1 and
ANK individually may help to elucidate the exact parts played by each enzyme
in order to determine the role that acid has. Additional information about the role
of E-NPP1 in mineralisation will come from experiments with primary
osteoblasts derived from E-npp1-/- mice in our laboratory.
Furthermore, because the Pi:PPi ratio was not altered to prevent
mineralisation as hypothesised, the question remains as to whether E-NPP1 in
mature osteoblasts might have another role. Overexpression of E-NPP1 by
muscle, adipose tissue and fibroblasts has been demonstrated in insulin-
resistant individuals. E-NPP1 overexpression inhibits insulin-induced activation
of the insulin receptor (Goldfine et al. 1998; Goldfine et al. 1999; Maddux et al.
2006). In addition, it has been postulated that bone is able to function as an
endocrine gland and plays a part in glucose metabolism (Ferron et al. 2010).
Therefore, the increase in E-NPP1 expression seen during this study may not
only play a part in regulation of mineralisation but might instead have a role in
energy metabolism.
There are a number of other factors that have a role in aberrant
ossification, including members of the BMP family. Unregulated BMP signalling
is involved in Fibrodysplasia ossificans progressive (FOP), which is
characterised by progressive heterotopic bone formation. Mutations in the
regulatory domain of the BMP type 1 receptor lead to aberrant pathway
activation, the receptor is hypersensitive to BMP ligands and in some cases is
activated even in their absence (Fukuda et al. 2009). The activation of the BMP
signalling pathway leads to heterotopic bone formation. Increased ossification of
the soft tissue can also occur following traumatic injury such as amputation.
Recent work has implicated excessive BMP2 stimulation in the soft tissue as
stimulating osteogenic activity and the cause of ossification (Wosczyna et al.
2012). In both cases the excess BMP stimulation and signalling has caused
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increased ossification. It may be worth investigating if decreased BMP signalling
results in decreased mineralisation and whether acidosis has any effect on this
signalling pathway in osteoblasts.
Chapter 6 investigated the role that the acid conditions of the tumour
microenvironment might have in the role of ‘the vicious cycle of bone
metastases’, whereby cancer cells that have metastasised to bone cause
osteolytic bone disease (Kingsley et al. 2007). This model, however, fails to
take into account the stimulatory effect that acid has on osteoclasts; which is
surprising given that the tumour microenvironment is known to be acidotic
(Fukumura & Jain 2007). The interactions between cancer cells and genuine
osteoclasts have so far been poorly investigated. Work presented in Chapter 6
involved development of a new in vitro co-culture model to study the osteoclasts
and the breast cancer cell lines MDA-MB-231 and MCF-7 but without the cells
coming into contact so that the different cell types could be analysed separately.
Surprisingly cancer cells were found to inhibit both formation and
activation of osteoclasts. Whether inhibitory effects were specific to the cell lines
I used or whether they represent a more general phenomenon remains to be
investigated. Work by (Pederson et al. 1999) has shown that different
combinations of growth factors produced by MDA-MB-231 cells can have both
inhibitory and stimulatory effects on osteoclastic resorption.
Overall, these findings were unexpected in view of the widely held
supposition that cancer cells stimulate osteoclast formation and activity.
However, when cancer cells were allowed to acidify cultures there were striking
increases in resorption pit formation. It was observed that when co-cultures
were clamped at pH 7.3, there was minimal resorption; however, when
osteoclasts were co-cultured with osteoclasts, there was 10 times the amount of
resorption than when osteoclasts were co-cultured with MCF-7 cells. This
provides evidence that a factor other than pH could be having a stimulatory
effect on osteoclast activity. A number of osteolytic factors reported to be
produced by the MDA-MB-231 cell line are listed earlier and any one of these
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may be responsible for the stimulation of resorption. The effect of each of these
cytokines and growth factors on osteoclast formation and activity can be
investigated separately from one another using the same experimental setup as
that for determining the effects of activin A. Furthermore, investigations using
conditioned medium from the cancer cells on osteoclast formation and activity
could be performed without addition of exogenous M-CSF or RANKL which
might help to elucidate whether factors produced by the cancer cells are having
an effect on osteoclast function.
Differences from the anticipated results compared to those observed
here may be because acidosis did not cause the effects as hypothesised. There
are a number of reasons why effects on osteoclasts are contradictory to those
expected, whether inhibitory effects were due to inhibitory cytokines or depletion
of essential nutrients in the culture medium remains to be investigated. Also,
this work was carried out in a heterologous system, and it needs to be repeated
in a homologous cell culture system.
In vivo, the situation is clearly more complex still. Acidosis occurs hand in
hand with hypoxia (Brahimi-Horn et al. 2007), and this would be expected to
have profound effects on both osteoclast and osteoblast activity (Arnett et al.
2003; Utting et al. 2006; Knowles et al. 2010; Utting et al. 2010). Additionally,
there are the many growth factors (such as TGFβ, BMPs) trapped within the 
bone matrix; following resorption of the bone by osteoclasts these are released
into the bone/cancer microenvironment. Once released from the bone matrix
these factors are then able to bind to cell-surface receptors on the cancer cells
and osteoclasts where they may have a stimulatory effect.
The bone cancer metastases microenvironment is a complex one and
provides a multi-factorial problem that needs to be studied further in order to
elucidate more precisely the role of acid. However, I have shown that acid does
have stimulatory effects on osteoclast activity when co-cultured with breast
cancer cells and so the effects of acid in the vicious cycle model should be
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taken into consideration when trying to understand the intricacies of this system.
A revised schematic for the ‘vicious cycle’ model can be seen in figure 7.1.
Figure 7.1 The vicious cycle of bone cancer metastases
Metastatic cancer cells in the bone microenvironment release cytokines and growth
factors that promote osteoclastogenesis and/or resorption (Garrett et al 1987; Bendre
et al 2003; Kudo et al 2003; Kingsley et al 2007; Yamashita et al 2007; Mohammad et
al 2009). Although not specifically addressed in the thesis, hypoxia will contribute to
osteoclast formation (Utting et al 2010). Acid produced by the cancer cells will stimulate
resorption. Resorption by osteoclasts will release growth factors (TGFβs, IGFs and 
BMPs) ordinarily trapped within the bone matrix into the extracellular microenvironment
where they are able stimulate further cancer cell proliferation (Kingsley et al 2007).
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In conclusion, it is clear that acid has profound effects on both osteoclasts
and osteoblasts which are detrimental to bone. The reciprocal effect of
increased osteoclastic bone resorption and decreased bone formation provide
an evolutionary ‘fail-safe’ mechanism to buffer life threatening decreases in
overall bodily pH in times of disease. However, in situations such as
osteoporosis for example, understanding the mechanism more thoroughly may
provide useful drug targets. The work presented in this thesis provides
evidence to rule out the TRP super-family of ion channels as the acid-sensor,
there are still several other possible candidates that may be worth investigating.
Furthermore, it has been shown that E-NPP1 plays an important role in
regulation of mineralisation of bone subjected to low pH levels still within the
pathophysiological range. Although more work is required to understand the
mechanism more thoroughly in relation to the other enzymes, specifically
PHOSPHO 1 and ANK, this may provide a potential therapeutic target to
prevent bone loss.
These data also indicate that acidosis is a key factor in ‘the vicious cycle
of bone metastases’. More research is required to understand exactly the
interplay between acidosis and other factors implicated in this model,
particularly growth factors and cytokines as well as hypoxia. This presents a
substantial challenge to model in vitro.
Overall, the experimental data presented in this PhD thesis demonstrate
that extracellular pH is a fundamental regulator of bone cell function.
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Appendix I
Primer sequences
Gene
product
Primer sequences (5’-3’) Product
size (bp)
Annealing
temperature
(˚C) 
β actin  S - GTTCGCCATGGATGACGAT 
AS - TCTGGGTCATCTTTTCACGG
332 53
Alkaline
phosphatase
S – CTCATTTGTGCCAGAGAA
AS - GTTGTACGYCTTGGAGAC
238 50
TRPV3 S – GACTTCAAGACCCAGAATGA
AS - ATATGCAGCAGTGTATGCAG
368 53
TRPV4 S – AGAACACCAAGTTTGTCA
AS - GTTGTAAACCAGGATCTCCA
311 53
TRPM8 S – GACCTATGGAACGTTATGGA
AS - ATAGATGACAGAGCGGAAGA
330 53
E-NPP1 S – GTCAGTATGCGTGCTAAC
AS - TGGCACACTGAACTGTAG
309 49
E-NPP2 S – GCCCTCCGTTAATCATCT
AS - GCAGAGAAAGCCACTGAA
399 51
E-NPP3 S – GCATGCAGAGGAATTGTC
AS - TGGGAACGGTGTATGAAC
296 53
E-NTPdase2 S – CCAGCTATGCAAATGAAC
AS - AACACCCCTTCATCCTGT
256 56
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E-NTPdase3 S – CAGCCAAACCTTCAGATG
AS - TGTGCCACAGGTTCTTCT
356 53
E-NTPdase4 S - AGGCAGTTGTGGAAGTCA
AS - CAGAAATGGAGCATCAGG
362 53
E-NTPdase5 S – TAGCTTGGGTTACCGTGA
AS – CTCCTTCCAACCATCTTG
315 53
E-NTPdase6 S – GGGATGACTGTGTTTCCA
AS - TTGTCATCCTCAGCAGGT
322 53
Table I.I Primers used for amplification of cDNA by RT-PCR (Rattus norvegicus)
Gene
product
Primer sequences (5’-3’) Product
size (bp)
Annealing
temperature
(˚C) 
GAPDH S – CTCACTCAAGATTGTCAGCA
AS - GTCATCATACTTGGCAGGTT
346 53
TRPV3 S – GAACGTCTCCAAAGAAAGTG
AS - CTTAAGCCAGGCATCTACAC
345 53
TRPV4 S – ACCACAGTGGACTACCTGAG
AS - TCATGAAGAGCAGGTACACA
367 53
Table I.II Primers used for amplification of cDNA by RT-PCR (Mus musculus)
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Gene
product
Primer sequences (5’-3’)
β actin S – GATCATTGCTCCTCCTGAGC 
AS - ACATCTGCTGGAAGGTGGAC
M-CSF S – GCAAGAACTGCAACAACAGC
AS - TCACTGCTAGGGATGGCTTT
RANKL S – AAGGAGCTGTGCAAAAGGAA
AS - GGCCAGATCTAACCATGAGC
OPG S – AGGAAATGCAACACACGACA
AS - CCTGAAGAATGCCTCCTCAC
IL-6 S – AAAGAGGCACTGGCAGAAAA
AS - TTTCACCAGGCAAGTCTCCT
TNFα S - TCTTCTGCCTGCTGCACTT 
AS - GCCAGAGGGCTGATTAGAGA
TGFβ1 S – GTGGAAACCCACAACGAAAT 
AS - CGGAGCTCTGATGTGTTGAA
TGFβ2 S - ACTGTCCCTGCTGCACTTTT 
AS - GTGCCATCAATACCTGCAAA
Table I.III Primers used for amplification of cDNA by qRT-PCR
(Homo sapiens)
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Appendix II
Abbreviations
µg Microgram
µM Micromolar
4αPDD  4 α-phorbol 12,13-didecanoate 
ABAM Antibiotic-antimycotic
ADAM A disintegrin and metalloproteinase
AEBSF 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride
ALP Alkaline phosphatase
AMG 6880 (2E)-3-[2-piperidin-1-yl-6-(trifluoromethyl)pyridin-3-yl]-N-
quinolin-7-ylacrylamide
AMG 7472 5-chloro-6-{(3R)-3-methyl-4-[6-(trifluoromethyl)-4-(3,4,5-
trifluorophenyl)-1Hbenzimidazol-2-yl]piperazin-1-yl}pyridin-
3-yl)methanol
AMG 9810 (2E)-N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-
dimethylethyl)phenyl]-2-propenamide
Aml3 Acute-myeloid-leukaemia protein 3
ANK Progressive ankylosis protein
ApnA Diadenosine polyphosphates
ASIC Acid-sensing ion channel
Atf-/- Activating transcription factor 4 knockout
ATF4 Activating transcription factor 4
ATP Adenosine triphosphate
BAFF B-cell activating factor
BCTC 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-
piperazinecarboxamide
BDNF Brain derived neurotrophic factor
BMP Bone morphogenetic protein
BSA Bovine serum albumin
BSP Bone sialoprotein
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Ca2+ Calcium
Cbfa1 Core-binding factor alpha 1
CCL4 Chemokines (C-C motif) ligand 4
CDK Cyclin-dependent kinase
cDNA Copy deoxyribonucleic acid
CO2 Carbon dioxide
Col 1 Type 1 collagen
CREB2 cAMP-response element-binding protein
CTX C-terminal telopeptide
DAPI 4',6-diamidino-2-phenylindole
DC-STAMP Dendritic cell specific transmembrane protein
dH2O Deionised water
Dlx Distal-less homeobox
DMEM Dulbecco’s modified Eagle’s medium
DMP-1 Dentine matrix protein 1
ECM Extracellular matrix
E-NPP Ecto-nucleotide pyrophosphatase/phosphodiesterase
E-NTPdase Ecto-nucleoside triphosphate diphosphohydrolases
FCS Foetal calf serum
FGF Fibroblast growth factor
FITC Fluorescein isothiocyanate
GM-CSF Granulocyte macrophage-colony stimulating factor
GRO Growth related oncogene
H+ Proton
H2CO3 Carbonic acid
H2O2 Hydrogen peroxide
HBSS Hank’s balanced salt solution
HCl Hydrochloric acid
HCO3- Bicarbonate ion
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HMRC Her Majesty’s Revenue and Customs
HRP Horseradish peroxidise
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IFN-γ   Interferon gamma 
IgE Immunoglobulin E
IGFBP Insulin-like growth factor-binding protein
IHH Indian hedgehog
IL Interleukin
IP-10 Interferon gamma induced protein 10
KO Knockout
LDH Lactate dehydrogenase
LDL Low-density lipoprotein
LIF Leukaemia inhibitory factor
LPA Lysophosphatidic acid
LRP Low-density lipoprotein receptor-related protein
MAFP Major acidic fibroblast-growth-factor stimulated
phosphoprotein
M-CSF Macrophage-colony stimulating factor
MEM Minimum essential medium
meq/L Milliequivalents per litre
MFR Macrophage fusion receptor
MgCl2 Magnesium chloride
MGP Matrix gla protein
MIP Macrophage inflammatory protein
ml Millilitre
MMP Matrix metalloproteinase
mRNA Messenger ribonucleic acid
Msx MSH homeobox homologue
NADH Nicotinamide adenine dinucelotide, reduced
NaOH Sodium hydroxide
NAP-2 Neutrophil-activating protein 2
NDP Nucleotide diphosphate
ng Nanogram
nM Nanomolar
NMP Nucleotide monophosphate
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NPPase Nucleotide pyrophosphatase phosphodiesterase
NPPα  Nucleotide pyrophosphatase phosphodiesterase α 
NPPβ  Nucleotide pyrophosphatase phosphodiesterase β 
NPPγ  Nucleotide pyrophosphatase phosphodiesterase γ 
NTP Nucleotide triphosphate
NTPPPH Nucleotide triphosphate pyrophosphohydrolase
Ocn Osteocalcin
OC-STAMP Osteoclastic stimulatory transmembrane protein
OH- Hydroxide ion
OPG Osteoprotegerin
OPGL Osteoprotegerin ligand
OPLL Ossification of the posterior longitudinal ligament of the
spine
Osf2 Osteoblast specific factor 2
Osx Osterix
Pax1 Paired box gene 1
PBMNC Peripheral blood mononuclear cells
PBS Phosphate buffered saline
PC-1 Plasma cell differentiation antigen 1
pCO2 Carbon dioxide partial pressure
PCR Polymerase chain reaction
PD- Iα  Phosphodiesterase-Iα 
PDGF-B Platelet-derived growth factor-B
PD-Iβ  Phosphodiesterase-1β 
PGE2 Prostaglandin E2
Pi Inorganic phosphate
PLAP-1 Periodontal ligament associated protein-1
PMSF Phenyl methyl sulfonyl fluoride
pNPP p-nitrophenylphosphate
pNP-TMP p-nitrophenyl thymidine 5’-monophosphate
pO2 Oxygen partial pressure
PO43- Phosphate
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PPi Pyrophosphate
PTHrp Parathyroid hormone related peptide
PVDF Polyvinylidene difluoride
qRT-PCR Quantitative real time polymerase chain reaction
RANK Receptor activator of nuclear factor kappa-B
RANKL Receptor activator of nuclear factor kappa-B ligand
RIPA Radio immunoprecipitation
RNA Ribonucleic acid
Runx2 Runt-related transcription factor 2
Runx2-/- Runt-related transcription factor 2 knockout
SA-CAT Stretch-activated cation channel
SB366791 N-(3-methoxyphenyl)-4-chlorocinnamide
SIRPα  Signal regulatory protein-alpha 
SOST Sclerostin
TGFβ   Transforming growth factor beta 
TIMP Tissue inhibitor of metalloproteinases
TNAP Tissue-nonspecific alkaline phosphatase
TNF Tumour necrosis factor
TNFSF11 Tumour necrosis factor ligand super family member 11
TRANCE Tumour necrosis factor-related activation-induced cytokine
TRAP Tartrate resistant acid phosphatase
TRPA Transient receptor potential ankyrin
TRPC Transient receptor potential canonical
TRPM Transient receptor potential melastatin
TRPM8 Transient receptor potential Melastatin type 8
TRPML Transient receptor potential mucolipin
TRPN Transient receptor potential no mechanopotential
TRPP Transient receptor potential polycystin
TRPV Transient receptor potential vanilloid
TRPV1 Transient receptor potential vanilloid type 1
TRPV1-/- Transient receptor potential vanilloid type 1 knockout
TRPV3 Transient receptor potential vanilloid type 3
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TRPV4 Transient receptor potential vanilloid type 4
VEGF Vascular endothelial growth factor
VSCC Voltage-sensitive calcium channel
WT Wildtype
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